Immune system involvement in metal hip implant

failure by Blowers, Pinar
i 
 
UNIVERSITY OF EAST ANGLIA  
FACULTY OF MEDICINE AND HEALTH SCIENCES 
 
 
 
Immune System Involvement in Metal Hip Implant 
Failure 
 
 
Submitted in accordance with the requirements for the degree of Doctor of 
Philosophy by 
 
 
MUNISE PINAR BLOWERS 
 
May 2015 
 
 
 
 
 
 
 
ii 
 
Acknowledgments  
First of all, I would like to express my gratitude to Professor Simon Carding for giving me 
this opportunity to undertake my PhD study in his lab. I also would like to extend my 
appreciation to past and present members of his group.  
A few names I must mention here in particular; I would like to thank to Dr Louise 
Wakenshaw for helping me to get up and running in the lab, to Dr Isabelle Hautefort for 
general scientific advice and discussions over morning coffees we shared together, to Dr 
Elisabeth Bassity for critical review of some written work and Dr Kamal Ivory for 
providing me with invaluable scientific advice and in general for being an awesome friend 
over the years. To the several other students of the lab who came and gone, too many to 
mention here; thanks for their contributions and their support to the project.   
I would like to thank Mrs Anna Mathews for providing me administrative support with 
great enthusiasm, she was always happy to help, it did not matter what the question might 
be! 
I would like to express my sincere gratefulness to Professor Simon Donell for his advice 
and support throughout the study. I have massive admiration for his work and it has been 
great to see his friendly face throughout, especially when things did not go according to the 
plan. I need to extend my thanks to his staff members especially Ms Tracey Potter for 
looking after my samples when I was late (only occasionally though!), and Mrs Laura 
Watson for helping me with ethics applications which I am still trying to learn to do 
properly...  
Mr Darren Ebreo deserves his own paragraph of appreciation for getting up very early to 
collect clinical samples and also doing his best to explain the study to patients, from which 
he had a very high consent rate. This study would not be possible without his commitment 
and hard work.  
I would like to acknowledge Dr Stefano Caserta, especially for stimulating discussions and 
for sharing his passion for immunology with me.  
At last but not least I would like to thank my dear husband Lee for standing by me through 
thick and thin of it. He managed to pretend to understand and even like (it’s a strong word, 
I know) my science over the years for that reason alone he deserves a medal. He survived 
iii 
 
through my moans, many late nights and weekend working. His patience and 
encouragement has been invaluable. I will love him forever. 
 
Statement of Declaration 
 
- This study was funded by DePuy Synthes UK, sponsored by Norfolk Norwich 
University Hospital (NNUH) and hosted by Institute of Food Research (IFR), 
Norwich, UK.  
- Stipend for PhD maintenance was paid by charity Action Arthritis, Norwich, UK. 
- HLA Typing was conducted for a fee-for-service basis by National Health Service 
Blood and Transplant (NHSBT) Colindale, UK. 
- Patient consents and clinical sample collection were conducted by Mr Darren Ebreo. 
- Illustrations were created by Paul Pople at Creative Designs, Norwich, UK. 
- Statistical advice was provided by Dr Marianne Defernez (Analytical Science Unit, 
IFR, UK). 
- TEM images were acquired by Mrs Kathryn Cross at the Norwich Research Park 
Bioimaging Centre, UK. 
- Laser ablation was processed by Particular GmbH, Germany.  
 
 
 
 
 
 
 
iv 
 
Abstract 
Immune system involvement in metal hip implant failure 
Osteoarthritis (OA) is the most common debilitating disease, especially in the elderly. 
Total Hip Replacement (THR) is a last resort treatment for hip OA and Metal-on-Metal 
(MoM) THR was used commonly for its durability. While this is an effective treatment for 
many, around 12% of hip implants were revised in 2012. MoM articulations had poor 
implant survival compared with non-MoM, displaying four times higher failure rate. 
Between 1997 and 2004, 652 hip replacement surgeries were undertaken in Norfolk using 
the Ultima TPS MoM THR system (DePuy) which resulted in a high rate of early implant 
failure (27.4% at year 7). One of the proposed reasons for MoM THR failure is the adverse 
reaction to metal wear debris and consequent immune system mediated osteolysis resulting 
in peri-prosthetic loosening.  To understand the immune system involvement in metal hip 
implant failure, a cohort of OA patients were recruited with and without an Ultima implant.  
This study investigated;  
 The Human leukocyte antigen (HLA) allelic variation and implant failure 
association. 
 Determined the composition and frequency of immune cells and inflammatory 
markers in Norfolk cohort. 
 And tested the metal particle impact on immune cells.  
These experimental approaches were utilised to elucidate whether the metal implant failure 
is a result of an inflammatory process.  
The genetic disposition to metal hip implant failure was tested by conducting HLA typing 
for 25 different alleles across three MHC class II loci which revealed a protective 
haplotype against implant failure being DQA1*01:02 - DQB1*06. The analysis of immune 
parameters showed that all patient groups had normal levels of immune cell composition 
and cytokine levels apart from the Ultima Asymptomatic group, suggesting a regulatory 
mechanism in place for metal hip implant survival. Analysis of metal particle effect on 
immune cells demonstrated that these particles are immune-reactive and results in 
macrophage-initiated and lymphocyte-mediated failure mechanisms.   
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1 CHAPTER 1: Introduction 
1.1 Definition and burden of Osteoarthritis  
 
Osteoarthritis (OA) is a condition that mainly presents with cartilage damage and pain of 
joints. Early stage OA starts with mild inflammation of the tissue around joints as a result 
of cartilage degeneration. OA is typically defined by the presence of osteophytes (bony 
projections form around joint margins), joint space narrowing, sclerosis, cysts and 
deformity [1]. Over time, osteophytes may impinge on soft tissues causing pain and 
stiffness due to increased surface area. The pain and stiffness may limit mobility. Several 
factors are contributory to the development of OA such as joint injury, obesity, ageing, or 
secondary to other arthropathies. There are differences between aged cartilage and OA 
cartilage indicating that OA is not simply wear and tear but involves complex genetic and 
environmental factors such as excessive load, trauma and injury.  OA is now described as 
a disease of “tear, flare and repair” which encompasses mechanical trauma plus an 
inflammatory process that results in disease progression [2].  
OA is the most common type of arthritis. In the last 7 years, 8.75 million people have 
been treated for osteoarthritis in the UK. This means 33% of people aged 45 years and 
over experience arthritic symptoms. Women are more likely than men to seek treatment; it 
was recorded that 49% of women and 42% of men aged 75 years and over are treated for 
OA in General Practice [3]. OA can occur in any joint, however, the most commonly 
affected are the spine, hand, knee and hip. The knee is the most common site for OA 
followed by the hip with 2.12 million people affected by hip OA (8% of whole population 
aged 45 and over in the UK) [4]. Table 1-1 shows the estimated number of people with 
OA by site of body affected in the UK.  
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Table 1-1: Number of OA patients in the UK by joint site 
The estimated number of people in the UK aged 45 or over with OA, adapted from 
Arthritis Research UK [3] 
Joint Percentage of population Estimated number (million) 
Knee 18% 4.7 
Hip 8% 2.1 
Hand and wrist 6% 1.5 
Foot and ankle 7% 1.7 
Two or more sites 7% 1.7 
 
1.2 Hip Joint Structure and Pathophysiology 
 
The hip joint is a ball and socket joint where the head of the femur (ball shape) articulates 
with the hip bone at the socket (acetabulum); a cup-like depression on the surface of the 
ilium (pelvic bone) Fig 1-1.  The bony articular surfaces of the hip joint are covered by 
cartilage and separated from one another by synovial fluid. The hip joint has three 
components 1) bone tissue 2) cartilage and 3) soft tissue structures around the joint 
(ligaments, muscles, vessel and nerves).  
Progression of hip OA occurs when cartilage loss, disturbance of bone remodelling and 
intermittent inflammation are present. Histological and cellular changes are seen in the 
cartilage, subchondral bone, synovium and ligaments. Cartilage consists of around 5%  
cellular matter (chondrocytes), 65-80% liquid phase (water and ions) and 20-30% solid 
phase (collagen and proteoglycans) [5]. Cartilage matrix is subjected to a dynamic 
remodelling process under normal conditions. Degeneration and regeneration occur in 
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balance such that net matrix volume is conserved in healthy individuals.  However in OA, 
this balance is tipped towards degeneration due to loss of collagen and proteoglycans.  
Although OA can be conceptualised as mechanically driven it is modulated by chemical 
and immunological mediators. Chondrocytes and synoviocytes are the only cells present in 
healthy cartilage, however inflammatory cell infiltration can be seen in OA. It is 
hypothesised that first proteolytic breakdown of cartilage matrix occur. This is followed by 
fibrillation and erosion of cartilage surface. The last stage involves inflammation where 
synovial cells phagocytose cartilage breakdown products and produce inflammatory 
cytokines; this process then attracts more inflammatory cells into the site. 
Degradation and synthesis of cartilage matrix are driven by mediators that are released 
from chondrocytes, synoviocytes and immune cells including matrix metalloproteinase 
(MMPs), cytokines, growth factors and free radicals [6] . Degenerative enzymes such as 
MMPs and aggrecanases are increased in OA cartilage. Particularly MMP1, MMP3 and 
MMP13 and a “disintegrin and Metalloproteinase with Thrombospondin Motifs” 
(ADAMTS) -4&5 have been shown to be involved in cartilage matrix degeneration [7-9]. 
IL-1 and TNF- promote cartilage degeneration by enhancing MMPs synthesis, 
prostaonid synthesis and chondrocyte apoptosis [10]. Several other cytokines including IL-
6, IL-15, IL-17, IL-18, IL-21, IL-8 and leukemia inhibitory factor  have also been shown to 
be important in OA [11].  On the other hand the growth factors are found to promote 
cartilage repair through down-regulating the expression of IL1 receptor, such as IL-1 
receptor antagonist (IL-1ra), soluble cytokine receptors (TNF receptor I &II) and anti-
inflammatory cytokines such as IL-4, IL-10 and IL-13 [12]. Tissue inhibitors of 
metalloproteinases (TIMP), Type II collagen and proteoglycans that lead to chondrocyte 
proliferation, can also counteract disease progression [13]. 
- 4 - 
 
 
Figure 1-1: Structure of the hip joint 
Anterior view showing hip structure and its anatomical components. Right side of the 
illustration representing natural left hip including pelvis and femur. Left side of the 
illustration representing right hip with an artificial total hip implant in place (illustrated by 
Paul Pople at Creative Designs, Norwich, UK). 
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1.3 OA diagnosis and therapeutic options 
 
OA can be diagnosed pathologically, radiologically, clinically or by a combination of 
these. The symptoms of OA can vary from patient to patient and the severity of symptoms 
does not always correlate with the radiological assessment. Because not all people with 
radiographic OA have clinical symptoms and not all persons who have joint symptoms 
demonstrate radiographic OA [14]. These differences may indicate varied sub-groups of 
clinical development.  
The American College of Rheumatology established the current classification of hip OA 
based on clinical and radiographical criteria in 1991 [15]. The diagnostic and therapeutic 
criteria are designed to separate patients with hip OA from patients with other joint 
diseases. It also identifies asymptomatic OA from symptomatic OA based on 
histopathological and radiographical changes. Clinical criteria include the history of the 
patient, pain score, and physical examination to assess range of motion in the hip. 
Radiological evaluation consists of findings such as narrowed joint space, sclerosis, 
formation of osteophytes and cysts. Laboratory tests include the Erythrocyte 
Sedimentation Rate (ESR) and Rheumatoid Factor (RH). These two parameters are 
significantly increased in Rheumatoid arthritis but not in Osteoarthritis.  
By this classification patients with OA are distinguished from other arthritidies and 
deformities. Furthermore, OA patients are classified into a) Idiopathic OA of the hip b) 
Idiopathic generalised OA, including hip c) Secondary OA of the hip (caused by another 
disease or condition).  
Similar to other arthritic conditions there is no cure for OA. The therapeutic approach is 
often based on managing symptoms. Treatment options can be categorised into one or 
more of the following [16];  
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1) Life style based approaches; losing weight, exercising and physiotherapy.   
2) Analgesic administration; paracetamol and non-steroid anti-inflammatory drugs 
(NSAIDs) and disease modifying osteoarthritis drugs (DMOADs), that inhibit matrix-
metalloproteinases (MMPs), bisphosphonates, cytokine blockers, calcitonin, inhibitors of 
inducible nitric oxide synthase (iNOS), doxycycline, glucosamine, and diacereine [17].  
3) Local administration of corticosteroids and visco-supplementation 
4) Surgery; usually total joint replacement.   
Hip replacement is considered when all alternative therapies have failed. Two different 
approaches are possible for a hip replacement; resurfacing or Total hip replacement (THR). 
Resurfacing surgery only replaces acetabular component where the head of the femur is 
reshaped and resurfaced with an artificial cup. However, total hip replacement involves 
removing the femoral head and replacing it with an artificial one, then the artificial femoral 
head is secured by a stem into the marrow cavity (Fig 1-1).  Resurfacing is often preferred 
in younger patients as the larger head size reduces the risk of dislocation. It can also, 
theoretically, allow the patient to return to a higher level of physical activity. Leaving more 
bone also may make subsequent revision easier. All resurfacing arthoplasty prosthesis 
currently on the market are metal-on metal (MoM). However the majority of hip 
replacement surgery comprise of THR; only around 1% of the hip surgeries were 
resurfacing in 2012,  a decline from 9% in 2005 [18].  
Some THRs are fixed with bone cement, polymethylmethacrylate (PMMA) at the bone-
implant interface (acetabular or stem compartments or both). A prosthesis where one of its 
components is fixed with cement and the other is cementless is called a hybrid implant. 
Different parts of a hip prosthesis are shown in Fig 1-2. Where the head of the hip implant 
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meets the cup is described as the bearing surface. The bearing surfaces can be made of 
metal, polyethylene or ceramic. The five main categories of bearing surfaces for THR are; 
1) Ceramic-on-Ceramic (CoC): both the head and the cup are ceramic 
2) Ceramic-on-Metal (CoM) : ceramic head with a metal cup 
3) Ceramic-on-Polyethylene (CoP): ceramic head with a polyethylene cup 
4) Metal-on-Polyethylene (MoP) : metal head with a polyethylene cup 
5) Metal-on-Metal (MoM): both the head and the cup are metal 
This categorisation describes bearing surfaces only, however, metal alloys are also used in 
other parts of the implant such as stem and acetabular shell.  
Implant selection depends on various factors, such as the patient’s age, activity, underlying 
hip physiology and the surgeon’s preferences. For many years the choice of bearing was 
MoP, however, long term experience from implant registries has shown that frequent 
failure was seen with these implants in the second decade due to polyethlyne wear. This 
prompted a switch to MoM use for young patients to reduce the risk of wear in the long 
term. Metal bearings allow use of larger femoral head sizes (36 mm or larger) which more 
resemble a natural femur head and acetabular socket [19]. Ceramic combinations of 
bearings are harder than metal, therefore, they display better wear characteristics. 
However, these types of bearings experienced fractures and squeaking from the site of the 
implant. Tribology of manufacturing has been much improved in recent years and 
historical problems faced with implant design have been reduced currently.   
The National Institute for Health and Care Excellence (NICE) technology appraisal 
guidance, February 2014 [20], recommends that “Prostheses for total hip replacement and 
resurfacing arthroplasty are recommended as treatment options for people with end-stage 
arthritis of the hip only if the prostheses have rates (or projected rates) of revision of 5% or 
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less at 10 years ”. Performances of hip prosthesis are monitored by a panel of experts 
known as the Orthopaedic Data Evaluation Panel (ODEP). ODEP provides the NHS with 
an approved list of prosthesis that meet the revision rate standards set out in the NICE 
guidance.  
 
1.4 Metal/Metal-on-Metal hip implant failure 
 
The majority of hip implants perform well and improve the lives of millions of people 
every year. In the UK alone around 90,000 hip replacements were conducted in 2012 
amounting to around half-a-million procedures since the records started in the UK, 
according to the 10
th
 annual report published by National Joint Registry (NJR) for 
England, Wales and Northern Ireland 2013 [18].  
One of the earliest hip designs had a MoM bearing (McKee-Farrar THR). Due to poor 
machining and subsequent wear-related problems this fell out of favour for MoP designs. 
In the 1990s MoM implants were reintroduced with the aim of increasing longevity by 
reducing wear. It was thought that better manufacture would overcome the previous 
problems. However, metal wear debris-associated hypersensitivity was reported [21-24] 
leading to implant failure from severe tissue reactions. These adverse effects seen in the 
peri-prosthetic tissue requires a revision surgery where MoM implant replaced with an 
alternative type of implant. Patients with a failed MoM prosthesis can suffer from groin 
pain, swelling, squeaking, heat at implant site and the need for an early re-replacement 
operation due to bone and soft-tissue degradation around the implant. In the UK in 2012, 
over 10,000 hip revisions were carried out, equating to 12% of all hip operations. The 
revision burden is now increased compared to previous years and aseptic loosening is 
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reported as the most common reason (40%) for revision surgery followed by adverse soft 
tissue reaction (13%) and infection (12%) [18].  
The revision rate following primary MoM hip replacement between 2003 and 2010 in the 
UK was 13.61%. This is around three times higher than non-MoM bearings at 7-year 
follow-up [19]. The use of MoM articulations has declined dramatically from 10.8% in 
2006 to 1.3% in 2012. Currently MoP is the most frequently used articulation type 
followed by CoC and CoP. The rapid decline of MoM bearings continues in the UK [18]. 
However, data from the USA indicates that 35% of artificial hips still having a MoM 
bearing [25].  
The 2010 NJR report demonstrated that MoM articulations had an unexpectedly high 
implant revision rate compared to non-MoM THR [19]. Since then several MoM 
articulation systems have been recalled by the manufacturers. The UK Medicine and 
Healthcare products Regulatory Agency (MHRA) issued an alert for all types of MoM hips 
recommending that patients to be followed up regularly by an orthopaedic surgeon [26]. 
MHRA advice was updated in 2012 and superseded previous guidelines [27]. The latest 
recommendation in guidance is that all patients implanted with a MoM articulation must be 
followed up annually for life by  
a) Measurement of cobalt and chromium ion levels in whole blood 
b) Performing cross sectional imaging including MRI or ultrasound 
c) Monitoring pain, soft tissue reaction, fluid collection or tissue masses 
If the imaging is abnormal and metal ion levels are rising, then revision surgery should be 
considered.  
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The Norwich metal-on-metal study group first reported issues concerning MoM implants 
particularly with the Ultima
®
 MoM THR TPS, (DePuy Synthes, Leeds UK) in 2006 [28]. 
Follow up studies of a large cohort of patients, (Donell et al 2010) from the Norfolk and 
Norwich University Hospital (NNUH) showed that the Ultima
®
 system had a high early 
failure rate (13.8 %)[29]. The latest data (October 2013) on this implant type shows a  
27. 4% failure rate with a mean time of revision of 6.7 years (Ebreo et al 2014, 
unpublished data).  
 
The Ultima
®
 THR is a modular hybrid system, Cobalt- Chromium- Molybdenum (Co-Cr-
Mo) alloy with a Tapered polished stem (TPS). A cemented low carbon femoral 
component with a 28mm Co-Cr-Mo acetabular bearing surface is secured in a titanium 
(Ti) alloy uncemented shell (Fig 1-2). During the revision operations it was noted that the 
bearing surfaces were macroscopically undamaged whereas corrosion was seen in the 
stem where it is in contact with acrylic bone cement (Fig 1-3). An unusual clinical 
presentation in this cohort was groin pain in the presence of normal radiographs. 
Collections of fluid around a pseudocapsule of the hip seemed to be causing the pain as it 
was relieved temporarily after aspiration. Furthermore, soft tissue changes were consistent 
with a fluid collection. Necrosis of surrounding tissue was found associated with metal 
released from the stem surface. Histological examination showed diffuse or nodular 
lymphocytic infiltration with many macrophages present [29].  
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Figure 1-2: Ultima
®
 THR TPS 
A photograph showing the components of the implant.  
 
Figure 1-3: Photograph of an explanted Ultima
®
 stem.  
Shows severe corrosion at the interface of the stem and acrylic cement.  
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Failure of MoM THRs has been attributed to the following reasons;  
a) Implant positioning  
High metal loss due to poor surgical technique resulting in misalignment of components 
have been reported; an abnormal inclination of the acetabular component can cause 
impingement on the neck of the femoral implant leading to wear [30]. The friction between 
the edge of the cup and the head generates metallic debris termed edge-loading. Edge-
loading is most pronounced during physical activities, hence it is believed to be more 
prevalent in younger patients. The association between metal ion levels in blood and cup 
inclination was reported to be exponential [31].   
Malpositioning in large MoM bearings usually involves cup inclinations above 50° and/or 
anteversion above 15° [32]. However, in the Norfolk cohort the majority of patients had an 
acetabular inclination within the safe zone. The Ultima
®
 THR TPS system has shown signs 
of wear mainly on the stem and not on the bearing surfaces, therefore, position related 
factors are unlikely. This implant was placed by three experienced surgeons with a well-
established track record of THR surgery. Only the Ultima
®
 THR TPS had an 
unprecedented frequency of failure whereas other MoM articulations implanted by these 
surgeons performed well.  
b) Implant material-related factors  
Tribology is the study of two surfaces in relative motion and their interactions. In the 
implant field, triboloy takes into consideration friction, lubrication and wear of the bearing 
surfaces. Implant tribocorrosion is a degradation process due to the combined effect of 
wear and corrosion resulting in the production of bioreactive species. Whilst wear is 
mechanical, corrosion is a chemical or electrochemical process. Wear may accelerate 
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corrosion and vice versa. Implant wear depends on the structure of the tribological system 
which means the properties of the material and environmental factors all contribute to wear 
generation. Considering a commonly cemented THR, there are two dominant types of 
wear; reciprocating sliding, and fretting.  These have been shown to occur at the bearing, 
head-neck and stem-cement interfaces.   Several wear mechanisms are known including 
abrasion, surface fatigue, adhesion and tribochemical reactions induced by the tribology. 
These result in changes in surface chemistry and tribofilm formation [33, 34]. Studies have 
suggested that the mechanism of MoM wear at the bearing interface is governed by 
predominantly tribochemical reactions and surface fatigue resulting in abrasion of the 
surfaces [35, 36]. Recent studies have shown that degradation of MoM bearings is a 
tribocorrosive process; wear is not the full picture.  Studies by Hesketh et al suggested that 
wear accounts for 86% of the total material loss, with corrosion accounting for the 
remaining 14% [37].  
Tribocorrosive mechanisms do not only occur on the bearing surfaces but has also been 
shown to be an important consideration at the stem-cement interface. Bryant et al showed 
that fretting and crevice corrosion at the stem-cement interface were the major reasons for 
adverse tissue reactions and subsequently large failure rates of the Norwich Ultima TPS 
MoM patient cohort [38, 39]. The mechanism of crevice corrosion was further 
demonstrated using an in vitro system where Co-Cr-Mo alloy specimens were cemented 
with PMMA cement for 7 days. Analysis of the metal-cement interface demonstrated a 
clear distinction between actively corroding areas and the non-corroded sections of the 
stem and corrosion was accelerated with the use of antibiotics and radio-opaque agents in 
cements [40]. Under cyclic loading conditions, corrosion was seen to be dominant at this 
interface with thick layers of blackening (tribological layer) observed, primarily consisting 
of Cr2O3 mixed with organic material, most probably derived from synovial fluid (SF).  
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Co-Cr-Mo alloys are passive in nature and spontaneously form a protective oxide layer. If 
the oxide layer is broken down by mechanical wear or corrosion, the base alloy is 
susceptible to rapid electrochemical oxidation [37]. Under friction the passive film is 
continuously removed and reformed allowing galvanic coupling between active and 
passive areas resulting in an increase in corrosion.  Electrochemical tests on the Ultima
®
 
stem demonstrated that 66-80% of all metallic ions released into the bulk environment 
originated from the stem-cement interface [41]. Galvanic corrosion caused by the 
combination of a Ti alloy shell and Co-Cr-Mo alloy stem has been reported for other MoM 
implants where incompatible metals with different electrode potentials come into contact 
in an electrolyte resulting in one metal corroding another [42].  
The literature indicates that total material loss from MoM implants is a combination of 
mechanical and electrochemical process. Using cement exacerbates this degradation.  
 
c)  Patient related factors 
The Ultima
®
 THR TPS population can be divided into two subgroups; successful and 
unsuccesful.  This raises the question of whether patient-related factors are important. 
Biological disposition can initiate an immune reaction to the metal wear debris in the 
unsuccesful patients. This thesis examines this third factor by investigating the 
immunological mechanisms behind the high revision rate that seen in the Ultima
®
 THR 
TPS cohort in Norwich.  
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1.5 Chemistry of Co-Cr-Mo alloys  
 
The Co-Cr-Mo alloys supplied to the manufacturer for surgical implant production must 
conform to a certain chemical composition. The American Society for Testing and 
Materials (ASTM) provides these specifications and sets the standards for medical 
products. The Ultima
®
 THR TPS is an ASTM F799 wrought metal alloy product and 
chemical composition is shown in the Table 1-2. The main metal elements in the Ultima 
are chromium (max 30%) and molybdenum (max 7%), nickel (max 1%), iron (max 0.75%) 
and cobalt. The latter is used to balance up to 100%, approximately 60% of the total 
composition.  
Table 1-2: Chemical composition of Ultima alloy 
Chemical composition of Ultima alloy  according to ASTM F799  
(modified from ASTM original standards document for F799) 
 Min (%) Max (%) Permissible 
variation (%) 
Chromium 26.0 30.0 0.30 
Molybdenum 5 7 0.15 
Nickel - 1.0 0.05 
Iron - 0.75 0.03 
Carbon - 0.35 0.02 
Silicon - 1.0 0.05 
Manganese - 1.0 0.03 
Nitrogen
&
 - 0.25 0.02 
Cobalt
#
 Balance N/A N/A 
& If N < 0.10, contents don’t have to be reported 
# Approximately equal to the difference between 100% and the sum percentage of the 
other specified elements. The percentage of cobalt by difference is not required to be 
reported.  
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Transition metals such as nickel (Ni) are known to be immune sensitisers with a low 
molecular weight. Ni is the most prevalent contact allergen in the industrialised world. Co, 
Cr and Mo are also transition metals. Cobalt is a naturally occurring element found in the 
environment.  It is a part of vitamin B12 which is necessary for many biological functions 
[43, 44]. Chronic exposure to hard metal fumes of cobalt results in “hard metal lung 
disease” which leads to lung fibrosis [45]. Although the primary sensitising route is the 
respiratory tract, cobalt poisoning is implicated via skin and gastrointestinal tract [46]. A 
large cohort study (n = 3042) involving healthy volunteers showed a median Co blood 
concentration of 0.5g/L with highest levels not exceeding 1.5 g/L. Clinical testing of 
serum Co concentration in MoM patients at an asymptomatic stage and using revision as 
endpoint revealed levels of 20g/L associated with metallosis and osteolysis [47]. 
Chromium is a micronutrient and is essential for biological functions at small doses 
however, the amount that is needed for optimal health is not well defined. Chromium has 
been shown to enhance the action of insulin and is involved in carbohydrate, fat and 
protein metabolism [48]. High doses of Cr are believed to be harmful and chromium 
toxicity depends on its oxidation state with Cr (VI) being 1000 times more toxic than Cr 
(III). While Cr (VI) acts as a toxic ion, Cr (III) has been shown to be antigenic causing 
inflammatory and allergic reactions [49]. Cr (VI) is unstable in the body and reduces to Cr 
(V)Cr (IV)Cr (III) in cells [50, 51] releasing free radicals. The toxicity of Cr may 
result from damage to cellular components during this process. In the blood the majority of 
Cr (III) is bound to proteins such as transferrin, whereas a small proportion is associated 
with low molecular weight proteins. Cr (III) is poorly absorbed and is mainly taken up by 
cells when organically coupled to serum proteins. Peri-prosthetic tissue analysis of failed 
ASTM F75 alloy (as in the Ultima
®
) showed that the majority of wear debris contained 
Cr
3+
 with trace amounts of oxidised cobalt [52]. Also, a further study reported that 
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Chromium (III)-phosphate was the predominant metallic species in the tissues surrounding 
MoM hip replacements, which could have arisen from corrosion, wear or a combination of 
both [53]. 
Molybdenum is found naturally in soil and it is a trace element which is essential for 
human metabolism.  The daily recommended intake of Mo is 0.1-0.3 mg for adults [54] . 
Apart from medical implants Mo is also used in the production of tungsten and pigments. 
Mo is an essential constituent of enzymes that catalyse redox reactions in animals and 
plants. It is a component of coenzymes necessary for the activity of xanthine oxidase, 
sulfite oxidase, and aldehyde oxidase. Mo also form complexes with carbohydrates , amino 
acids, flavins, porphyrins [55]. Excessive dietary intake of molybdenum induces secondary 
copper deficiency that leads to osteoporosis often manifesting in by bone fracture. 
Molybdenum competes with phosphorus utilisation, resulting in reduced mineralisation of 
bone in animals [56].  
Although Co, Cr, Mo are needed for biological functions and materials used in 
orthopaedics hip implants are chosen for their inertness, the dose and valency of these 
elements appear to be decisive factors in whether they are bio-active or not. 
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1.6 Immunnological failure mechanism 
 
Histological examination of peri-prosthetic tissue in failed implant patients has been shown 
to display aseptic lymphocytic vasculitis-associated lesions (ALVAL) characterised by 
tissue necrosis and a dense perivascular lymphocytic infiltrate, also known as lymphocytic 
cuffs, characterised by the absence of infection. After hip implant surgery a neocapsule 
forms around the implant consisting of fibrous tissue, fat, muscle and bone. It is important 
that post-surgical empty spaces are filled by regenerated bone rather than fibrous tissue to 
ensure implant stability.  The neocapsule is contained at the inner surface with the 
pseudosynovial membrane. Studies on surgical tissue from revised MoM patients reveal 
that high lymphocytic infiltration in perivascular tissue is present at the implant-neocapsule 
interface. Surface ulceration of the neocapsule in MoM was reported to be extensive 
compared to well-fixed  MoP implants (Fig 1-4) [57-59]. This phenomenon raises the 
question of whether the immune system is involved in MoM implant failure. The most 
predominant cause of implant failure is aseptic loosening which happens when the bone 
tissue around the implant starts to degrade and loses its mass with histological evidence of 
hypersensitivity. Inflammation and oedema are seen in many patients and are believed to 
be the cause of joint pain. Pseudotumours have been found in 60% of patients both failed 
and well-functioning MoM implants [60] [61]. The pathological spectrum consisting of all 
symptoms and histological findings is collectively described as Adverse Tissue Reaction to 
Metal Debris (ARMD). 
The main concept in the peri-prosthetic osteolysis is that osteo-resorption dominates over 
osteogenesis therefore high rate of bone loss results in aseptic loosening of implants.  The 
effects of metal particles on osteogenesis might be direct via disruption of osteoclast 
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functions or indirect orchestrated by other cells in the area such as fibroblasts, osteoblasts 
and immune cells (Figure 1-5). 
There is some debate about whether the nature of the immune response to particulate 
debris is driven by innate and/or adaptive immune cells [62]. The prevailing view is that 
prolonged exposure to metal debris results in a non-specific and continuous immune 
reaction initially involving innate cells such as monocytes and granulocytes, which may 
self-resolve. However, if such response is persistence, it can result in a more specific T 
cell-mediated response, reported in a subset of patients experiencing implant failure. It has 
been suggested that this might be similar to metal contact sensitivity [63] as seen in 
delayed type IV hypersensitivity [64].  
Metal debris that break away from implants could be in several different forms including, 
particles, colloidal organometallic complexes, inorganic metal salts/oxides and metallic 
ions [65]. The fate of these particles depends on the cell-type they encounter. Clearance of 
metal particles is attempted by phagocytes, mainly neuthrophils, macrophages and 
dendritic cells. Histopathology data from failed implant patients suggests that macrophages 
and lymphocytes are the main immune cells that infiltrate the peri-prosthetic tissue. 
Neutrophil infiltration is not often reported in peri-prosthetic tissue, presumably because it 
might be long passed by the time of sample collection.  
This is also seen in other chronic conditions such as asthma and tuberculosis. Wear debris 
exposure also results in resident cell damage to generate danger signals (DAMPs: damage 
associated molecular pattern molecules) that are recognised by immune cells in the absence 
of any pathogen. This is termed sterile inflammation because large quantity of immune 
cells migrate from blood circulation and infiltrate the inflamed site even in the absence of 
infecting pathogens. This however results in local inflammation and may perturb 
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osteoclastogenesis and/or any regulatory mechanism away from check-points for bone 
homeostatis. Although there is almost no literature on altered regulatory mechanisms in 
osteolysis and subsequent implant failure, in the absence of the negative feedback loop 
from regulatory cells, a pro-inflammatory local response may persists for longer and 
favour osteolysis.  
The chemical elements that cause hypersensitivity in humans often falls into transition 
metals group of the periodic table, such as titanium (Ti), chromium (Cr), cobalt (Co), nikel 
(Ni), molybdenum (Mo) and palladium (Pd). These elements are characterized by their 
valance electrons that are present in more than one atom shell resulting in several oxidation 
states. Metal elements which cause hypersensitivity appear to share common properties; 
for example, the presence of two electrons in the outer atomic shell which allows creating 
coordination sites with organic molecules. How these metal elements are recognised by 
immune cells and how they activate neighbouring resident bone cells are theorised by 
various mechanism.  
In the following paragraphs current understanding of immune system activation by metals 
is discussed; 
1.6.1 Innate recognition of metals 
Macrophages are believed to be the main cell-type involved in response to chronic metal 
exposure, this is because: 
a) As highly phagocytic cells, macrophages promote the clearance of metal debris by 
phagocytosis 
b) Macrophages have been reported to localise in high numbers at inflamed sites in 
peri-prosthetic tissue.  
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c) Mechanistic studies had shown that these cells respond to both metal particles and 
metal ions 
The proposed mechanisms of macrophage activation by metal wear debris include; (i) 
direct ligation of cell surface receptors such as Toll-like receptors (TLRs) and/or  
internalization of metal particles and subsequent intra-cellular processing (Fig 1-5 ii, ii, iv).  
Direct TLR engagement and subsequent macrophage activation was shown with several in 
vitro models. In a mouse model of C57BL/6J, it has been demonstrated that bone marrow 
macrophages incubated with Ti activate and produce of TNF-, IL-1 and IL-6 [66].  
Ligation of TLRs was also reported with Co and Pd in monocyte derived dendritic cells 
(MoDC) through TLR4 ligation shown in TLR4/MD2 transfectant cell lines [66]. Other 
groups also showed TLR4 activation by Co, similar to endotoxin triggered response [67]. 
Using mutant receptor proteins revealed that His 456 and His 458 of TLR4 (non-
conserved) are required for activation by Ni
+2 
[68]. Polyethylene wear particles are also 
shown to upregulate TLR2 in mice models recently [69]. This is an indication of direct 
activation by metal ions without any further ligation requirements. Other TLRs such as 
TLR2, may be involved in particle recognition even though so far only polyethylene 
particles were shown to activate TLRs.  
It should be noted that the readouts measured in the above studies are generally late events, 
downstream of TLR receptor signalling including the induction of cytokine expression 
such as IL-1, IL-6, TNF- and IL-8. Hence it is yet unclear whether metal ions effect 
directly the conformational changes of TLR and/or its signalling.  
Metal particles effects on macrophages viability also have been documented. It has been 
shown that Co
+2
 and Cr
+3
 induce macrophage mortality in a concentration dependent 
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manner in vitro [70]. Short-term exposure (24 hours) of metal ions results in macrophage 
apoptosis at low concentrations (Co
+2
 < 6 ppm, Cr
+2
 < 250 ppm). However increased metal 
ion concentrations (Co
+2
 = 6-10 ppm, Cr
+3
 = 250-500 ppm) with longer exposure (48 
hours) results in macrophage necrosis [71]. This highlights the fact that necrosis is likely to 
be the main mechanism of macrophage death after chronic exposure to high concentrations 
of metal ions. While apoptosis is an active form of cell death and part of the body 
homeostasis, necrosis results in an inflammatory response facilitated by the release of 
proteolytic enzymes, DAMPs and cytokines (Fig 1-5).  
Toxic metal particles/ions enter the cells via several different pathways. Three main 
transport mechanisms are proposed in the literature;  
1) Through non-specific ion transporters followed by metal ion oxidisation in the 
cytosol (Fig 1-5 ii).  
2) Phagocytosis followed by a series of oxidative processes in the phagocytosome 
leading to generation of metal ions and free radicals (Fig 1-5 iii).  
3) Binding to metal-binding proteins such as transferrin and ferritin via the divalent 
metal transporter 1 (DMT1) (Fig 1-5 iv). In the cytosol, metal ions are realised and 
eventually reduced/oxidised [64].  
Metal ion oxidation/reduction generates free radicals such as reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) which are detrimental to cellular function.  
Metal wear debris released from a MoM implant cannot be eliminated by metabolic 
degradation and has to be excreted via the renal or gastrointestinal route. Indeed animal 
studies suggest that Co/Cr ions accumulate in the liver and kidney [72].  Accumulated 
particles can be phagocytised by macrophages [73, 74], leading to cellular toxicity. It is 
thought that macrophages eventually lyse, thus resulting in local inflammation. This 
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recruits more phagocytes and other antigen presenting cells (APC) to the site of metal ion 
accumulation [58, 59], potentially followed by a specific adaptive immune response. After 
the innate recognition of metals, internalised metal ions are thought to be presented by 
macrophages to T cells which results in T cell activation (Fig 1-5 v, vi). Activated T cells 
proliferate and undergo expansion and differentiation into cytokine producing effectors, 
leading to production of RANK-L, M-CSF [75] [76] which meditates transformation from 
pre-osteoclast into osteoclast (Fig 1-5 vii) and this promotes bone destruction. Other T 
cells differentiate into IFN-, IL-6 and IL-10 producing effectors which block osteoblast 
and fibroblast functions (Fig 1-5 viii). Thus, these two T cell mediated mechanisms 
synergistically promote bone damage.  
Fibroblasts recovered from peri-prosthetic tissue in the presence of metal particles have 
shown to affect the differentiation and the bone reposition capacity of osteoclasts [77, 78]. 
Phagocytosis of metal ions by fibroblasts results in RANKL, and TNF- productions two 
cytokine known to be osteoclastogenic, plus differentiation from pre-osteoclasts to 
osteoclast requires cell to cell contact between osteoclast precursors and fibroblasts (Fig 1-
5 x). 
It has been reported that osteoblast are also respond to metal particles. Ti induced IL-8 and 
MCP-1 production from these cells [79]. This activation was time and concentration 
dependent. Mechanistic study showed that the chemokine expression was via NF-KB-
mediated transcriptional activation and controlled by the MAPK signal transduction 
pathway. IL-8 and MCP-1 are both chemoattractant for macrophages, particle induced 
expression of these chemokine would results in macrophage infiltration from periphery 
(Fig 1-5 xi).  
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1.6.2 Adaptive recognition of metals 
T cell activation in presence of metals involves four components: TCR, MHC, antigen and 
metal ions. TCRs recognise their cognate antigens through complementary determining 
regions (CDR) on them. The germ line-encoded residues in CDR loops of the TCR are 
evolutionary conserved for interaction with matched MHC. Therefore metal induced T cell 
activation may be due to an aberration of either the conformational interactions of these 
molecules or the recognition of antigens presented by these molecules in the presence of 
metal ions.  
In general, metal ions lead to the generation of neo-antigens by one of the proposed 
mechanisms. Four different models explain possible T cell recognition of metal ions (Fig 
1.5. v and vi): 
v. a) Metal ion binds at TCR recognition site of MHC molecule involving both peptide 
and MHC polypeptide: The most common hypothesis for non-peptide moieties 
recognition by T cells that they act hapten-like. Haptens are molecules with low molecular 
weight which have the potential to covalently modify proteins therefore they are strong 
inducer of immune system. It is postulated that metal ions are associated with or 
covalently bound to the surface of an MHC-self peptide complex, near to Ag binding 
groove. This interaction creates a new site for TCR interaction which results in T cell 
activation. The exact structure of the “MHC-peptide-metal ion” complex is not known, 
however Yin et al showed that Ni
+2
 becomes part of such ligand [80]. By generating in 
vitro mimotope libraries, as a surrogate for Ni
+2
-reactive T cell epitopes, the authors 
demonstrated that, even in the absence of Ni
+2
, reactive ANi2.3 T cell clone can be 
activated. Depending on a DR52c molecule consisting lysine at p7 position. They have 
shown that this positively charged lysine occupies the same position in the mimotopes as 
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the Ni
+2
 does in the natural complex. In summary, metal ion occupies a space at MHC 
coordination site which results in altered steric conformation leading to neo-antigen 
formation.  
v. b) Modified self-peptide binding to specific MHC molecules: Metal ions bind inside of 
the MHC-peptide binding groove to drastically change the repertoire of self-peptides 
normally bound to MHCs. The continuous presence of metal ions perturbs the loading and 
the stability of self-peptides during endosomal loading skewing the peptide repertoire 
presented by MHC molecule away from cognate self-peptide and providing a site for new 
antigen in the periphery. It has been shown that there is a change in the endogenous self-
peptides bound to MHC II when Be
+2
 complex recognised by HLA-DP2 restricted CD4+ 
T cells in Chronic Berylium disease (CBD). These peptides possess residues of aspartic 
acid at p4 and glutamic acid residues at p7 which represents Be
+2
 coordination sites [81]. 
Metal ion capture in this way can results in conversion of a self-peptide into a neo-
antigen. Creation of neo-antigens in peripheral organs, after thymic selection, can lead to 
non-self recognition and T cell-mediated response. In summary, MHC peptide loading is 
altered which results in aberrant antigen presentation.  
v. c) Transition metal ion interference at inside of the MHC polypeptide: Chelating of 
metal ions alters the structure of MHC molecules / chains. TCR recognise metal-
modified amino acid residues of the MHC molecule itself or metal provokes 
conformational changes potentially in the MHC molecule, effectively providing a new 
structure for different TCRs to bind. It has been shown in the CBD that the TCR does not 
interact directly with the Be
+2
 ion but instead recognizes changes in the surface of HLA-
DP2/peptide complex. This induced by the internally bound Be
+2
 which  by changing the 
MHC polypeptide loops favours the formation of a new TCR ligand coordinated by both 
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MHC and peptide amino acids [82]. In summary, MHC structure is modified which results 
in autoimmune reaction to self MHC molecules.  
vi ) Antigen independent mechanism: Metal ions are sufficient to form a coordination 
complex between the TCR and MHC molecules in a peptide independent manner [83]. 
This model proposes a mechanism independent of requirement for antigen and antigen 
processing. It has been demonstrated that fixed APCs resulted in activation of Ni-reactive 
T cell clones. This scenario is similar to T cell activation by superantigens which bridge 
TCR with MHC molecule independent of the peptide or TCR specificity. However the 
difference from superantigen activation is that metal ion recognition requires a more 
specific contact within the TCR - significantly enhances the specificity of this interaction. 
However the interaction of metal ions between TCR and MHC requires a much more 
specific sequence recognition in the TCR chain than what seen with sperantigens, which in 
contracts can activate many TCR clonotypes. For instance Ni
+2
 hypersensitivity involves 
with the SE9 T cell  clone activation by Ni crucially depends on Tyr29 in CDR1, Tyr94 
in CDR3, and a conserved His81 in the HLA-DR -chain [84]. Thus also the MHC 
sequence is specifically affecting such TCR: MHC bridging coordination products 
mediated by metal ions. Due to positive selection in thymus all peripheral cells possess the 
ability of a short and instable MHC interaction. In the presence of metal ions, self-peptide/ 
MHC molecules may stabilise interactions with TCR, resulting in T cell activation.  
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Figure 1-4: Metal particle associated lymphocytic infiltrate and peri-vascular cuffing 
A representative micrograph of tissue section stained with Hematoxylin and eosin from a failed MoM hip 
implant replacement. A: Displaying demarcated tissue layers of neocapsule Surface layer (Layer 1) shows 
sign of ulceration with loss of the pseudosynovial lining. Subsurface layer (Layer 2), between the tissue 
surface and the vascular layer, contains limited cellular infiltration. Layer 3 displaying vasculated tissue with 
cuff of lymphocytes are present predominantly. (x40 magnification). B: Lymphocytic cuffs with higher 
magnification (x100). Adapted from Davies et al 2005 [56].  
A
B
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Figure 1-5: Proposed model of immune system contribution to metal implant failure. 
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Legend for Figure 1-5: Macrophages can be activated directly by metal particles via TLR 
receptors on them (i) or internalisation  of these particles are mediated by various 
mechanism such as through ion transporters (ii), through phagocytosis (ii) or through 
DMT1 (iv) which all can lead to macrophage activation. On the other hand metal particles 
can also be toxic to macrophages, resulting in necrosis of these cells. Necrosis will lead to 
production of pro-inflammatory mediators and subsequently, infiltration of newly recruited 
peripheral macrophages. Macrophages and other APCs are involved in altered antigen 
presentation to T cells in the presence of metal ions (v). T cells also can be directly 
activated via metal particles (vi). Activated T cells produce cytokines such as RANKL and 
MCSF facilitate osteoclast formation (vii). Subset of T cells thought to have inhibitory 
effects on tissue resident cells such as Fibroblast and Osteoblast (viii), which slow down 
tissue formation. Direct particle exposure to osteoclasts results in differentiation of pre-
osteoclast to activated osteoclast (ix). Fibroblasts can activate osteoclasts either by 
cytokine mediated manner or cell to cell contact (x). The other tissue resident cells such as 
osteoblast also are involved in osteoclast activation and further recruitment of 
macrophages through cytokine and chemokines (xi), which result in bone resorption. This 
cascade of pathways, perhaps all not mutually exclusive result in perturb bone homeostatis 
therefore osteolysis that seen in metal hip implant failure.  
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1.7 Hypothesis and Aims 
 
This thesis set out to test the following hypothesis; 
Metal implant wear debris modifies the function of antigen presenting cells (APCs) leading 
to the activation of T cells that results in inflammation and destruction of bone tissue 
causing implant failure.  
The hypothesis has been tested by addressing the following aims. 
1. To define the HLA allele types in Ultima patients; 
Do the patients with failed metal implants have different HLA genotype, predisposing to 
metal hip implant failure? HLA genotyping was aimed at identifying whether there is 
allelic variation between failed versus well-functioning hip implants. Identifying the 
distribution of MHC alleles would be the first step towards understanding adaptive 
immune response in metal hip implant failure (Chapter 3), as most likely adaptive 
responses could be MHC-restricted. 
2. To determine If Adverse Reactions to Metal Debris (ARMD) an inflammatory 
process; 
What is the evidence of immune system dysregulation in the Norfolk cohort? Immune 
cells composition and activation status were investigated in the Norfolk cohort of Metal-
on-Metal (MoM) patients. Cytokine and growth factors were analysed in serum and 
synovial fluid of these patients (Chapter 4). Any difference in cytokine levels or activation 
status of the cells may suggest an inflammatory ongoing in vivo response to metal hip 
implants.  
3. To investigate if immune cells mount a response to implant wear debris? 
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The impact of the Ultima wear-particles on peripheral blood mononuclear cells (PBMCs) 
was determined by investigating phagocytosis, proliferation and cytokine production 
profile upon exposure to Ultima particles in vitro (Chapter 5).  
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2 CHAPTER 2:   Study Protocol 
 
2.1 Obtaining ethical approval 
 
The National Research Ethics Service (NRES) facilitates ethical review through its 
Regional Ethics Committees (REC) based across England. The application for research 
ethics approval was made via the Integrated Research Application System (IRAS), which 
is an online file management system for completion of all required documentation. After 
registration and completion of the IRAS forms, the application was accompanied by the 
research protocol and supporting documents including but not limited to Patient 
Information Sheets (PIS), Consent Forms, Invitation Letter, GP Information Letter, 
Contracts with the sponsor and the funder, Investigator’s CVs and Standard Operating 
Procedures (SOPs) where relevant (Appendix 1). A “favourable opinion” for the study was 
gained in February 2012 by Cambridge East REC, reference number 11/EE/0488.  
It was also necessary to obtain ethical approval for procuring blood samples from healthy 
volunteers for assay development and in vitro assessment. This required approval from the 
local UEA Faculty of Medicine and Health Sciences (FMH) Research Ethics Committee, 
which was approved in January 2012, reference number 2011/2012-13.  
This study was registered in the clinical trials website as per the funder’s (DeyPuy Synthes, 
UK) terms and conditions, reference number NCT01517737.  Details can be found at  
http://clinicaltrials.gov/ct2/show/NCT01517737?term=2011+Orth+04S+%2868-06-
11%29&rank=1 
This prospective cohort study was also approved by the Research Governance Committee 
of the Norfolk & Norwich University Hospital and conducted in accordance with the 
Declaration of Helsinki.  
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Laboratory experiments were conducted in Institute of Food Research (IFR), Norwich UK. 
The study was approved by IFR Research Governance Committee (March 2012).  
2.2 Patient Recruitment 
 
This study was designed to investigate the immune system involvement in MoM Ultima
®
 
THR TPS implant failure. The other type of metal implants were also studied as control 
including the MoP and MoC since NJR data suggest that MoM implants are three times 
more likely to fail compared to other types [19]. Patients undergoing primary or revision 
total hip replacement were recruited at the NNUH Orthopaedics Department during their 
routine visit to hospital. Whole blood, serum and synovial fluid were collected from these 
patients. Non-operative patients were recruited in the Outpatient Clinic during routine 
follow-up and asked to donate blood samples only.  
Patient Inclusion Criteria:  
- Undergone an Ultima® TPS THR in Norwich  
- Ultima® TPS THRs undergoing revision  
- Undergoing primary hip replacement with osteoarthritis  
- Other metal THRs undergoing revision  
Patient Exclusion Criteria:   
- Undergoing primary THR with rheumatoid arthritis 
- Other inflammatory arthritides  
- Secondary infection 
- Taking immunosuppressant medication 
- Unable to provide informed consent 
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2.3 Patient recruitment number and study power 
 
It is not well established as to which immunological parameter is the most relevant 
biomarker in diagnosis of metal implant failure. So far blood ion levels are the best wet-
biomarker available for clinicians. For this reason serum metal ion levels were used to 
calculate the sample size for this study; considering the view that elevated serum ion levels 
are an indication of metallosis leading the implant failure. 
Null hypothesis: Metal ions released from failed MoM implants are NOT different than 
non-MoM implants.  
A power test was performed to ensure that the study was adequately planned and the 
appropriate number of patients was recruited. Statistical considerations for a parallel 
testing were utilised using the online tool at 
http://hedwig.mgh.harvard.edu/sample_size/js/js_parallel_quant.html 
For this calculation the following factors were considered.  
 Probability of type I error (false positive) = p < 0.05 
 power — the probability of avoiding Type II error (false negative) = 80% 
 the effect size that study should be able to detect; difference between control and tested 
patients  
 : Standard deviation in the population (between subjects) =1 
Zα: Z is a constant (set by convention according to the accepted α error =1.96 (2-sided, 5%)  
Equation 2-1: Formula for sample size calculation for parallel studies 
     
     n = 2 (Z + Z )
2
 2 /2 
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Metal ion concentrations in the blood were used to established study effect size. Maroni et 
al compared MoM with normal controls and found the effect size to be 1.7 for chromium 
[85]. Pretest power analysis, performed by using one standard deviation of the control 
subjects, indicated a sample size of 14 had an 80% power to detect a difference between 
groups and sample size of 18 gave 90% power. As for the quantification of soluble 
biomarkers in serum and synovial fluid, Osteoarthritis Research Society International 
(OARSI) & Food and Drug Administration (FDA) guidelines were followed [86]. Based 
on 2-sample t-test (2-sided  = 0.05) effect size: 1.23 with 2 SD. The number needed was 
15 per group provided 90% of study power whereas 12 patients per group provided 80% 
study power. Therefore it was aimed to recruit between 12-18 patients/per clinical group.  
 
2.4 Patient demographics 
 
A total of 56 patients were recruited for this study. The patient’s demographics are 
depicted in Table 2-1. The study cohort was stratified into four groups according to the 
radiological screening and clinical status as follows;  
1. Pre-Implant group: OA patients that have no metal implant and undergoing primary 
hip replacement (n = 15) 
2. Ultima Asymptomatic group:  OA patients that have an Ultima implant and 
tolerating well (n = 17) 
3. Ultima Symptomatic group: OA patients that have a failed Ultima implant and 
awaiting a revision operation (n = 12) 
4. Other Symptomatic group: OA patients that have another type of failed metal 
implant and awaiting a revision operation (n = 12) 
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Table 2-1: Patients Demographics 
 Pre-Implant Ultima 
Asymptomatic 
Ultima  
Symptomatic 
Other  
Symptomatic 
Clinical 
Status 
No implant 
present 
Implant 
present, not 
failed 
Implant 
present, failed 
and revised 
Implant 
present, failed 
and revised 
Number 
Recruited  
15 17 12 12 
 
Mean age  
(in years  
with range) 
 
70 (41-83) 
 
68 (55-84) 
 
64 (45-80) 
 
70 (54-86) 
 
M/F ratio 2/13 10/7 8/4 5/7 
 
In situ implant 
time  
(months ± SD) 
 
N/A 
 
130 ±26 
 
139±23 
 
123±54 
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2.5 Human Tissue Collection  
 
Operative patients were identified from the NNUH institutional database (Bluespier Int, 
Worcs, UK) by a member of the clinical team. Outpatient patients were recruited during 
their hospital visit to routine MoM clinics run by consultant orthopaedic surgeons at the 
NNUH. Patients were approached to provide informed consent for collection and analysis 
of blood and synovial fluid at the time of providing consent for their surgical procedure by 
a member of the clinical team. For the outpatients group, 50 mls of blood was collected. 
For the operative groups, 50mls of blood was obtained from each patient in the anaesthetic 
room. Blood sampling was performed using standard venepuncture techniques with a 
Vacutainer system (Becton-Dickinson). Samples were aspirated into glass silicone tubes 
for serum assay, Na-Heparin tubes for PBMC analysis, K2EDTA for immunophenotyping, 
HLA typing, and trace element analysis. Intra-operatively once the capsule of the hip joint 
had been identified, synovial fluid was aspirated via a 21G stainless steel needle through 
the capsule so as to prevent contamination with blood from the general circulation. 
Synovial fluid was transferred aseptically to a Na-Heparin tube for further analysis.  
Down-stream processing of samples and details of data analysis are described in the 
relevant chapters.  
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3 CHAPTER 3: Role of HLA molecules in immune responsiveness to metal hip 
implants 
3.1 Introduction  
 
MHC molecules in humans are named Human Leukocytes Antigens (HLA). Following on 
from earlier mouse work involving  recognition of the differential antigens responsible for 
tumour rejection led to the discovery of the first human HLA antigen [87] . In 1958 three 
separate groups published [88] [89] [90] their findings studying sera from multiple blood 
transfused donors showing the antisera detecting alloantigens on human leucocytes. The 
discovery of HLA molecules is attributed to Dausett and his associates who received the 
Nobel Prize in 1980 sharing with it Snell and Benacerraf. This led to our understanding 
that human leukocytes possess mismatched determinants (antigens) that mount an immune 
response.  
HLA tissue mis-matching was initially noted in organ transplantation where allogenic 
MHC molecules of a donor were recognised by the recipient’s immune system leading to 
graft-versus-host disease and therefore resulting in transplant failure [91] . Vredevoe et al 
first showed the positive correlation between HLA matching and kidney allograft survival 
in 1965 [92].  Even though earlier work by many groups had shown that HLA molecules 
possess strong histocompatibility antigens [87] , the immunobiological functions of MHC 
molecules were demonstrated using mouse models. Mozes and McDevitt et al used a 
mouse model which had eight different HLA serotypes of different genetic backgrounds 
[93]. On injection of synthetic antigens only certain MHC serotypes of mice responded 
strongly to the antigen whilst other mice did not; even though each sero-group of mice 
had different genetic backgrounds. From control experiments, including using those 
different antigens, serotypes and different strains of mice, it was concluded that genes 
linked to the HLA-complex control the immune response. It was also postulated that, 
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either there are multiple HLA gene loci, or a single gene locus expresses many alleles. 
Using modern investigation tools, we now know that both assumptions were true.  
The actual function of HLA molecules was not elucidated until the1970s. It was first 
shown that T cells and B cells were involved in MHC compatibility [94]. Then the same 
was true for macrophage MHC antigens [95] highlighting the requirement for 
histocompatible macrophages and lymphocytes. T cell recognition of an antigen directly 
involves the MHC-complex termed MHC restriction which was first demonstrated by 
Doherty and Zinkernagel [96, 97]. 
Even though traditionally the role of MHC molecules is associated with adaptive 
immunity, our current understanding of MHC molecule’s role in innate immunity is also 
expanding. The evidence suggests that MHC class II molecules synergize with TLR-2 and 
TLR4 in inducing an innate immune response where MHC-II knock-out mice shows 
reduced responsiveness to ligation of these receptors [98]. The mechanism of MHC 
involvement in innate immune response was elucidated where MHC class II deficiency 
resulted in attenuated development of endotoxic shock. Intracellular MHC class II 
molecules interact with the Btk (thyrosine kinase) via the costimulatory molecule CD40 
and maintains Btk activation. The Btk interacts with adaptor molecules MyD88 and TRIF. 
The absence of this interactions results in defective TLR signalling [99].  Therefore, 
intracellular MHC class II molecules can act as adaptors, promoting full activation of TLR-
triggered innate immune responses. These finding highlight the fact that apart from central 
role in adaptive immunity MHC molecules are also important in innate inflammatory 
response.  
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The genes encoding the HLA molecules are mostly located on the short arm of 
chromosome 6. HLA molecules are key immune determinants and an individual possesses 
a particular HLA type. HLA type and its disease association have been well described for 
some time now. This has led to an understanding that a wide range of autoimmune and 
malignant diseases occur more frequently in individuals with a certain HLA haplotype. 
The HLA molecules can mediate disease-promoting effects by presentation of modified 
disease-triggering peptides. On the other hand, HLA molecules can also be protective by 
promoting regulatory cells thus resulting in homeostasis. HLA association has been shown 
to have diagnostic value in clinics where the relative risk value (disease frequency among 
individuals carrying associated MHC antigens) is well established in several conditions 
(e.g. HLA-B27 and ankylosing spondylitis).   
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3.1.1 MHC Genetic organisation and structure  
 
The MHC can be divided into three genetic loci;  
a) Class I  containing HLA-A, B, C loci 
b) Class II containing HL-DR, DQ, DP loci 
c) Class III containing non-classical HLA genes of immune function such as TNF, 
complement factors, and heat shock proteins. 
By the early 1980s, it was generally understood that there were at least six different series 
of determinants (loci) causing variation in HLA types. Molecules A, B and C are present 
on most nucleated cells and are named Class I, whereas DR, DP and DQ are mainly 
present on antigen presenting cells and named Class II. These six main loci are now called 
classical HLA antigens. Since then other antigens have been discovered with more limited 
tissue distribution. These newer HLA molecules are not routinely involved in antigen 
presentation and are named non-classical HLA (class III) molecules. 
 
The MHC class I molecule is a heterodimer consisting of two polypeptide chains; an  
and a 2-microglobulin chain. The  chain contains 3 domains, 1, 2 and 3; the 3 
domain spans through the cell membrane and is non-covalently bound to 2-
microglobulin. The 3 domain and 2-microglobulin show similarities to immunoglobulin 
C domain and have similarly folded structures. However the 1 and 2 domains fold 
together into a single structure (Fig 3-1 A). The folding of 1 and 2 creates the peptide 
binding groove for MHC class I molecules (red in Fig 3-1 A).  
MHC class II molecule is also a heterodimer consisting of 2  and 2  domains. However, 
the MHC class II molecule has two trans-membrane glycoprotein chains (Fig 3-1 B). Each 
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chain has two domains and two chains which together form the four domain MHC class II 
structure. Again 2 and 2 domains are similar to the immunoglobin C domain where 
these two span through the cell membrane. The MHC class II molecule peptide binding 
groove is comprised of 1 and 1 chains (Fig 3-1) are formed by different chains and 
therefore not covalently bonded. The peptide binding groove sits on 1 and 1 chains (red 
in Fig 3-1 B).  
 
Genes encoding the  chains of MHC class I molecules and the  and  chains of MHC 
class II molecules are linked within the complex on the short arm of chromosome 6 
whereas the genes for 2-microglobulin of MHC class I complex are on chromosome 15 
with the invariant chain of the MHC class II complex located on chromosome 5.  
Different alleles of MHC class molecule have specificity to bind different peptides. 
Allelic variation occurs only at specialised sites within the MHC molecules. In the MHC 
class I molecule, both 1 and  chains display polymorphism. However within the MHC 
class II DR molecule only the  chain is significantly polymorphic; the DR  chain 
virtually invariant. As for the DQ and DP molecules, both 1 and 1 chains displays 
variation at the peptide binding groove [100, 101]. 
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         A                                                                      B                                                
 
 
Figure 3-1: Structure of MHC class I and MHC class II molecules 
A) Schematic depiction of MHC class I molecule. Top panel showing a ribbon diagram of 
subunits for MHC class I molecule. It is composed of two polypeptide chains, a long  
chain and a short  chain (2-microglobulin). Peptide binding groove consist of two α 
helices forming a wall on each side and eight β-pleated sheets forming a floor. Bottom 
panel is showing MHC I molecule interaction with cell. Transmembrane3 domain of the 
molecule anchors to cell. Peptide binding region shown in red where most of the allelic 
variation occur B) MHC class II molecule is composed of two polypeptide chains.  Top 
panel showing a ribbon diagram depicting protein structure of subunits. 1 and 1 
domains consisting of peptide binding groove. Bottom panel displaying transmembrane 
region (2 and 2 domains). Peptide binding regions marked in red (Illustrated by Paul 
Pople at Creative Designs, Norwich, UK). 
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3.1.2 HLA Polymorphisms 
 
MHC genes are highly polygenic and polymorphic giving immune cells an advantage in 
recognising many different antigens and differentiating self from non-self. MHC genes are 
the most polymorphic genes in humans indicative of their rapid and constant evolution. 
Much of the allelic variation is limited to the peptide binding groove. The number of 
alleles assigned to different HLA molecules is ever expanding. The number of alleles that 
have been assigned by World Health organisation (WHO) as of July 2014 are shown in  
Table 3-1.  
 
Table 3-1: Number of HLA Alleles 
HLA Alleles assigned by WHO as of July 2014 [102] 
 
HLA Class I Alleles 8,976 
HLA Class II Alleles 2,870 
Other non-HLA Alleles 
(MICA, MICB, TAP1, TAP2) 
164 
Number of confidential Alleles 
(waiting to be published) 
4 
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3.1.3 HLA Nomenclature 
 
The WHO oversees the coordination of the nomenclature for HLA typing. An example is 
as shown in Fig 3-2 [103] which was used for genotyping in this study. Each allele has a 
unique number corresponding to a specific allele with up to four sets of digits separated by 
colons. Each section separated by a colon is called a “field”. The length of the allele 
designation depends on the sequence of the allele and its nearest relative. Most of the 
alleles are named up to field 1 and field 2. Longer names are used if necessary to separate 
it from close relatives. The first field describes the allelic group, the second and so on 
describe the specific allele. These numbers are assigned for a specific DNA sequence to 
determine allelic classification. If it differs in amino acid sequence of the encoded protein, 
another number is then assigned. The third field shows alleles that differ for synonymous 
nucleotide sequences within the coding region whereas field 4 indicates the differences in 
the untranslated region. A number in field 4 may have a suffix attached to it such as N for 
Null or S for secreted. 
The HLA nomenclature was updated in 2010. The WHO Nomenclature Committee for 
Factors of the HLA System, determines assigned allele types and is also responsible for 
maintaining the HLA nomenclature. Details can be found at 
http://hla.alleles.org/nomenclature/index.html. Additionally, laboratories input their finding 
into this database called “The expert assigned types” which represents more cells and 
therefore more alleles. 
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Figure 3-2: HLA Nomenclature 
Schematic illustration of HLA tissue typing results. Numbers, letters and symbols are 
explained for interpretation. http://hla.alleles.org/nomenclature/naming.html 
 
Common notations are;  
HLA  the HLA region and prefix for an HLA gene  
HLA-DRB1  a particular HLA locus i.e. DRB1 HLA-DRB1*13 a group of alleles which 
encode the DR13 antigen or sequence homology to other DRB1*13 alleles  
HLA-DRB1*13:01 a specific HLA allele  
HLA-DRB1*13:01:02 an allele that differs by a synonymous mutation from 
DRB1*13:01:01  
HLA-DRB1*13:01:01:02 an allele which contains a mutation outside the coding region 
from DRB1*13:01:01:01  
HLA-A*24:09N a ‘Null’ allele, an allele which is not expressed  
HLA-A*30:14L an allele encoding a protein with significantly reduced or ‘Low’ cell 
surface expression  
HLA-A*24:02:01:02L an allele encoding a protein with significantly reduced or ‘Low’ 
cell surface expression, where the mutation is found outside the coding region  
HLA-B*44:02:01:02S an allele encoding a protein which is expressed as a ‘Secreted’ 
molecule only  
HLA-A*32:11Q an allele which has a mutation that has previously been shown to have a 
significant effect on cell surface expression, but where this has not been confirmed and its 
expression remains ‘Questionable’ 
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3.1.4 HLA expression, antigen processing and presentation 
 
T cells only recognise antigens presented by antigen presenting cells through the MHC. 
There are two different classes of MHC molecules, MHC class I and MHC class II,  
involved in antigen presentation. All nucleated cells express MHC class I molecules as 
many as 100,000 (apart from erythrocytes and sperm cells). MHC class II molecules are 
conditionally expressed (around 30,000) by professional antigen presenting cells such as B 
cells, macrophages and dendritic cells, as well as by thymic epithelial cells. 
Antigens might be derived from an intracellular or extracellular source; MHC class I 
molecules process antigens derived from cytosol and deliver them to the cell surface where 
they are recognised by CD8+ T cells. However, MHC class II molecules process antigens 
that originate from extracellular sources. These antigens are internalised by a vesicular 
system where the MHC II molecule gets loaded and is then delivered to the cell surface. 
The MHC class II-peptide complex is recognised by CD4+ T cells.  
Therefore, the HLA class I pathway deals with endogenous pathogens and immunogens 
such as viruses, intracellular bacteria and products of proteasome degradation 
(nonapeptides). Peptides that bind to MHC class I are actively transported from the cytosol 
to the endoplasmic reticulum (ER) by transporters associated with antigen processing 
(TAP) proteins where they are processed.  Cytosolic proteins are degraded by a 
multicatalytic protease complex called a proteasome. The proteasome chops up peptide 
ligands for the MHC class I molecule. Antigens are then transported from the cytosol to the 
ER by TAP1 and TAP 2 proteins. These two TAP proteins form a heterodimer and load 
peptides to the MHC class I molecule in the ER. A fully-loaded MHC class I molecule 
with peptide then leaves the ER and is transported to the cell surface within the Golgi 
apparatus where it is recognised by CD8+ T cells. CD8+ T cells are specialised to kill any 
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cells that present with foreign peptides. This process is crucial for homeostasis hence 
almost every cell in the body serves the class I pathway. Proteasome also can degrade 
proteins in the cytosol that originate from the vesicular system. This process is called 
retrograde transportation and allows APCs to release peptide into the cytosol and then be 
presented by the class I pathway, termed cross-presentation [100, 101].  
On the other hand the HLA class II pathway deals with intra-vesicular peptides that are 
generated by receptor mediated endocytosis, phagocytosis and pinocytosis. These peptides 
originate from exogenous pathogens and immunogens and only APCs can present such 
antigens. MHC class II molecules are also located in the ER however they cannot bind to 
their antigens readily due to an accompanying invariant chain which binds to and blocks 
their peptide-binding groove. The MHC II molecule binds to its peptides in the endosome 
where active proteases catalyse invariant chain release. Once dislodged from the invariant 
chain, peptides are loaded onto class II molecules. MHC class II molecules can also 
capture molecules within the endosome that are derived from metabolic degradation where 
cytosolic proteins move into the vesicular system through the process of autophagy.  
Loaded MHC class II molecules within Golgi apparatus then move to the cell surface 
where they can be recognised by CD4+ T cells. CD4+ T cells are specialised in activating 
macrophages, helping B cells to produce antibodies, and regulate immune responses [101] 
[100].  
 
3.1.5 MHC-Peptide-TCR Interaction 
 
In the adaptive immune system, B cell receptor (BCR) recognises antigens directly, 
whereas T cell receptor (TCR) will only recognises antigens in the context of an MHC 
molecule. MHC molecules, when loaded with antigen, form a ligand, then a TCR 
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recognises the matched MHC molecule-antigen complex. Antigen, MHC molecule and 
TCR altogether form an immunological synapse. This formation only occurs where 
foreign/self-antigens are presented by matched MHC molecules to their cognitive T cells; 
this mechanism is called MHC restriction. MHC restriction dictates that the epitope seen 
by a given TCR is a combination of a cognitive peptide with a matched MHC molecule. 
This means that the TCR must recognise both antigen and MHC molecule type 
concomitantly.  
Two main factors are involved in the immune responsiveness against a given antigen that 
are not necessarily mutually exclusive; determinant selection and T cell repertoire.  
Different alleles of MHC molecules in an individual select a given determinant with 
varying affinity with the higher the strength of the binding resulting in a greater likelihood 
of a potent response. The discrimination of a non-self/immunogen from a self/non-
immunogen is determined by the T cell repertoire. T cell clones capable of recognising 
self-antigens are deleted in the thymus during T cell development and the establishment of 
central tolerance. This is the result of positive and negative selection events in the thymus 
which are determined by MHC-self protein TCR interactions. The interaction between a 
selected T cell clone and its cognate antigen could be weak or strong and thus determines 
the extent of the response. It is also important to consider that the reaction to non-self-
antigens might be due to a breakdown in central and/or peripheral tolerance where self-
reactive T cell clones escape thymic deletion and enter into the periphery.  It is likely that a 
combination of these two mechanism result in an autoreaction. Hence an individual’s 
MHC genotype controls the ability of the immune system to detect or respond to a specific 
immunogen. Therefore a particular HLA allele with a certain haplotype may predispose or 
protect an individual to a specific disease.  
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3.1.6 HLA and Disease 
 
Many studies have demonstrated that expression of MHC molecules are closely associated 
with auto-immune diseases. Amiel et al reported in 1967 that patients with Hodgkin’s 
disease displayed a higher frequency of HLA-B5 antigens (51%) compared to healthy 
individuals [104]. The HLA-DQ2 and HLA-DQ8 alleles are strongly predispose to type 1 
diabetes [105]. Ninety per cent of Caucasian anklyosing spondylitis patients carry HLA-
B27 allele whereas only 9% of healthy population do [106]. Rheumatoid arthritis , 
narcolepsy, coeliac disease, and multiple sclerosis, have all been shown to have an 
association with HLA alleles [107] [108]. Many chronic inflammatory diseases are 
associated with MHC class II genes, due to their central role in presenting immunogens to 
T cells. It has been shown in rheumatoid arthritis that some of the autoantigens 
responsible for this condition are derived from type II collagen, which has a single 
immunodominant T cell epitope that is bound by both HLAD-R1 and HLA-DR4.1 
molecules [109] [110] [111]. 
 
Regarding OA, the literature is limited and conflicting. It is not known if any autoantigens 
are primarily involved. There are a few previous reports of HLA association with OA 
using different typing techniques, classification systems and varying ethnic background, 
making it difficult to compare studies or demonstrate any association.  
Riyazi et al studied OA of the distal interphalangeal (DIP) joint’s association with HLA-
DR alleles. They have found no association of DIP compared to healthy population. 
However comparison between OA patients revealed that HLA-DR2 (DRB1*15/16) was 
more common in DIP + OA patients compared to DIP- OA patients (OR = 2.4 ;95% CI = 
1.1-5.0) whereas HLA-DR4 (DRB1*04) showed decreased frequency (OR = 0.3; 95% CI 
= 0.1-0.7) in their comparison [112]. Suggesting DR2 might be a risk factor to develop 
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DIP in OA patients. DR4 involvement has not been reported before; this allele may need 
further scrutiny. 
Merlotti et al, showed over representation of HLA-B35, B40, DQ1 and CW4 (*B15 and 
*B35, *B40, DQB1*05 and DQB1*06, *C04) alleles in primary OA of the hand. 
Haplotype analysis showed an association of B35-DQ1, B40-DQ1 and DR2-DQ1 with 
increased OA risk [113]. Rovetta et al  indicated that haplotype DRB1:07*e *04 is more 
frequent in OA compared to healthy controls, HLADR*13 was most prevalent in patients 
with OA of the hand [114].  Moos et al analysed HLA-DRB1 loci in primary OA patients 
[115] and showed increased DR2 (*15/*16) , frequency of this allele was 26.5% 
compared with only 17% in the control (OR = 1.58). On the other hand, decreased DR5 
(*11, *12, *13) frequency was observed in patients compared to controls indicating a 
negative association (OR = 0.542). These results are varied largely and inconsistent and 
the only common finding of these studies is allele DR2 (*15/*16)’s association with OA.  
Metal sensitivity to Ni and beryllium (Be) through T cell involvement is well documented 
with both being associated with particular MHC class II alleles (HLA-DR52c and HLA-
DP2) [116]. There are almost no reports on Co-Cr-Mo sensitivity and MHC association. 
Fisher et al studied labourers working in hard metal manufacturing and reported no 
deviation in HLA phenotype in cobalt-sensitive individuals [117] . No MHC allele or 
isotype association have been reported regarding sensitivity to metal alloy debris generated 
by hip prostheses. It has been shown in Ni allergy that metal-specific T cell clones require 
autologous APC for response to metal ions, indicating a role of specific peptide and/or 
specific MHC variants in metal binding and therefore interactions with the TCR [83]. How 
metal ions influence MHC + peptide complex recognition by TCR is not fully understood. 
It has been proposed however that metal ions may bind to MHC molecules and this 
interaction induces changes in MHC+ peptide complexes leading to alteration in ligand and 
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presentation as neo-antigens. This altered ligand is recognised by T cells and causes 
hypersensitivity. This may be a mechanism for the immune response to metallosis seen in 
hip implant failure.   
Traditionally, HLA tissue typing used to be conducted by serology using reactive 
antibodies for MHC molecules. Serotyping yields low resolution results by today’s 
standards since the exact amino-acid sequence or nucleotide sequence cannot be 
determined. As the technology has advanced, molecular typing tools have become the 
choice for tissue typing where higher resolution results can be achieved. The Polymerase 
Chain Reaction- Sequence Specific Oligo Probes (PCR-SSOP) method is the most 
commonly used technique today to type HLA molecules and gives intermediate resolution. 
Sequencing can be further conducted on the samples in case higher typing resolution is 
required. This would determine the exact sequence of the HLA gene and resolves most of 
the degeneracy seen in the results. Disease association studies only look at the general 
allelic group, therefore intermediate resolution is often sufficient.  
Since literature is very limited on OA and metal implant failure in terms of HLA 
association the current study was undertaken to determine whether there is an association 
between HLA class II gene frequencies and metal hip implant failure by investigating, 
first, the whole cohort for their allelic frequencies (OA patients), then looking at the failed 
hip implant group. HLA-DR and -DQ frequencies are often altered in auto-immune 
diseases, arthropathies and recognition of transition metals hence these two alleles were 
investigated in the current study.  
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3.2 Materials and Methods 
 
Patients 
A total of 56 consecutive patients were recruited for this analysis consisting of Cohort 1 of 
OA patients considered for hip arthroplasty, Cohort 2 of 24 OA patients (sub group of 
Cohort 1) that had a failed metal hip implant requiring revision. The control group was 
matched with patient groups for ethnic background and geographic location. The 537 
control subjects were all Caucasians from Norfolk, England [118]. 
Sample processing 
PBMCs were isolated from EDTA-blood using Ficoll Hypaque density gradient 
separation.  6 mls of anti-coagulated blood was layered onto Histopaque-1077 (Sigma, 
Cat No: 10771) in Accuspin tubes (Sigma, Cat No: A2055-10EEA) and centrifuged at 800 
g for 15 minutes. Opaque interface containing mononuclear cells were aspirated with a 3 
ml Pastette. Cells were washed and transferred into cryovials containing freezing media 
consist of 90% Foetal Bovine Serum (FBS) + 10% Dimethyl sulfoxide (DMSO) and 
stored at -80
0
C for further use in tissue typing.  
HLA Typing 
This was undertaken by the National Health Service Blood and Transplant (NHSBT) 
Colindale Laboratory, on a fee-for-service basis. HLA Class II typing was carried out for 
HLA-DRB1, -DQA1, -DQB1 using commercial PCR-SSOP kits (LABType®, One 
Lambda). In this method DNA is amplified with PCR with locus-specific biotin-labelled 
primers. The products were interrogated with oligonucleotide probes attached to beads 
which were analysed on a Luminex™ platform. HLA types were obtained at intermediate 
resolution which resolves major allele groups to a minimum of two digits (within the first 
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field). Analysis of HLA-DRB1, -DQA1, -DQB1 types were performed at the two digit 
level except for HLA-DQA1*01 (4 digit).  
This level of resolution can produce a certain degree of degeneracy between related alleles 
however it identifies main allelic groups. 
The allele frequency (AF) is described as the frequency of possessing a particular copy of 
an HLA allele amongst all alleles being considered at a genetic locus. HLA genes are 
expressed as co-dominant meaning both parental and maternal phenotypes are present in 
off-spring. AF is calculated as in equation 3-1.  
 
Equation 3-1: Allelic frequency calculation 
 
𝐴𝐹 =
(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑙𝑙𝑒𝑙𝑒𝑠 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑜𝑓 𝑀𝐻𝐶 𝑣𝑎𝑟𝑖𝑎𝑛𝑡)𝑥100
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐ℎ𝑟𝑜𝑚𝑜𝑠𝑜𝑚𝑒𝑠 (2𝑛)
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Statistical analysis 
Allelic frequencies of investigated genes were compared between patients and controls 
using the Fisher Exact test and associations were expressed as Odds Ratios (ORs) with 
95% confidence intervals (CIs). P< 0.05 value was considered significant.  
OR is a measure of association between an exposure and an outcome. The OR represents 
the odds that an outcome will occur given a particular exposure, compared to the odds of 
the outcome occurring in the absence of that exposure [119].   
In the current study it was tested whether possessing certain allele increase the risk of 
developing implant failure. Statically significant differences then were interpreted as  
 OR=1 Exposure does not affect odds of outcome (no association) 
 OR>1 Exposure associated with higher odds of outcome (Predisposing) 
 OR<1 Exposure associated with lower odds of outcome (Protective) 
High polymorphism is seen at HLA loci (20 or more alleles per locus), in addition to 
extensive linkage disequilibrium (LD) between immunogenetic loci is present which 
requires correction of analysis. Multiple testing correction was done using a technique 
developed by Benjamini and Hochberg called the “false discovery rate ” [120], based on 
the number of tests and the original p-values using R software. pc represents corrected P 
values. 
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Study Power Calculation 
Retrorespective assessment of the study power was calculated for failed implant group. 
Effect size (OR) calculation was conducted using Stata software (Texas, USA).  
The calculation was based on recruitment number for case (2n = 48) and control (2n = 
1074) groups, = 5 % was considered statically significant and 80% study power deemed 
to be desirable.  
The difference in allele frequencies between case and control was assessed by conducting a 
simulation test to determine required OR value to achieve a study power ≥ 0.8. Following 
Stata script was utilised.  
Stata commands used: 
cci 1 47 11 1063  /  cci 8 40 11 1063 
cci 25 23 365 709  /  cci 43 5 365 709 
sampsi 0.02 0.01, alpha(0.05) n1(48) n2(1074)   
sampsi 0.17 0.01, alpha(0.05) n1(48) n2(1074)   
sampsi 0.52 0.34, alpha(0.05) n1(48) n2(1074)   
sampsi 0.90 0.34, alpha(0.05) n1(48) n2(1074) 
The worst case scenario (lowest allele frequency) and best case scenario (highest allele 
frequency) in controls were calculated and compared with patient’s allele frequencies for 
given loci.  
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3.3 Results 
 
Molecular typing was conducted for a total of 25 different alleles across three MHC class 
II gene loci, DRB1, DQA1 and DQB1 (for complete raw data See Appendix 2). 13 HLA-
DRB1, 7 HLA–DQA1 and 5 HLA-DQB1 alleles were interrogated. “A” represent  chain 
of the respective molecule whereas “B” represent  chain. HLA-DR  chain does not have 
any variation hence only B chain was investigated, on the other hand at the DQ loci both  
and  chains display allelic variation.  
Table 3-2 shows the comparison of HLA-DRB1, -DQA1, -DQB1 gene frequencies in 
Cohort 1 OA patients, and normal controls.  HLA-DRB1*01 (p = 0.0405) showed 
increased frequency in OA patients compared with controls. HLA-DQA1*01:02 (p = 
0.0089) and DQB1*06 (p = 0.0342) showed decreased frequency in OA patients 
compared to controls. After correcting for multiple comparisons significance was lost for 
the differences in frequency of HLA-DRB1*01 (pc = 0.3375), -DQA1*01:02  
(pc = 0.2225) and -DQB1*06 (pc = 0.3375) alleles (Table 3-2).  
Analysis of Cohort 2, the failed implant group, was also conducted against the control 
population (Table 3-3). There was an increased frequency of DQA1*05 (p = 0.0303) 
whereas DQA1*01:02 (p = 0.0003) and DQB1*06 (p = 0.0026) showed decreased 
frequencies in patients compared to controls. The difference in frequency of DQA1*05 
did not withstand multiple testing correction (pc = 0.1889) although both DQA1*01:02  
(pc = 0.0075) and DQB1*06 (pc = 0.0325) were still significant after correction.   
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Table 3-2: HLA gene frequencies in Cohort 1 
HLA-DR and HLA-DQ gene frequencies in Cohort 1, OA patients (2n=112) compared with controls
 
(2n=1074) [118] 
HLA type Patients Control Odds Ration with 
“Confidence Interval ” 
p  pc 
% (n) % (n) 
DRB1*01 19.6 (22)  12.5 (135)  1.700 "1.031 to 2.803" 0.0405 0.3375 
 
DRB1*03 17.0 (19) 15.3 (165) 1.126 "0.6687 to 1.894" 0.6805 0.8953 
 
DRB1*04 15.2 (17) 20.1 (217) 0.7067 "0.4129 to 1.210" 0.2607 0.5013 
 
DRB1*07 17.0 (19) 12.8 (138) 1.386 "0.8198 to 2.342" 0.2401 0.5002 
 
DRB1*08 3.6 (4) 3.5 (38) 1.010 "0.3536 to 2.884" 1.0000 1.0000 
 
DRB1*09 0 (0) 1.1 (12) 0.3778 "0.02220 to 6.428" 0.6177 0.8680 
 
DRB1*10 0 (0) 0 (1) 3.184 "0.1288 to 78.68" 1.0000 1.0000 
 
DRB1*11 9.8 (11) 5.8 (63) 1.748 "0.8921 to 3.424" 0.1020 0.3642 
 
DRB1*12 1.8 (2) 1.0 (11) 1.757 "0.3844 to 8.031" 0.3515 0.5543 
 
DRB1*13 4.5 (5) 9.3 (101) 0.4502 "0.1794 to 1.130" 0.0835 0.3642 
 
DRB1*14 0.9 (1) 2.8 (31) 0.3031 "0.04096 to 2.243" 0.3548 0.5543 
 
DRB1*15 10.7 (12) 11.0 (119) 0.9630 "0.5137 to 1.806" 1.0000 1.000 
 
DRB1*16 0 (0) 1.2 (13) 0.3495 "0.02062 to 5.922" 0.6250 0.8680 
 
DQA1*01:01 20.5 (23) 14.1 (152) 1.568 "0.9607 to 2.558" 0.0914 0.3642 
 
DQA1*01:02 10.7 (12) 20.7 (223) 0.4579 "0.2471 to 0.8486" 0.0089 0.2225 
 
DQA1*01:03 4.5 (5) 2.2 (24) 2.044 "0.7642 to 5.469" 0.1849 0.4622 
 
DQA1*02 17.0 (19) 12.8 (138) 1.386 "0.8198 to 2.342" 0.2401 0.5002 
 
DQA1*03 15.2 (17) 20.7 (223) 0.6829 "0.3992 to 1.168" 0.1755 0.4622 
 
DQA1*04 2.7 (3) 2.2 (24) 1.204 "0.3567 to 4.065" 0.7358 0.9158 
 
DQA1*05 29.5 (33) 21.2 (228) 1.550 "1.006 to 2.387" 0.0546 0.3412 
 
DQB1*02 26.8 (30) 22.5 (242) 1.258 "0.8083 to 1.957" 0.3443 0.5543 
 
DQB1*03 33.9 (38) 34.2 (368) 0.9852 "0.6531 to 1.486" 1.0000 1.000 
 
DQB1*04 3.6 (4) 2.9 (32) 1.206 "0.4185 to 3.475" 0.7693 0.9158 
 
DQB1*05 20.5 (23) 14.9 (161) 1.465 "0.8994 to 2.388" 0.1313 0.4103 
 
DQB1*06 15.2 (17) 24.2 (260) 0.5602 "0.3282 to 0.9564" 0.0342 0.3375 
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Table 3-3: HLA gene frequencies in Cohort 2 
HLA-DR and HLA-DQ gene frequencies in Cohort 2, OA patients (2n = 48) compared with controls
 
(2n=1074) [118] 
HLA type Patients Control Odds Ration with 
“Confidence Interval ” 
p  pc 
% (n) % (n) 
DRB1*01 14.6 (7) 12.5 (135)  1.188 "0.5221 to 2.701" 0.6572 0.9894 
 
DRB1*03 20.8 (10) 15.3 (165) 1.450 "0.7083 to 2.967" 0.3093 0.7732 
 
DRB1*04 16.7 (8) 20.1 (217) 0.7899 "0.3643 to 1.712" 0.7124 0.9894 
 
DRB1*07 22.9 (11) 12.8 (138) 2.016 "1.005 to 4.047" 0.0513 0.1889 
 
DRB1*08 4.2 (2) 3.5 (38) 1.185 "0.2773 to 5.067" 0.6874 0.9894 
 
DRB1*09 0 (0) 1.1 (12) 0.8763 "0.05109 to 15.03" 1.0000 1.000 
 
DRB1*10 0 (0) 0 (1) 7.385 "0.2967 to 183.8" 1.0000 1.000 
 
DRB1*11 10.4 (5) 5.8 (63) 1.866 "0.7140 to 4.877" 0.2064 0.645 
 
DRB1*12 0 (0) 1.0 (11) 0.9534 "0.05533 to 16.43" 1.0000 1.000 
 
DRB1*13 6.3 (3) 9.3 (101) 0.6422 "0.1960 to 2.104" 0.6146 0.9894 
 
DRB1*14 2.1 (1) 2.8 (31) 0.7159 "0.09561 to 5.360" 1.0000 1.000 
 
DRB1*15 2.1 (1) 11.0 (119) 0.1707 "0.02333 to 1.250" 0.0529 0.1889 
 
DRB1*16 0 (0) 1.2 (13) 0.8106 "0.04746 to 13.85" 1.0000 1.0000 
 
DQA1*01:01 16.7 (8) 14.1 (152) 1.213 "0.5570 to 2.642" 0.6716 0.9894 
 
DQA1*01:02 2.1 (1) 20.7 (223) 0.0811 "0.0111 to 0.5920" 0.0003 0.0075 
 
DQA1*01:03 4.2 (2) 2.2 (24) 1.902 "0.4362 to 8.296" 0.3066 0.7732 
 
DQA1*02 22.9 (11) 12.8 (138) 2.016 "1.005 to 4.047" 0.0513 0.1889 
 
DQA1*03 16.7 (8) 20.7 (223) 0.7632 "0.3522 to 1.654" 0.5867 0.9894 
 
DQA1*04 2.1 (1) 2.2 (24) 0.9309 "0.1232 to 7.032" 1.0000 1.0000 
 
DQA1*05 35.4 (17) 21.2 (228) 2.035 "1.106 to 3.743" 0.0303 0.1889 
 
DQB1*02 35.4 (17) 22.5 (242) 1.885 "1.026 to 3.466" 0.0523 0.1889 
 
DQB1*03 39.6 (19) 34.2 (368) 1.257 "0.6952 to 2.272" 0.4421 0.9894 
 
DQB1*04 2.1 (1) 2.9 (32) 0.6928 "0.09263 to 5.182" 1.0000 1.0000 
 
DQB1*05 16.7 (8) 14.9 (161) 1.134 "0.5212 to 2.468" 0.6833 0.9894 
 
DQB1*06 6.3 (3) 24.2 (260) 0.2087 "0.0643 to 0.6774" 0.0026 0.0325 
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Statistically significant increased frequencies are indication of disease susceptibility 
whereas decreased frequencies are interpreted as disease protection. Both the OA and 
failed implant group had protective alleles in common (DQA1*01:02 and DQB1*06), 
whereas DRB1*01 was specific to OA predisposition and DQA1*05 was specific for the 
metal hip implant failure in this cohort of patients. The summary of these findings depicted 
in Fig 3-3. Genetic association in multi-factorial diseases such as OA often produce small 
OR values (1.2 to 2.0), because of large number of alleles involved conferring small risk 
that combined with environmental factors confers a greater range of susceptibility. Taking 
this into consideration predisposing alleles showed considerably large OR values; 
DQB1*01 = 1.7 and DQA1* 05 = 2.035 (Table 3-2 and 3-3). 
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          Protective         Predisposing
0 1 2 3 4
DQA1*01:02 (Failed implant)
DQA1*05 (Failed implant) 
DQB1*06 (Failed implant)
DRB1*01 (OA)
DQA1*01:02 (OA)
DQB1*06 (OA) 
Odds Ratio
 
Figure 3-3: Odd ratios for MHC class II gene expression 
A forest plot depicting Odd Ratios calculated for patient’s MHC class II allelic variation 
versus control population. “OA” denotes total study population (Cohort 1) of Osteoarthritis 
patients. “Failed implant” denotes (Cohort 2) patients with failed metal implant undergoing 
revision operation. Statically significant differences plotted with 95% CI. OR< 1 indicating 
protective effect, OR > 1 indicating Predisposing effect.  
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Retrospective assessment of statistical power in the study of HLA association with implant 
failure was conducted for “worst case scenario” and “best case scenario” to assess effect 
size in this population.  
Worst case scenario: The HLA allele with lowest frequency in controls was DRB1*12, 
allele frequency with 1.0 %. The statistical power for a range of odds ratios given that this 
sample size of controls was 2n = 1074 and sample size of cases was 2n = 48 (odds ratio 
considered as the effect size in a case-control study).  
Table 3-4: Effect size calculation for worst case scenario  
Allele frequency 
 in controls  
(%, [n]) 
Allele frequency 
 in patients 
(%, [n]) 
Odds ratio Statistical power 
0.01 [11] 0.02 [1] 2.1 0.0816 
0.01 [11] 0.04 [2] 4.2 0.3440 
0.01 [11] 0.08 [4] 8.8 0.7490 
0.01 [11] 0.10 [5] 11.2 0.8518 
0.01 [11] 0.17 [8] 19.3 0.9803 
 
Best case scenario: The HLA allele with highest frequency in controls was DQB1*03 
allele frequency with 34.2%.  
Table 3-5: Effect size calculation for best case scenario  
Allele frequency 
 in controls  
(%, [n]) 
Allele frequency 
 in patients 
(%, [n]) 
Odds ratio  Statistical power 
0.34 [365] 0.52 [25] 2.1 0.6654 
0.34 [365] 0.56 [27] 2.5 0.8352 
0.34 [365] 0.69 [33] 4.3 0.9984 
0.34 [365] 0.83 [40] 9.1 1.000 
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Statistical power increases with increasing sample size, increasing allele frequency and 
increasing effect size (odds ratio). The sample size was fixed and the tables (Table 3-4 & 
Table 3-5) above shows statistical power for two extreme allele frequencies for a range of 
odds ratios. It is clear that for the worst case scenario where the allele frequency is very 
low, only associations with unrealistic odds ratios (11.2) could reach statistical significance  
with 85% study power (Table 3-4).  
In the best case scenario for the HLA allele with the highest frequency in controls, an 
association with an odds ratio of 2.5 or higher would reach statistical significance. Thus, 
for the range of allele frequencies, the minimum odds ratio would have to be 2.5 for an 
association to reach statistical significance. For any allele other than the one with the 
highest frequency, it has to be greater than 2.5. This equates to number of alleles in 
patients that are required, n = 27 with 83 % study power (Table 3-5).  
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3.4 Discussion  
 
Only a small proportion of hip prostheses progress to implant failure. In the Norfolk  
cohort the same type of implant was used for arthroplasty by the same set of surgeons of 
which the majority were successful. The failure rate for most MoM implants is 
approximately 9.5% at 6 years follow-up but was 24.6% for the Ultima
®
 THR TPS. 
However the Ultima performed well in other clinical centres (Richard Farrar, personal 
communication). This implies that host-related determinants may cause an aberrant 
immune response in Norfolk cohort.  
 
No clear HLA association with OA has been documented previously apart from -DR2 
(*15/*16). In this study an increased frequency of HLA-DRB1*01 was observed in OA 
group. This might be attributed to the presence of other arthropathies. HLA-DRB1*01 
have been reported to increase in RA. And DRB1 is known to be the principal locus 
contributing to RA development. Although RA patients were excluded from recruitment 
procedure, subclinical RA might be present in some patients. RA presents itself as a co-
morbidity in some of the OA patients , but there was no observed increase in the 
frequency of HLA-DRB1*04, which is the HLA type primarily associated with RA [121].   
 
The comparison of HLA type frequencies between Cohort 2 Patients (failed implants) and 
controls revealed several significant differences. HLA-DQA1*05 is present at increased 
frequency in failed patients.  HLA-DQA1*05 includes both HLA-DQA1*05:01, 
associated with HLA-DRB1*03, and HLA-DQA1*05:05 associated with HLA-DRB1*11 
[122]. Both HLA-DRB1*03 and HLA-DRB1*11 were present at higher frequencies in 
Cohort 2 Patients than in controls but the differences were not significant.  The 
frequencies of HLA-DRB1*07, -DQA1*02 and –DQB1*02 were present at increased 
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frequency in Cohort 2 patients than in controls; these HLA types occur in strong 
association with each other (HLA-DQB1*02 are also associated with HLA-DRB1*03). 
This represents an increase in the presence of this haplotype which is an indication of 
biological link in failed cohort.  
 
The frequency of differences identified was not significant following correction of p 
values for the number of comparisons. However, the most striking differences in HLA 
frequencies  between Cohort 2 Patients (failed implants) and controls are those of HLA-
DQA1*01:02 and HLA-DQB1*06, the decreased frequencies of which remain significant 
following correction.  HLA-DRB1*15 e DQA1*01:02 e DQB1*06 occur together as a 
haplotype in the UK and other populations [123]. There was only one instance of HLA-
DRB1*15 in Patient Cohort 2 (2.1%) whereas the frequency in controls is 11.0%, which 
suggests that this HLA type or haplotype might be protective against implant failure. 
HLA-DQB1*06 is also associated with HLA-DRB1*13 in the UK and is also present in 
patient Cohort 2 at a reduced frequency compared with controls. But whilst HLA-
DRB1*15 is strongly associated with HLA-DQA1*01:02 e DQB1*06:02 in the UK, 
HLA- DRB1*13 it is generally found associated with HLA-DQA1*01:02 and found with 
a variety of different HLA-DQB1*06 alleles e.g. HLA-DQB1*06:03 and -DQB1*06:09. 
The results showed that DQA1*01:02 and DQB1*06 were decreased in frequency in the 
OA cohort suggesting a protective effect of these alleles. This may be a unique finding in 
OA, as it has not been previously reported.  
The general UK distribution of allele DQA1* 01:02 is 18.11% (n =1245, Dr Colin Brown, 
personal communication) whereas it was 2.1 % in our failed cohort. This data is agreeable 
with current analysis where there is a significant reduction of this allele in failed cohort 
compared to controls of Norfolk. There is no data available for this allele in other 
geographical regions of the UK. It would be a great interest to compare DQA1*01:02 
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frequency and correlation to both failed and survived implants in other parts of the UK. 
Regional comparisons could help to establish if high rate of failure is due to regional bias 
in Norfolk population where this allele is expressed in significantly low frequency in 
failed groups.  
On the other hand, UK distribution of allele DQB1*06 is 1.21% (n = 132119, Dr Colin 
Brown, personal communication) whereas it was 6.3% in failed cohort which suggesting 
an increase in frequency of this allele in failed group. This contradicts the current analysis 
where decreased allele frequency was observed in failed groups compared with control 
group of healthy Norfolk population. This highlights the fact that Norfolk group in 
general shows very high frequency of DQB1*06 allele compared to UK population. This 
allele may not be related to the hip implant survival hence both survived and failed groups 
show high frequency in our study compared to rest of the UK.  
 
HLA-DQA1*05 showed a higher prevalence in the failed implant group. This allele has 
also been recently reported as predictive of non-responsiveness to anti-TNF- treatment 
in RA patients, suggesting anti-TNF therapy is unable to control inflammation within 
this group of patients [124]. A similar situation may exist in inflammation caused by 
metal wear debris. By comparison, frequencies of HLA-DRB1*15, -DQA1*01:02 and -
DQB1*06 are decreased in the failed implant group suggesting a “protective” effect. 
These phenotypes were also protective in Cohort 1, implying that it might have an overall 
protective effect in inflammation. In the failed implant group this phenotype stood up to 
multiple testing correction, which is stronger evidence for a “protective” association. The 
HLA-DRB1*15, -DQA1*01:02 and -DQB1*06 haplotype has been shown to be 
“protective” against type 1 diabetes [125],  whilst it is a susceptibility factor for multiple 
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sclerosis [126]. DRB*15 allele is also shown to be a susceptibility factor for OA [112] 
[115] however frequency of associated DQ alleles have not been reported before.  
 
Genome-Wide-Association Studies (GWAS) are utilised to investigate disease association 
with HLA genes and non-HLA genes. Nakajima et al reported two single-nucleotide 
polymorphism (SNPs) that are associated with knee OA [127]. These variants are in the 
region containing HLA class II/III genes, namely rs7775228 and rs10947262 in Japanese 
subjects (n=~4800). These two SNPs sequences are located between the upstream region 
of HLA-DQA2 and HLA-DQB1 suggesting OA is an immunological disorder. However, 
Shi et al studied Han Chinese and Australian populations in knee OA for the same SNP 
association demonstrating that there was no disease association between the two SNPs 
and knee OA in either population [128]. Another large scale replication study was unable 
to show any association of these two SNP regions in European Caucasian OA populations 
[129]. 
The discrepancy seen in different reports might be due to large Linkage Disequilibrium in 
different populations of these genes. Analysis of the Japanese data by Valdes et al showed 
that Japanese populations have a high frequency of protective haplotype (DRB1*15:02 e 
DQA1*01:03 e DQB1*06:01) compared to European populations [129]. This might 
explain failed repeat experiments in different populations. Even though GWAS is an 
accurate method for gene association studies of genetic contribution to disease 
susceptibility it is limited to looking at a few SNPs at a time. HLA typing produces more 
compressive outcomes generally.  
 
The results reported here indicate that there are differences in HLA class II frequencies in 
the Norfolk Ultima cohort compared to controls especially in “protective” alleles of the 
failed implant group. However analysis of greater patient numbers and different 
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populations to compare these results might help to achieve conclusive answers. The 
findings of this study need to be confirmed in another MoM cohort. Achieving a larger 
cohort size was not possible with Ultima hence this prosthesis was discontinued in 2005 
and many patients have already been revised since. The number of patients who still have 
an Ultima in situ is very limited.  
HLA-DQA1*01:02 e DQB1*06:02 haplotype showed strong under-representation in the 
current study. Further studies can focus on functional roles of these alleles in metal hip 
implant failure. These variants might be involved in regulatory functions and in the 
absence of given alleles, immune response might be overwhelmed with metal ions and 
resulting in aberrant immune reaction. A follow up study could be conducted by recruiting 
patients with and without given haplotype and metal processing functions of immune cells 
can be assessed via delayed type hypersensitivity for antigen specific regulation, such as 
demonstrated in lung transplantation patients [130, 131].  
Each MHC allele has a distinct peptide binding motif which favours certain amino acids at 
particular regions in their sequence (anchor residues). MHC binding motifs for metal-
protein complexes can be identified for under or over represented variants by nucleotide 
sequencing of MHC molecules. Matching amino acid sequences can then be determined by 
MHC-II binding predictions. MHC binding assays shown to identify potential 
immunogenic motifs [132, 133] therefore metal haptenisation for these motifs could be 
investigated additionally. Peptide bound HLA molecules can be identified by biochemical 
analysis by elution of MHC+protein complexes. Antigen loading and presentation can be 
shown functionally to see if these specific MHC molecules have a role in T cell expansion 
and antigen specific clone generation for epitope specificity. Phenotype of the functional 
cell types involved and immunogenic epitopes could be determined using combination of 
these approaches in future studies. 
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HLA type and disease association have been long reported however there are no reports of 
HLA type of patients with failed MoM implants. Metal ions are small molecules and may 
be acting in a similar fashion to other small molecules such as drugs. Small molecule 
interactions with MHC class I alleles are demonstrated in various drug treatments; HLA-
B* 57:01 for abacavir [134], HLA-B*15:02 e –A*31:02 for carbamazepine [135] and 
HLA-B*58:01 for allopurinol hypersensitivity [136], all of which are MHC class I alleles. 
More studies are needed to identify HLA type and molecular interactions with metals in 
failed MoM cohorts. It should perhaps include class I alleles too. This can be used as a 
screening process before deciding on choice of implant type.  
3.5 Summary 
 
This study investigated the association of metal implant failure and polymorphism of MHC 
class II molecules. The analysis of data indentified under represented alleles in patients 
with failed MoM implants namely HLA-DQA1*01:02 and HLA-DQB1*06. Not having 
these alleles in the germline might be a confounding factor in metal hip implant failure. 
These molecules might be involved in regulatory mechanisms of immune cells such as 
regulatory T cell education. There is no HLA data available at present for other centres 
where Ultima implants were used. Comparing HLA frequency with implant survivals rate 
across different part of the country would help to understand if the Ultima failure was HLA 
associated or other confounding factors involved, perhaps not all biological. Larger and 
further studies are required to determine frequencies in failed implant patients and to 
elucidate functional role of these alleles.  
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4 CHAPTER 4: Investigation of immune parameters in metal hip implant 
patients                            
4.1 Introduction 
 
The metal sensitivity seen in MoM THR patients is thought to be caused by reactivity of 
immune cells to metal particles/ions. Many different cell types are involved in the immune 
reaction process as detailed in Chapter 1. In the reaction to metal implant wear debris , 
high levels of monocytic and lymphocytic infiltration have been observed histologically in 
the peri-prosthetic tissue, resulting in ALVAL [56, 58, 137]. It is postulated that metal 
particles elicit phagocyte responses of monocytes and dendritic cells initially which then 
these cells involved in recruitment of adaptive immune cells (T or B lymphocytes) into site 
of corrosion. 
Aberrant cell counts are observed in several conditions such as autoimmune diseases, viral 
infections and malignancies.  A comprehensive immunophenotyping permits to find out if 
there is also any alteration of these immune cell’s composition in metal implant failure. To 
investigate phagocytes and lymphocytes, peripheral whole blood was assayed using a 18  
parameter flow cytometry for each patient (Table 4-1) consisting of three panels (Table 4-
3). The first panel identifies B cells (CD19+HLADR+) and T cells (CD3, CD4, CD8) plus 
their activation status (HLADR) and commitment to secondary lymph organ homing 
(CD62L) (Fig 4-1). Cell surface CD62L expression by T cells was analysed as this protein 
facilitates recirculation between blood and lymph nodes, which is important in immune 
surveillance and therefore timely responses to challenge. Naïve and memory T cells are 
CD62L+ whereas effector cells are CD62L- [138] . Immune activation correlates with an 
increase in HLADR expression by memory T cells, while naïve T cells express HLADR 
only following antigenic stimulation. 
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The second panel defines monocytes in detail with their involvement in metal implant 
failure well documented [139-141]. They readily uptake metal wear debris as demonstrated 
in Chapter 5 and by others [71, 142]. Macrophages are also involved in the activation of 
lymphocytes through antigen presentation and release of inflammatory cytokines that 
meditate osteoclast differentiation and maturation. Increased osteoclastogenesis results in 
implant loosening which is the lead cause of implant failure. Investigation of monocyte 
subsets was conducted according to the nomenclature established by Zeighler-Heitbrock et 
al [143-145]. Peripheral monocytes are divided into three groups (Fig 4-2); 
1) CD14+CD16- classical (inflammatory) monocytes  
 2) CD14-CD16+ non-classical (resident) monocytes  
3) CD14+CD16+ intermediate (transitional) monocytes  
The expression of HLADR was also utilised for monocyte identification as they all express 
high levels of HLADR.  Additionally, expression of migration (CX3CR1), activation 
(CD86) and maturation (CD83) markers in these myeloid lineage cells were studied (Table 
4-1).  CD86 and HLADR expression are upregulated upon Co/Cr metal exposure in vitro 
[146]. CD86 is a co-stimulatory molecule expressed by APCs that works in tandem with 
CD80 to activate T cells. Upregulation of these molecules is indicative of APC activation.  
After activation, the myeloid cells mature to become effector cells; CD83 is a marker for 
maturation and involved in cell-to cell interaction during antigen presentation. Interferon- 
mediated antigen presentation, T cell proliferation and phagocytosis were demonstrated by 
CD14+CD83+ cells and these cells were able to stimulate memory responses [147].   
De novo activation of lymphocytes requires DCs. Even though these cells are rare in blood 
and tissues, they are very potent APCs. DCs are often overlooked in metal implant failure 
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with very few reports showing DC presence in periprosthetic tissue [148].  This might be 
due to their scarcity plus difficulty of determining specific markers for these cells. DC 
response to polyethylene wear particles has shown that these particles cause increased 
MHC II expression and IL-12 production, which are hallmarks of DC activation [149]. In 
blood, DC are divided into two main groups, myeloid DC (mDC) and plasmacytoid DC 
(pDC). They both represent heterogeneous group of cells leading to further subdivisions. 
mDCs are mainly involved in T cell activation, produce large amounts of IL-12, drive Th1 
differentiation and CTL responses. On the other hand pDCs seem to be involved mainly in 
viral infections and produce type-I interferons. Four different subtypes of DCs were 
investigated in the current study (Fig 4-3).  
1) Myeloid CD11c+  
2) Myeloid CD1c+  
3) Plasmacytoid CD123+  
4) Plasmacytoid  CD303+  
The role of DCs and other APCs in metal implant failure is unknown. Therefore antigen 
presenting cells along with B and T cells were phenotyped in failed implant patients and 
compared to patients with well-functioning in situ implant.  
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Table 4-1: Immunophenotyping of PBMCs in whole blood 
 Target 
antigen 
Cellular expression 
in peripheral blood 
Function 
1 CD3 T cells  Associates with TCR and involved  in signal 
transduction 
2 CD4 T subset, monocytes MHC class II co-receptor, T cell 
differentiation/activation 
3 CD45 Haematopoietic cells 
apart from platelets and 
erythrocytes  
 
Enhanced TCR and BCR signalling 
4 HLA-DR APC, Tact Presentation of peptides to CD4+ T 
lymphocytes 
 
5 
 
CD303 
 
pDC 
Type II C-type lectin. Endocytic receptor; 
mediating antigen uptake and presentation. 
Inhibit IFN- production. 
6 CD11b Myeloid cells, NK Binds CD54, fibrinogen and iC3b 
 
7 
 
CD62L 
B, naïve and memory T, 
monocytes, granulocytes, 
NK 
CD34, GlyCAM and MAdCAM-1 receptor 
Leukocyte homing, tethering and rolling 
8 CD19 Immature B cells Complex with CD21 and CD81, BCR co-
receptor. B cell activation/differentiation.  
9 CD14 Monocytes and 
granulocytes (low) 
Receptor for LPS/LBP 
10 CX3CR1 NK cells, CD8 cells, DC, 
monocytes 
Receptor for Fractalkine on endothelial cells. 
Leukocyte migration and adhesion.  
11 CD86 Monocytes, DC, Bact  
Tact cells 
Binds to CD28, CD152, T cell costimulation 
 
12 
 
CD83 
 
Bact, Tact, DC 
Marker for DC maturation, may play a role in 
cell-cell interaction during antigen 
presentation 
13 CD16 Neutrophils, monocytes, 
NK 
Component of low affinity FcIII receptor, 
phagocytosis and ADCC 
14 Lin CD3, CD14, CD16, 
CD19, CD20 & CD56  
Peripheral blood DCs and basophils can be 
distinguished from other leukocytes by their 
lack of Lin antigen expressions 
 
15 
 
CD1c 
 
mDC, B subsets 
MHC Class I-like molecule, associated 
withmicroglobulin. Has specialised role in 
presentation of non-protein antigens 
 
16 
 
CD11c 
 
DC, myeloid cells, NK, 
B, T subsets 
 
Binds CD54, fibrinogen and iC3b 
17 CD123 Lymphocyte subsets, 
basophils, mϕ. DC 
IL-3 receptor -chain 
18 CD8 Cytotoxic T cells, NK, 
DC subset 
Co-receptor for MHC Class I. T cell 
differentiation and activation  
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Bone metabolism is a dynamic process and bone cells rely on complex signalling pathways 
involving cytokines, hormones and growth factors to maintain healthy bone structure. Any 
disruption of bone metabolism may result in conditions such as periprosthetic loosening 
leading to implant failure. Investigation of bone-related soluble biomarkers in our cohort of 
patients may aid to understand this complex condition. Cellular composition and cytokine 
profile have been shown in revised hip implant tissue with in situ hybridisation, 
demonstrating high T lymphocyte and macrophage infiltrates expressing IL-6, IL-1 and 
TNF- mRNA [150]. However, various other cytokines have not been studied in metal 
implant failure.  
The effects of cytokine signalling work in two different manners;  
1) Pleiotropic: where each cytokine acts on multiple targets   
2) Redundant: where several cytokines respectively elicit similar cellular response. 
Therefore, investigating multiple cytokines collectively may be more informative than 
individually in immune dysregulation. Table 4-2. details important cytokines and their 
biological function in bone metabolism. These cytokines were identified as significant 
soluble mediators which may potentially affect bone turnover in metal implant patients.  
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Table 4-2: Soluble immunological mediators affecting bone turnover 
Analyte Producer cells Actions Role in bone metabolism 
GM-CSF 
 
mϕ, T cells, mast cells, 
NK cells, endothelial 
cells and fibroblasts 
Stimulates stem cells to 
produce monocytes and 
granulocytes especially 
neutrophils. 
Found high levels in arthritic 
joints.
  
Regulates mononuclear 
osteoclast fusion and activation 
[151]. 
IFN- 
 
T cells, NK and NKT 
cells 
Activates mϕ and inhibit viral 
replication directly, promotes 
Th1 cell differentiation, 
supress Th2, Ig class 
switching. 
Inhibits RANKL-induced 
osteoclastogenesis, Suppresses 
osteoclast formation by 
degrading RANK adaptor protein 
TRAF6 [152].  
 
IL-10 
 
Monocytes and CD4+ 
T cells, T regs, 
activated T cells and B 
cells 
Down regulates mϕ activity 
and activates B cells and 
antibody production. 
Dampens NK cell action. 
Anti-inflammatory cytokine. 
Most haematopoietic cells 
express IL-10R. 
Immunoregulatory, blocks  
NF-KB activity. 
 
IL-1 
 
 
mϕ, epithelial cells 
 
T cell and mϕ activation, 
induce fever.  
Proinflammatory cytokine 
associated with cartilage 
degeneration [153]. IL-1 receptor 
antagonists treatment slows 
down bone erosion [154]. 
 
IL-6 
 
 
T cells, mϕ and 
endothelial cells, 
osteoblasts, stromal 
cells 
T and B cell growth, 
induction of fever, stimulates 
acute phase protein 
production. Effects are 
interrelated with IL-1, THF 
and PTH.  
Enhances bone resorption by 
increasing the pool of 
osteoclastic progenitors and their 
differentiation into mature 
osteoclasts [155] 
 
Leptin 
 
 
Adipose tissue 
secreted cytokine 
(adipokine) 
 
Stromal cell, osteoblasts.  
Mediator of metabolic 
homeostatis and joint 
remodelling. Stimulate osteoblast 
activity and proliferation [156, 
157] and inhibits 
osteoclastogenesis.  
 
RANKL 
 
 
Osteoclasts, 
osteoblasts, activated T 
cells, DC, stromal and 
epithelial cells 
 
Ligand for RANK which is 
mainly expressed on cells of 
myeloid lineage such as DC, 
pre-osteoclasts and 
osteoclasts.  
Lymphocyte development and 
osteoclast 
differentiation/activation. 
Inhibition of osteoclast apoptosis. 
RANKL knock-out mice a shows 
severe osteopetrosis and  loss of 
osteoclasts [75].  
 
OPG 
 
Osteoblasts and 
stromal cells 
Decoy receptor for RANKL. 
Inhibits osteoclastogenesis by 
preventing RANK-RANKL 
interactions.  
Blocks osteoclasts differentiation 
from precursor cells, prevents 
bone lose [158].  
 
M-CSF 
  
T cells, bone marrow 
stromal cells, 
osteoblasts, 
fibroblasts.  
 
Stimulates growth of 
monocytic lineage cells.  
M-CSF is necessary along with 
RANKL for the complete 
differentiation of osteoclastic 
precursors into mature 
osteoclasts [76].  
 
TNF- 
 
Activated mϕ, NK 
cells, T cells also non-
heamatopoetic cells.  
Activation of many cells, 
cytotoxic, antiviral, pro-
coagulatory and growth 
stimulatory effect. Potent 
bone-resorbing factor. 
Osteoclast stimulating molecule, 
promotes RANKL production by 
stromal cells hence induce 
osteoclast formation indirectly 
[159]. 
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MoM implants are made of around 60% Co, 30% Cr and 7% Mo. Even though these 
elements are required for biological functions, they are toxic at high concentration in 
biological systems [160, 161]. MoM THR patients are advised to have their Co-Cr levels 
checked periodically as increased ion levels could be a surrogate measure of in vivo device 
wear. MHRA issued an alert in June 2010 and updated this alert in June 2012 stating, “soft 
tissue reaction may be caused by metal wear debris”. MHRA highlighted the high failure 
rate with MoM THR and resurfacing and recommended annual monitoring of the hip using 
imaging and measurement of metal ion levels in the blood to determine whether a revision 
is needed in people with MoM hip replacement prostheses who have symptoms. The 
diagnostic positive cut off level for both Co and Cr is 7g/l. Hart et al found this cut-off 
level to be useful in distinguishing failed versus well-functioning implants. They also 
reported that lowering cut of levels to 4.97 g/l showed increased sensitivity but reduced 
specificity for identifying failed implants [162]. It is not certain if raised serum levels of 
metal ions are indicative of metallosis in the peri-prosthetic tissue. However De Smet et al 
found that serum Co and Cr levels in patients with metallosis were approximately ten times 
higher compared to patients without metallosis [163]. They also studied metal ion levels in 
joint fluid of revision patients. There was a good correlation between serum and joint fluid 
metal concentrations and implant failure. For practical reasons it is not always possible to 
assess metal ion levels of joint fluid, therefore monitoring serum levels serves as a 
pragmatic option for the clinical management of these patients.   
This work aimed to investigate the immune status in the Norfolk cohort with a detailed 
characterisation of antigen presenting cells (monocytes, dendritic cells and B cells) plus T 
cells. Levels of soluble biomarkers such as cytokines and growth factors were tested. 
Correlation of these immune parameters with metal ions levels was examined.  
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4.2 Material and Methods  
 
4.2.1 Immunophenotyping by Polychromatic Flow Cytometry 
 
The frequency and composition of human leukocytes in the body can be used as an 
indicator of health or disease. These cells are monitored in patients by identifying their 
surface markers by immunophenotyping using flow cytometry. To investigate blood 
leukocytes in metal implant patients, three polychromatic flow cytometry panels were 
designed. Target molecules included subset-defining lineage-specific markers, co-
stimulatory molecules, activation-associated markers, cytokine and chemokine receptors.  
These panels were specifically designed for the project and were adapted from a published 
protocol [164], which required extensive refinement, optimisation and validation.  The 
immunophenotyping panels consist of three panels of 9 Abs each, i.e. 18 different 
parameters in total (Table 4-3). An absolute quantification protocol was also standardised 
for whole blood samples using the “Lyse-no-wash” method [165] which provides the exact 
cell number of interest in the sample by normalising cell readings to known amounts of 
bead count (equation 4-1). The flow cytometry panels that were developed for this study 
used minimally manipulated ex-vivo blood samples plus absolute counting beads, which is 
the gold standard in immunophenotyping.  
Compensation is an integral part of multi-colour flow cytometry. It became apparent that 
compensation beads are more suitable than single colour cell controls due to the low level 
expression of some antigens in these panels. The OneComp beads were used for this 
purpose (eBioscience, Cat No: 01-1111-42).  
Since multiple antibodies (Ab) in a single tube were used, an appropriate concentration of 
each Ab was determined by titration preliminary experiments to avoid non-specific 
binding. The second step was to test isotype-matched control Abs utilising the same 
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flurochrome as the test antibody to assess background signals. Isotype control Abs were 
used at the same concentrations as the test Abs. Low background levels were confirmed 
before proceeding to staining study samples.  
The functions of the markers investigated are detailed in Table 4-1. Details of the lasers, 
filters, and the long pass dichroic mirrors are shown in Table 4-3. Appendix 4-1. shows 
details of Abs used, suppliers and catalogue numbers plus isotype controls for these Abs. 
Flow cytometry staining was carried out by adding appropriate amount of Ab to 
TruCOUNT
TM
 tubes (BD, Cat No: 340334) followed by 100 l of fresh EDTA-blood. 
Tubes were centrifuged for 30 seconds, vortexed gently and left to incubate for 30 mins in 
the dark at 21°C for staining. Following Ab staining, erythrocytes were lysed by adding 0.5 
ml of RBC Lysing Buffer (BioLegend, Cat No: 420301) and incubated 10 mins at 21°C. 
Samples were acquired using BD FACS ARIA II. Events were threshold at 1,000 
fluorescence units in CD45: PerCP-Cy5.5 channel to eliminate majority of debris. A 
minimum of 50,000 events were acquired in the monocytic/lymphocytic gate.   
 
 
Equation 4-1: Absolute quantification of the cell events calculation 
 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠 𝑖𝑛 𝑐𝑒𝑙𝑙 𝑔𝑎𝑡𝑒
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠 𝑖𝑛 𝑏𝑒𝑎𝑑𝑠 𝑔𝑎𝑡𝑒
 𝑋
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠 𝑝𝑒𝑟 𝑝𝑒𝑙𝑙𝑒𝑡∗
𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑢𝑙)
= 𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑐𝑜𝑢𝑛𝑡 (
𝑐𝑒𝑙𝑙𝑠
𝑢𝑙
)  
 
*This value is found on the TruCOUNT Absolute Count Tube foil pouch label and might vary from lot to lot. 
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Table 4-3: Flow Cytometry configuration, filter settings and panel distribution   
Instrument configuration, filter settings and panel distribution   
 Laser/Filter/ 
LP mirror 
Panel 1 Panel 2 Panel 3 
FL1 B 530/30 520LP 
 
CD3:FITC 
 
CX3CR1:FITC 
 
Lin:FITC 
 
FL2 B 585/42 556 LP 
 
CD4:PE 
 
CD86:PE 
 
CD1c:PE 
 
FL3 B 695/40 655 LP 
 
CD45:PerCP-
Cy5.5   
CD45:PerCP-
Cy5.5  
CD45:PerCP-
Cy5.5    
FL4 B 780/60 735 LP 
 
HLADR:PE-Cy7 
 
HLADR:PE-Cy7 
 
HLADR:PE-Cy7 
 
FL5 R 660/20  N/A 
 
CD303:APC 
 
CD83:APC 
 
CD11c:APC 
 
FL6 R 730/45 710 LP 
 
CD11b:AF700 
 
CD16:AF700 
 
CD11b:AF700 
 
FL7 R 780/60 750 LP 
 
CD62L:APC-Cy7 CD62L:APC-Cy7 CD62L:APC-Cy7 
FL8 V 450/40  N/A 
 
CD19: PacBlue 
 
CD19: PacBlue 
 
CD123:EF450 
 
FL9 V 530/30 520 LP 
 
CD8:PacOrg CD14:V500 
 
CD14:V500 
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Gating Strategy and Data Analysis  
Flow cytometry standard (FCS) data files were manually curated and analysed according to 
the panel design and protocol (Table 4-3) using Kaluza
®
 Flow Analysis Software, 
(Beckman Coulter, Inc). Representative gating strategies are shown in Figs 4-1 to 4-3. 
Events are displayed as “dot plot counter with density” for clarity to distinguish 
populations. Absolute cell numbers /l were calculated using equation 4-1 and results 
between clinical groups were compared using one way ANOVA (mean ± SD) with Tukey 
post-hoc correction in GraphPad Prism5.  Statistical significance was donated to the 
symbols below throughout the document.  
Symbol  Value  Interpretation 
ns  p  ≥ 0.05  Not significant  
*  p  ≤ 0.05  Significant 
**  p  ≤ 0.01  Very significant 
***  p  ≤ 0.001  Highly significant 
****  p  ≤ 0.0001  Extremely significant 
 
Identification of T and B cell subsets 
At first PBMCs were identified according to their characteristically low side scatter profile 
and high CD45 expression with a polygonal gate constructed around the relevant 
populations (Fig 4-1 A). In this way, granulocytes with a high side scatter and low CD45 
expression were excluded from further analysis. Beads were identified in the same 
cytograph through their inherent far red fluorescence intensity that falls in the PerCP-
Cy5.5 channel and by their high side scatter; two characteristics that set them apart from 
either granulocytes or PBMCs.  All subsequent subset identification was effected within 
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the PBMC gate. B cells were identified and gated by their CD19+HLADR+ surface 
expression and their numbers per l blood were evaluated within this gate (Fig 4-1 B). It 
was necessary to include CD3 as a T cell lineage-specific marker in the panel as CD4 and 
CD8 molecules are also expressed by non-T cells within the PBMC gate; T cells were 
identified as either CD3+CD4+ T helper cells (Th) or CD3+CD8+ cytotoxic T 
lymphocytes (CTL) and, relevant gates were constructed (Fig 4-1 C and D). 
CD3+CD62L+ and CD3+CD62L̶  T cells were gated for absolute cell counting (Fig 4-1 F). 
At the same time the activation status of CD3+ T cells present within peripheral blood was 
determined through their enhanced HLADR expression.  CD3+HLADR+ T cells were 
selected (Fig 4-1 E) as an indicator of T cell stimulation.  ` 
Identification of monocytes 
HLADR molecules are highly expressed on monocytes hence they are the most abundant 
APCs. PBMC gating was followed by gating HLADR +ve events to identify monocytes 
(Fig 4-1 D). In peripheral blood, the low affinity Fc receptor, CD16, is found on natural 
killer cells, neutrophils and monocytes [166] . Neutrophils were excluded from analyses by 
gating on PBMC prior to defining membrane expression of surface antigens (Fig 4-2 A). 
CD14 is a receptor for LPS/LPB and the main lineage marker for monocytes. It is weakly 
expressed by granulocytes. Again the PBMC gate was used to first identify both 
CD14+HLADR+ monocytes. Also this gating strategy allowed the identification of 
transient monocytes CD14+CD16+HLADR+ (Fig 4-4 E). CD86 is involved in antigen 
presentation and T cell activation. CD86 expression of monocyte subsets were determined 
using dot plots CD16 vs CD86, (Fig 4-2 B) and CD14 vs CD86 (Fig 4-2 C).  
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DCs identification 
DCs are rare cells in peripheral blood consisting of less than 1% of PBMCs. One of the 
current conventions of identifying these cells is to use a lineage marker (lin) to exclude 
other major cell populations (T/B/NK cells and monocytes) from analysis. Hence some DC 
markers are also expressed on non-DC populations. Therefore, this strategy identifies DCs 
as Lin-HLADR+ phenotype in blood (Fig 4-3 B). This strategy was utilised to assess total 
numbers of DCs with DC subsets identified as CD11c+ mDCs and CD123+ pDCs (Fig 4-3 
D). CD1c is a MHC I class like molecule and highly expressed by mDCs. CD1c+ mDCs 
were also identified with this strategy. It was observed that all CD1c+ cells also express 
CD62L hence this double expression was utilised to identify this subset of DCs (Fig 4-3 
E). Specific expression of CD303 identifies a subset of pDCs using this marker only. pDCs 
also express high levels of HLADR molecule. This double positive expression was utilised 
to identify this subset of DCs (Fig 4-3 C).  
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Figure 4-1: T and B cells gating strategy 
Representative data of peripheral whole blood obtained from patients with/without metal hip implants. 
Blood was stained within an hour of phlebotomy and acquired subsequently. PBMC fraction was 
analysed using gating strategy below. Representative sample shown using pseudoclour contour 
bivariate dot plots. A: Ungated total events: cell events for CD45 (pan leukocyte lineage marker) vs 
SSC (indicative of granularity). This plot type permits distinguishing PBMCs from granulocytes, debris 
and counting beads (labelled as “Beads”). Subsequent cytographs are displayed within PBMCs gate. B: 
Identification of B cells are conducted by plotting events for CD19 (B cell-specific marker) expression 
versus HLADR positivity (highly expressed on APCs). C: CD4+ T cells identified by CD3 positivity 
(T cell-specific marker) and CD4 expression. D: CD8+ cells identified by CD3 vs CD8 positivity. E: 
Activated T cells are shown by CD3 vs HLADR expression (CD3+HLADR+). Non-activated T cell 
numbers are shown in the gate of CD3+HLADR-. F: CD62L positivity (L-selectin , lymph node 
homing marker for lymphocytes) used to distinguish naive (CD3+CD62L+) vs effector (CD3+CD62L-
)T cells.
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Figure 4-2: Monocyte gating strategy 
Representative data of peripheral whole blood obtained from patients with/without metal hip implants. 
Blood was stained within an hour of phlebotomy and acquired subsequently. PBMC fraction was 
analysed using gating strategy below. Representative sample shown using pseudoclour contour 
bivariate dot plots. 
A: CD45 (pan leukocyte lineage marker) vs SSC distinguishes PBMC population from other cell types 
and debris. Further plots are derived from the PBMC gate. B: CD86 expression on the CD16+ 
monocytes, CD86+ve and –ve events gated accordingly. C: CD86 expression on the CD14+ 
monocytes, CD86+ve and –ve events gated accordingly. D: pre-gating for high HLADR expression 
before sub-classification of monocyte subsets. E: monocytes segregated according to CD14 vs CD16 
expression into either CD14+CD16- (classical monocytes), CD14-CD16+ (non-classical monocytes) or 
CD14+CD16+ (intermediate monocytes) gates.  
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Figure 4-3: DC gating strategy 
Representative data of peripheral whole blood obtained from patients with/without metal hip implants. 
Blood was stained within an hour of phlebotomy and acquired subsequently. PBMC fraction was 
analysed using gating strategy below. Representative sample shown using pseudoclour contour 
bivariate dot plots. 
A: PBMCs identified utilising CD45
high
 vs SSC
low
 characteristics. B: CD303+ alone identifies another 
subset of pDCs, directly derived from from PBMC gate C: Lin-HLADR+ gate donates all DCs. 
Lineage antibody is a combination of CD3, CD14, CD19, CD20 and CD56 markers and absence of this 
staining provides specificity of DC identification.  D: CD11c+ mDCs and CD123+ pDCs determined 
within Lin-HLADR+ gate. E: CD1c+ DCs all displaying high levels of CD62L in peripheral blood 
(Pre-gated in Lin-HLADR+).  
A
B
C
D
E
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4.2.2 Measurement of serum and SF cytokines 
Soluble analytes were measured in serum and synovial fluid (SF) using a commercial kit in 
10-plex format (Procarta Immunoassay kit , Affymetrix), according to the manufacturer’s 
instructions. SF samples were centrifuged at 10,000 x g for 10 mins and the supernatants 
collected for assay. The kit utilises xMAP beads and Luminex technology. Briefly, xMAP 
(magnetic microspheres) which are internally labelled with red and infrared fluorophores 
with different intensity. Red laser excites both of these dyes which produce spectral 
signatures to locate the bead for a given analyte. Proteins of interest in test sample are 
captured by antibody coated beads followed by biotinylated detection of Ab. The sample is 
then incubated with a Streptavidin-PE conjugate, which is the reporter dye, and excited by 
the green laser. The digital signal generated from both red and green laser excitations are 
collected through photomultiplier tubes in Luminex200 instrument. Fig 4-4. demonstrates 
the details of experimental work flow. Luminex assays have a greater dynamic range of 
~1-10,000 pg/ml than alternatives i.e. ELISA, MSD. Hence it was chosen as method of 
choice. 
Serum and SF levels of GM-CSF, IFN-,IL-1, IL-6, IL-10, Leptin, M-CSF, TNF- 
,OPG, RANKL were determined. All samples were assayed in duplicate. Data was 
generated using StarStation 3.0 software, (Applied Cytometry Systems). Median 
Fluorescence intensity (MFI) was determined for each analyte with concentration 
calculated using 5Pl algorithm for the best curve fit, displayed as pg/ml. Serum versus SF 
read outs were compared with two-tailed student t-test test using GraphPad Prism 5.0. 
Multivariate analysis was conducted in MATLAb, MATWorks, inc. The Matlab 
commands script was written by Dr Marianne Defernez,(Analytical Science Unit, IFR).  
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Figure 4-4: Schematic description of Luminex based assays 
How Luminex based assays work. Capture protein: samples are incubated with magnetic 
beads overnight on a rocker. Detect capture protein: after a wash, biotinylated detection 
Ab is added and incubated for 30 mins.  Label with SAPE: after a wash, reporter dye 
added to sample and incubated for 30 mins. Read on Luminex: after the final wash, beads 
are resuspended in read buffer and run at Luminex 200 instrument. Further details can be 
found at  
 (https://www.panomics.com/products/multiplex-immunoassays/procarta-
immunoassays/overview ) 
Copyrights permission for the schema was granted from Procarta, Affymetrix , March 
2014.  
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4.3 Measurement of serum metal ions 
Serum samples were collected in Vacutainer Trace Element tubes (BD, 368380) and 
analysed by University Hospital of Wales, Cardiff. Serum levels of chromium and cobalt 
were analyzed using an Agilent 7700x Inductively Coupled Plasma Mass Spectrometer 
(ICP-MS), (Agilent Technologies UK LTD, Berkshire, UK). Samples, standards and 
quality control material were diluted 1 in 15 with diluent (0.1% EDTA, 0.01% Triton x100, 
0.2% ammonia and 20ppb of germanium) as an internal standard. Aqueous standards were 
used for calibration. Cr was analyzed at mass 52 and Co at mass 59 with helium as a 
correction gas.  
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4.4 Results 
 
The aim was to develop a rapid and sensitive assay which could be used during routine 
blood work to establish immune status of arthroplasty patients. Therefore a high content-
high dimension, 18 parameter flow cytometry assay was developed and this assay was used 
to detect immune cell numbers and composition in these patients. Absolute cell numbers 
were calculated along with expression of activation and adhesion molecules using ex-vivo 
whole blood samples. Cytographs were manually curated. Immune cells first were 
subdivided into T cells, B cells, monocytes and DCs based on specific lineage markers 
thereafter expression of activation and adhesion molecules were investigated. Patients 
comprising the four study groups were stratified according to their clinical status detailed 
in Chapter 2. G1: Pre-implant, G2: Ultima Asymptomatic, G3: Ultima Symptomatic and 
G4: Other Symptomatic. 
Immune cells composition 
All four patient groups displayed normal absolute levels of CD3+CD4+ T cells, 
CD3+CD8+ T cells and CD19+HLADR+ B cells (Table 4-4) compared with standard 
blood counts of healthy individuals. There were no significant alterations between clinical 
groups when group means were compared (Fig 4-5 A, B and C) however a few individuals 
showed increased number of CD8+ T cells (Fig 4-5 B) in the Ultima Asymptomatic group. 
Further, T cell analysis revealed that HLADR expression by CD3+ cells was also increased 
in Ultima Asymptomatic groups. HLADR expression by T cell is an indication of their 
activation. Analysis of CD62L expression demonstrated that CD62L+ T cells were 
increased in Ultima Asymptomatic group compared with Ultima Symptomatic group. This 
shows expansion of a less polarised T cell, consisting of naïve and central memory T cell 
population in this group (Fig 4-5 E). On the other hand there were no significant 
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differences between clinical groups in effector T cell populations, CD3+CD62L- (Fig 4-5 
F). No alterations of CD11b expression was observed between either cell type or clinical 
groups hence this parameter was excluded from further analysis.  
Monocyte subsets were categorised into three groups; investigation of first category 
classical monocytes, CD14+HLADR+ (Fig 4-6 A) showed elevated numbers of these cells 
in the Ultima Asymptomatic group. Further the myeloid cell activation marker CD86 was 
utilised to investigate activation status of these cells. Although the Ultima Asymptomatic 
group had a slightly increased mean signal for this group, the result was not statistically 
significant compared with other groups (Fig 4-6 B). Analysis of the second monocytes 
subsets, non-classical monocytes, CD16+HLADR+ did not reveal any differences between 
clinical groups (Fig 4-6 C). There were also no alterations in CD86+ expression (Fig 4-6 
D). A very similar picture was also present for the third monocyte subsets, intermediate, 
CD14+CD16+HLADR+. Cell numbers and activation status were comparable between the 
four clinical groups (Fig 4-6 E & F).   
Reference values for classical monocytes are well established and in this study classical 
monocytes were within the normal range for all groups (Table 4-4) with the only exception 
being the Ultima Asymptomatic group.  This group of patients had an elevated monocyte 
count above reference values which was statically significant compared to Ultima 
Symptomatic group (p = 0.0170). Non-classical and intermediate monocytes are emerging 
subsets therefore their reference values are not established. However, on average it is 
estimated that classical monocytes counts for around 90%, non-classical monocytes for 
10% and intermediate monocytes consist of very small and variable percentage of total 
monocytes. The results of this study also reflect this proportional distribution above Fig (4-
6 A, C & E).  
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There was very low or no detectable expression of CX3CR1 and CD83 by monocytes 
using ex-vivo samples in this study. Analysis of these markers was not possible on fresh 
non-manipulated blood.  
Total dendritic cell population plus four different subsets were investigated. The mean total 
blood DC number was 29.6 ±17.2 l/cells for all study groups. Table 4-4 details the 
average numbers for the individual groups. The results show that the total DC number was 
increased in the Ultima Asymptomatic group compared with the Symptomatic patients (p = 
0.0018) (Fig 4-7 A). Detailed analysis of DC subsets revealed that this increase was due to 
CD1c+ DCs (Fig 4-7 B) whereas all other DC subsets displayed numbers within the 
normal range (Fig 7-4 C, D, E & F).  
Overall immunophenotyping of this cohort of patients elucidated that immune cells 
investigated were within the normal range for all groups apart from Ultima Asymptomatic 
group. Specifically these alterations were confined to naïve/central memory T cells, 
classical monocytes and CD1c+ mDCs.  
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Table 4-4: Peripheral blood immune cell numbers in Norfolk cohort  
Normal range of immune cell numbers compared with patient’s results (mean ± SD) 
stratified into clinical subgroups 
 Reference 
values  
(cells/l) 
[100, 
101] 
 
Pre- 
implant 
(n = 15) 
Ultima 
Asymptomatic 
(n = 17) 
Ultima 
Symptomatic 
(n = 12) 
Other 
Symptomatic 
(n = 12) 
Th cells 
CD3+CD4+ 
500-1600 1014 ± 
372.3 
951.6 ± 
425.8 
639.0 ± 
188.9 
772.3 ± 
392.5 
 
CTL 
CD3+CD8+ 
300-900 360.5 ± 
189.6 
535.8 ± 
456.2 
255.2 ± 
180.7 
256.1 ± 
106.4 
 
B cells 
CD19+HLADR+ 
72-460 194.0 ± 
89.75 
159.9 ± 
92.48 
118.6 ± 
90.42 
172.9 ± 
104.0 
 
Monocytes 
CD14+HLADR+ 
150-600 417.9 ± 
133.3 
631.6 ± 
348.6 
394.8 ± 
203.2 
346.7 ± 
176.7 
 
Dendritic cells 
Lin-HLADR+ 
13-37 
[167] 
28.22 ± 
16.82 
41.61 ± 
18.73 
22.22 ± 
7.979 
21.99 ± 
14.44 
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Figure 4-5: Peripheral blood T and B cell absolute counts with activation markers 
Peripheral blood was analysed ex vivo. Patients were stratified into 4 groups according to clinical 
presentation. A: CD4+ T cell numbers. B: CD8+ T cell numbers C: B cell numbers D: Activated T cell 
numbers. E: Naïve and central memory T cell numbers F: Effector T cell numbers 
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Figure 4-6: Peripheral blood monocyte counts with activation markers 
Peripheral blood was analysed ex vivo. Patients were stratified into 4 clinical groups. A: Presents classical 
monocytes. B: CD86 expression on monocytes is indicative of activation. C: Presents non-classical 
monocytes. D: activated non-classical monocytes. E: Transitional monocytes express both CD14 and CD16 
markers named as intermediate monocytes F: activated intermediate monocytes, CD14+CD16+CD86+ . 
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Figure 4-7: Peripheral blood DC counts with activation markers 
Whole blood was analysed for dendritic cell constitution. All DCs express high levels of HLADR molecule 
hence used for identification. A: total number of denditic cells shown across different clinical groups. B: 
Representing CD1c+ myeloid DCs. C: Representing CD11c+ mDCs. D: Representing CD123+ plasmacytoid 
DCs E: Representing CD303+ plasmacytoid DCs. F: Dentritic cells almost always positive for CD62L. 
Lin-HLADR+
DCs
0
100
200
300
400
500 *
c
e
ll
s
/ 
l
CD1c+HLADR+
mDC
0
20
40
60
80
100
**
**
c
e
ll
s
/ 
l
Lin-HLADR+CD11c+
mDC
0
20
40
60
80
100
c
e
ll
s
/ 
l
Lin-HLADR+CD123+
pDC
0
20
40
60
80
100
c
e
ll
s
/ 
l
CD303+HLADR+
pDC
P
re
 - 
Im
pl
an
t
U
lti
m
a 
A
sy
m
pt
om
at
ic
U
lti
m
a 
S
ym
pt
om
at
ic
O
th
er
 S
ym
pt
om
at
ic
0
5
10
15
20
c
e
ll
s
/ 
l
CD303+CD62L+
pDC
P
re
 - 
Im
pl
an
t
U
lti
m
a 
A
sy
m
pt
om
at
ic
U
lti
m
a 
Sy
m
pt
om
at
ic
O
th
er
 S
ym
pt
om
at
ic
0
5
10
15
20
25
c
e
lls
/ 
l
A B
C D
E F
- 96 - 
Ex vivo cytokine measurement 
The Luminex assay displayed high sensitivity and robust experimental outcome technically 
as shown by the standard curves generated (Fig 4-8). The patient’s serum contained very 
low or undetectable levels of IFN-, IL-10, IL-6, IL-1, M-CSF, TNF- and RANKL (Fig 
4-9 & Table 4-5) whereas GM-CSF, Leptin and OPG were detectable. SF levels of IFN-, 
IL-10 and TNF- were also low however GM-CSF, IL-1, IL-6, Leptin, M-CSF, OPG and 
RANKL were readily detectable in this sample type (Fig 4-10 & Table 4-5). There were no 
significant differences in the levels of cytokines between the clinical groups analysed 
either in serum (Fig 4-9) or SF (Fig 4-10). However when the data was paired for the 
individual’s serum versus SF readings, there were significant differences in summated 
cytokine levels favouring SF samples. Seven out of 10 analytes investigated showed higher 
concentrations in SF compared to blood (Fig 4-11). The respective p values are displayed 
in the graphs.  
The data was further scrutinised with multivariate analysis using an unsupervised data-
reduction method; Principal Component Analysis (PCA). PCA considers all measurements 
at once and expresses the data in a simplified manner. PCA has the potential for more 
vigorous assessment of the immune status in accordance with the multifunctional nature of 
cytokines. This method was applied to both serum and SF data with and without scaling. 
Data scaling did not influence the outcome therefore results was presented without scaling. 
Patient 35 was excluded from analysis of PCA in serum, hence identified as an outlier 
skewing analysis. 
First the loading characteristics of each measurement were tested in serum and SF (Fig 4-
12 A & Fig 4-13 A). Loading indicates the weight of each measurement in the combination 
of analytes measured.  Leptin (PC1) and OPG (PC2) were the main principal components 
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in serum. Leptin was also the main variable in SF (PC1) however PC2 was IL-6 in this 
sample type. 
PC1 versus PC2 was plotted to see if there was any clustering effect firstly for individual 
patients (Fig 4-12 B & Fig 4-13 B), secondly for clinical groups (Fig 4-12 C & Fig 4-13 C) 
and thirdly for gender (Fig 4-12 D & Fig 4-13 D).  
Having compared all the analytes together, there was no clustering effect between any of 
the individuals either in serum or in SF samples. Analysis of clinical groups also did not 
reveal any confounding differences between groups. Stratifying patients into male and 
female also did not correspond to any gender-related effect in this cohort. Apart from 
analysis of Leptin showed that this cytokine is at higher concentrations in females 
compared to males (Fig 4-12 D and Fig 4-13 D). Leptin is produced by adipose tissue and 
females tend to have higher percentage of body fat compared to males, therefore this result 
was expected.  
Correlation between every single analytes against each other was investigated using 
Pearson correlation test for both serum and SF readings. In order to deal with multiple 
testing error, a simulation test was carried out. Statically significant (p < 0.05) threshold 
value was calculated for R values by carrying out simulation test. Simulation was applied 
10,000 repeats of normal distributed random numbers using the same sample size as study, 
(10 columns x n = 55) for serum and (10 columns x n = 24) for SF. Correlation matrix then 
interrogated for R values. The results revealed that r = 0.42 was statically significant for 
serum and r = 0.62 for synovial fluid.  
A large number of analytes were correlated in the serum, respective correlation coefficient 
are displayed in the Fig 4-14. This is expected since all of these patients are representing 
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osteoarthritis and co-morbidities are common in this age group. However there were no 
differences in cytokine levels between the groups as shown in Fig 4-9.  
There were not any considerable correlations in synovial fluid (Fig 4-15). 
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Figure 4-8: Standard curves for cytokine measurement 
Standard curves generated for Luminex assay using 5 Parameter logistic curve fit and sample concentration 
was calculated by extrapolating mean fluorescence intensity from these plots. Correlation Coefficient value 
(R
2
) is presented on relevant graphs.  
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Figure 4-9: Serum cytokine levels 
Ten different cytokine levels were measured in patient’s serum, displayed as pg/ml. Data was stratified according to clinical groups and was analysed using one-way 
ANOVA. There were no statically significant differences between groups. (Pre-implant n=15, Ultima Asymptomatic  n=17, Ultima Symptomatic n=12, Other  =12).  
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Figure 4-10: SF cytokine levels 
Synovial fluid was collected intra-operatively and analysed for ten different cytokine levels, displayed as pg/ml. Data was stratified according to clinical groups and was 
analysed using one-way ANOVA. There were no statically significant differences between groups. (Pre-implant n=15, Ultima Asymptomatic n=17, Ultima 
Symptomatic n=12, Other Symptomatic n=12).  
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Table 4-5: Summated cytokine concentration in patient’s serum and SF 
Serum (pg/ml) GM-CSF IFN- IL-10 IL-1 IL-6 Leptin M-CSF OPG RANKL TNF- 
Minimum 30.94 0.1884 0.0313 0.2500 0.4290 1463 0.2500 2.000 0.3732 0.2500 
25% Percentile 93.15 0.6538 0.2346 0.2500 0.4290 5046 0.2500 442.5 0.3732 1.380 
Median 145.9 1.892 0.5348 0.5260 0.4290 9148 0.5604 656.2 0.3732 2.391 
75% Percentile 221.4 3.936 0.8149 0.8210 8.715 15354 0.8707 1370 8.301 4.641 
Maximum 524.8 15.33 8.957 9.190 56.43 37725 2.357 3973 118.1 25.53 
Mean 171.3 2.744 0.8262 0.8423 9.022 12011 0.6763 955.8 7.145 3.580 
Std. Deviation 110.7 2.947 1.299 1.298 15.86 9228 0.5224 759.3 22.43 3.823 
Std. Error 14.80 0.4254 0.1737 0.1800 3.738 1244 0.08158 102.4 4.316 0.5203 
Lower 95% CI of 
mean 141.6 1.888 0.4782 0.4808 1.135 9516 0.5114 750.5 -1.727 2.536 
Upper 95% CI of 
mean 200.9 3.599 1.174 1.204 16.91 14506 0.8412 1161 16.02 4.623 
SF (pg/ml)  
Minimum 104.2 1.043 0.6923 0.7012 8.000 993.4 21.58 394.5 2.000 0.3850 
25% Percentile 166.8 2.702 3.850 3.134 860.1 3506 149.4 856.6 7.736 0.3850 
Median 202.5 5.064 6.205 32.86 3647 6168 274.0 1619 63.77 2.306 
75% Percentile 307.3 13.30 9.649 104.4 10429 11170 666.4 9318 154.7 6.866 
Maximum 579.4 55.70 25.39 491.0 27125 73145 1345 12390 236.8 25.59 
Mean 254.2 8.912 7.589 91.48 6203 10816 434.9 4251 81.41 4.150 
Std. Deviation 126.2 11.32 5.885 144.0 7096 15010 393.6 4613 79.07 5.512 
Std. Error 25.77 2.311 1.201 29.39 1448 3064 80.35 1191 19.18 1.125 
Lower 95% CI of 
mean 200.9 4.131 5.104 30.69 3206 4478 268.7 1697 40.76 1.823 
Upper 95% CI of 
mean 307.5 13.69 10.07 152.3 9199 17154 601.1 6806 122.1 6.478 
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Figure 4-11: Comparison of cytokine levels in serum versus synovial fluid 
Concentrations of respective analytes in serum (n = 56) and SF (n = 24) was compared. Each data point represents a patient. Matching 
samples were paired where possible. Serum concentration of cytokines levels were compared with SF concentrations using two tailed paired 
t-test. 
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Figure 4-12: PCA analysis of cytokines in serum 
G1: Pre-Implant, G2: Ultima Asymptomatic, G3: Ultima Symptomatic, G4: Other 
Symptomatic. F: Female, M: Male  
Principal Components Analysis of serum mean MFI data (no scaling). A: Loadings for 
PC1 (blue) shown to be Leptin and PC2 (green) shown to be OPG B: showing individual 
patients demonstrated by their study number. C: Indicating patients stratified into their 
clinical groups D: Male versus female compared. Axes labels indicates percentage 
variance represented by each component. 
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Figure 4-13: PCA analysis of cytokines in synovial fluid 
Key: G1: Pre-Implant, G2: Ultima Asymptomatic, G3: Ultima Symptomatic, G4: Other 
Symptomatic. F: Female, M: Male  
Principal Components Analysis of synovial fluid in operative patients; groups G1, G3 and 
G4. Mean MFI data (having removed OPG due to 7/24 missing values) (no scaling). A: 
Loadings for PC1 (blue) shown to be Leptin and PC2 (green) shown to be IL-6 B: showing 
individual patients demonstrated by their study number. C: Indicating patients stratified 
into their clinical groups D: Male versus female compared. Axes labels indicates 
percentage variance represented by each component. 
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Figure 4-14: Analysis of cytokine correlation coefficients in serum 
a) Each histogram showing the distribution of one of the analytes (labelled respectively) X 
axis = unit of measurement (median fluorescence intensity), y axis = frequency. b) Scatter 
plots showing correlation matrix. The level of each cytokine (median fluorescence 
intensity) was compared to the other cytokine (9x9).  c) Table displaying values for R. 
correlations that are higher than cut off value of 0.42 (determined by simulation test) were 
highlighted in blue, n = 55.   
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Figure 4-15: Analysis of cytokine correlation coefficients in synovial fluid 
a) Each histogram showing the distribution of one of the analytes (labelled respectively) X 
axis = unit of measurement (median fluorescence intensity), y axis = frequency. b) Scatter 
plots showing correlation matrix. The level of each cytokine (median fluorescence 
intensity) was compared to the other cytokine (9x9).  c) Table displaying values for R. 
there were no significant correlations that are higher than cut off value of 0.62 (determined 
by simulation test), n = 24.  
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Metal ion Levels 
Serum metal ion levels were measured and the results revealed that both Co and Cr levels 
were elevated in patients with a MoM compared to the control Pre-implant group. Serum 
Co levels were significantly increased in both Ultima Asymptomatic (p = 0.0007) and 
Ultima Symptomatic group (p = 0.002) compared to pre-implant. Mean serum Co levels in 
the Other MoM group were also increased however it was not significant compared to the 
Pre-implant group (Fig 4-14 A). Showing Co levels were much higher in Ultima groups 
compared to other metal implant groups. Mean Co serum levels were 13.06 g/L (range 
3.66 to 47.42) for the Ultima asymptomatic group and 10.04 g/L (range 1.49 to 29.05) for 
the Ultima symptomatic group. This indicates that both of the Ultima groups had serum 
levels higher than the diagnostic cut off (7g/L).  
Serum Cr levels also were raised in all three MoM implant groups compared to the Pre-
implant group (Fig 4-14 B). The Ultima Asymptomatic and the Symptomatic groups had 
elevated Cr levels compared to the Pre-implant group (p = 0.0015 and p = 0.0407). 
However the mean serum levels were below the diagnostic cut off level of 7g/L.  
Highest levels of both Co and Cr were found in the Ultima Asymptomatic group which had 
a well-functioning implant. This elevation was not due to the in-situ implant time as three 
groups had a similar average in situ period (G2:130 ± 26, G3:139 ± 23 and G4:123 ± 54 
months).  Mean cobalt levels were higher than chromium levels in the Ultima groups. 
Cobalt is the most abundant metal in the Ultima implant which may explain higher levels 
of Co compared with Cr.  
The mean Co levels were much higher than clinical recommendation in Ultima groups, this 
was especially very significant in Ultima Asymptomatic group (p = 0.0007). This finding 
correlates with this group’s cell counts demonstrated with immunophenotyping. This was 
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the only group had an aberrant immune cell values in peripheral blood. Increased Co levels 
may explain the altered immune cell composition in the Ultima Asymptomatic group.  
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Figure 4-16: Serum cobalt and chromium levels 
(A) Serum Cobalt and (B) Chromium Levels; Determined by ICP-MS. Levels expressed in 
g/L for Pre-Implant (n = 11), Ultima Asymptomatic (n = 15), Ultima Symptomatic (n = 
11) and Other Symptomatic patients (n = 9). Metal ion levels were compared between 
groups using unpaired t test with Welch’s correction and p values displayed on the graphs. 
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4.5 Discussion  
 
MoM implant patients were investigated for their immune cell composition, serum and SF 
cytokine levels and serum metal ion concentrations.  
Assessment of the quantitative and phenotypic modifications of peripheral blood 
leukocytes was conducted by flow cytometry. An extensive immunophenotyping was 
undertaken; investigating 18 different antigenic targets concurrently. Blood leukocyte 
levels were normal in all groups studied apart from the Ultima Asymptomatic group. In 
this group variation was evident in T lymphocytes with increased expression of HLADR 
and CD62L. Naïve T cells do not normally express HLADR antigen and increased 
abundance of it is an indication of immune stimulation hence CD3+HLADR+ phenotype 
identifies activated T lymphocytes. CD62L is a ligand for CD34, GlyCAM and 
MAdCAM-1 receptors in secondary lymph nodes and expression of this ligand is an 
indication of lymph node homing for T cells therefore T cell-mediated heighten immune 
surveillance was evident in this group. Whilst some groups showed CD8 lymphopaenia 
[168] others demonstrated the opposite; increased levels of CD8+HLADR+ lymphocytes 
in MoM patients [169, 170].  
The MoM literature often demonstrates the relative cell numbers comparing one study 
group to another with single colour staining. However, in the current study the absolute 
cell numbers were determined with multiple markers ensuring lineage specificity. This is 
important to warrant integrity of the data and subsequent interpretation.   
In the current study, there was also an increase of CD3+HLADR+ cells. This was due to 
the CD8 population in the Ultima Asymptomatic group but not in the failed groups. 
Increased HLADR expression on CD8+ T cells attributed to enhanced telomerase activity 
and proliferation and are distinct from cytolitic CD8+ T cells [171]. Elevation of 
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CD8+HLADR+ T cells were observed in stable Human Immunodeficiny virus-infected 
individuals [172] and proposed to be marker for a stable acquired immune deficiency 
syndrome in the presence of normal levels of CD4+ cells. This suggests a protective 
mechanism might have been maintained by this subset of T cells. The results of the current 
study is in agreement with literature where stable MoM patients demonstrated increased 
number of CD8+HLADR+ T cells in the presence of normal CD4+ counts.  
Particulate debris generated by wear is the main initiator of the destructive process that 
leads to peri-prosthetic osteolysis [173] . The most important cells in this scenario are 
monocytes/macrophages which respond to particle challenge by phagocytosis. This 
mechanism should ensure decreased inflammation by containment of the wear particles.  
However monocytes are associated with tissue destruction in the literature [174]. 
Inflammation is a highly regulated process tightly linked to simultaneous stimulation of 
tissue protective and regenerative mechanisms to prevent collateral damage. Monocytes 
either could be inflammatory or homeostatic/regulatory. In the current study, finding an 
increased number of monocytes in the Asymptomatic group might be due to regulatory 
processes that are in place in this group.  
Further, CD1c DCs were also increased in the same group. CD1c+ DCs are the most 
abundant subpopulation of DCs and have a specialised role in presentation of non-protein 
antigens. The presence of DCs in synovial fluid and synovial tissue is documented in 
arthritic conditions [175]. CD1c+ myeloid DCs have been shown to induce T cells in RA 
patients [176]. However, CD1c+ DCs also have shown to have an immunoregulatory 
function [177] [178]. The classical macrophages and myeloid dendritic cells are two major 
source of antigen presentation. APCs are needed for antigen-specific T cell activation 
which may explain increased number of APCs along with activated T cells in this group. 
Finding increased CD1c+ DCs, along with activated T cells and classical monocytes, might 
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be an indication of a regulatory mechanism that keeps metal sensitisation under control in 
the Asymptomatic Ultima group. The nature of this increase is not known in the current 
study hence specialised markers for regulatory cells were not investigated. However one 
would assume that the heightened immune status might be due to the immune surveillance 
or even a regulatory mechanism resulting in this group which has a well-functioning 
implant.  
CD86 is a co-stimulatory molecule and binds to CD28 and CD152 (CTLA-4) on T cells. It 
is up regulated in activated monocytes and crucial for T cell activation.  Investigation of 
CD86 up-regulation in all three monocyte subsets did not reveal any difference between 
the clinical groups. Altaf et al demonstrated increased CD86 expression on monocytes 
after challenge with Co/Cr particles in vitro [146] compared to non-challenged cells, 
demonstrating induction of antigen presentation upon metal challenge. This was not 
evident in the current study. Two investigation set up is quite different from each other. In 
the current study cell were not re-challenged in vitro, instead samples were analysed 
directly ex-vivo and only had been challenged in vivo by in situ implant.  
A lymphocyte-mediated inflammatory reaction has been shown around the metal implants 
histologically [56], which demonstrated lymphocytic infiltration into implant site. In this 
study, the local cellular immune response was also investigated in synovial fluid. The cell 
composition was analysed using flow cytometry with panels above, utilising an enzymatic 
digestion prior (data not shown). It was not feasible to demonstrate reliable cell counts 
with this type of sample due to the nature of the SF matrix having complex proteins results 
in viscous material. It was concluded that SF was not a suitable sample type for a routine 
flow analysis. This difficulty was also reported by other groups [175] [179] however some 
groups have demonstrated the presence of T cells, macrophages and DCs in SF [176].  
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Soluble mediators such as cytokines, chemokines and growth factors are known to be 
involved in the pathophysiology of implant failure [150, 180]. Using a sensitive assay, 
investigation of ten different analytes has not shown a strong link between the known 
clinical groups examined and the array of cytokines measured in this study. However other 
sources of variability, not tested in the current study, might be present. Beekhuizen et al 
also investigated SF samples in OA patients for 47 different analytes. They looked at end-
stage OA patients and found that IL-6, IP-10, MDC, PDGF, Leptin, IL-13, MIP-1b, 
CD40L and RANTES were higher, whereas eotaxin and G-CSF levels were lower in OA 
patients compared to healthy controls [181]. Comparing available data from Beekhuizen’s 
study with the present study reveals that the Ultima cohort had higher levels of IL-10 and 
IL-1 however lower levels of IFN- and Leptin. IL-10, IL-1 and IFN- all were at very 
low levels in both studies questioning the reliability of these read outs. Wong et al reported 
that a screening study of healthy individuals also revealed the serum IL-1, IFN- were 
undetectable in the majority of samples [182]. All of these studies had too few numbers of 
subjects to come to definitive conclusions however this explorative approach might be a 
valuable reference for future experiments.   
Serum cytokine levels might be transient in these patients therefore hard to monitor. 
Cytokines levels were almost always higher in SF compared to serum. SF might be a better 
sample type to study cytokine levels however this sample type is not easily obtainable. 
Investigation of serum and SF soluble mediators did not show strong evidence of 
inflammation in this cohort, which contradicts with the body of literature. 
Having found significant differences in serum Co/Cr levels post-operatively has been 
described in MoM patients previously [183, 184] However, finding the higher levels of Co 
in the Asymptomatic metal implant group is striking. The mean serum Cr levels were also 
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highest in these patients, however they were mostly under the diagnostic cut off (7 g/L) in 
this study. There is some dispute regarding acceptable levels of metal ions and their 
clinical significance [162]  therefore these levels may need adjustment in future. On the 
other hand, the mean serum Co levels were above the clinical diagnosis cut off. The Ultima 
alloy consists predominantly of Co and this may be the main source of the problem. It has 
been shown that cobalt is more reactive than chromium in human macrophages. The cobalt 
exposure to peripheral immune cells results in inflammatory macrophage induction [185]. 
Hart et al investigated peri-prosthetic Ultima retrieval tissue using synchrotron-X-ray 
absorption spectroscopy (XAS). They found that cobalt was most abundant in the peri-
prosthetic tissue of Ultima patients. They also compared the ratio of Co to Cr for each 
tissue and showed than Co is 10 times more abundant than Cr in the tissue surrounding 
Ultima hips [186].  
The Ultima implant carrying patients are rare as this implant was discontinued in 2005 
which limited the number of cases that were available for the study. The total number of 
subjects was 56, with the Ultima group consisting 29 patients. Even though the number of 
parameters studied were extensive, the number of subjects was limited which constrained 
the analysis. Therefore this pilot study in metal implant failure should inform of parameters 
studied and further work necessary to confirm these data.  
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5 CHAPTER 5 – In vitro assessment of metal particle impact on immune cells 
5.1 Introduction 
 
Aseptic loosening as a result of osteolysis is the most frequent cause of implant failure. 
The cell mechanisms involved in this phenomenon are of major research interest. 
Osteolysis in the MoM implant hip is described as active resorption of bone matrix at the 
location where bone meets the implant (peri-prosthetic osteolysis). Peri-prosthetic 
osteolysis leads to an imbalance in structural bone loading and chronic inflammation. In 
healthy individuals bone resorption by osteoclasts is followed by bone formation by 
osteoblasts and is a natural part of osteogenesis.  However, in implant failure this cycle is 
disturbed; osteolysis overwhelms ossification process. In total hip replacement, osteolysis 
is thought to be the result of an immune response where immune cells attempt to clear 
implant wear particles. Clinically, osteolysis can be asymptomatic, however chronic 
exposure to wear particles results in continuous immune cell infiltration at the implant site. 
Subsequent inflammation can cause the symptoms seen in implant failure [187].  
Osteoclasts are the main bone absorbing cells although macrophage-mediated bone 
resorption has been demonstrated [188]. Osteoclast activity is modulated by neighbouring 
stromal cell, osteoblasts and immune cells. In the absence of infection, macrophages have 
been shown to be activated by implant debris which leads to osteoclastogenic activity. 
Macrophages challenged by metal particles produce pro-inflammatory mediators that 
facilitate osteolysis [189] . IL-1, TNF- and IL-6 secreted by macrophages and T cells 
enhance bone resorption by increasing the pool of osteoclastic progenitors and also by 
stimulating differentiation to mature osteoclasts [155, 190]. Therefore, secondary cell 
types, such as immune cells can contribute to bone remodelling by either direct contact or 
soluble factors i.e. cytokines and growth factors [191]. For example, M-CSF, GM-CSF 
- 117 - 
along with RANKL are necessary for osteoclast activation. On the other hand IFN- 
inhibits RANKL-induced osteoclastogenesis [192]. Leptin and IL-10 have been shown to 
inhibit osteoclastic activity by stimulating osteoblasts and blocking NFkB pathway in 
osteoclasts, respectively [193].  
How the metal wear debris incite an inflammatory response is not fully understood. 
However, host proteins are thought to be involved in metal particle recognition by immune 
cells. Serum protein coupling to alloy particles can be described as opsonisation which 
influences recognition and uptake of foreign material by phagocytotic cells. With respect 
to orthopaedic wear debris, opsonisation of alloy particles with serum has been shown to 
enhance phagocytic capacity and activation of macrophages [194]. The protein binding 
profile of Co-Cr-Mo alloy particles is different compared to elemental cobalt or chromium 
particles. It has been shown by micro-sequencing that Co-Cr-Mo alloy couples with two 
distinct serum proteins of 68 kDa albumin and 47 kDa alpha-1 antitripsin [195] . Also, 
serum coupling to metal alloys has been shown to increase lymphocyte reactivity [196]. 
Opsonisation therefore, might be important in the activation of lymphocytes contributing to 
implant failure. This was investigated in the current study where cells were cultured in the 
presence of autologous serum.  
Interactions between metal particles and cells depend on the size, number of particles 
present, material composition, chemical state and interaction matrix [197-199] . It has been 
shown that nanoparticles smaller than 10 nm are internalised by the cells in an energy- 
independent manner using pre-existing pores in the membrane. Whereas the large particles 
with size distribution of 20-100 nm, are taken up through micropinocytosis and larger 
particles utilise macropinoctotic pathways [200]. Particles larger than 100 nm are not 
extravasated into blood vessels and remain trapped at the location of generation. They are 
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therefore expected to dominate the immune reaction at the site of generation. On the other 
hand smaller particles can accumulate in distant organs via blood circulation, or can be 
transported from organ to organ in vivo.  
Doorn et al studied 13 Co-Cr-Mo revision patients. Enzymatic digestion of peri-prosthetic 
tissue revealed that most of the Co-Cr-Mo wear particles were smaller than 50 nm on 
average (range 6-834 nm) and round to oval in shape with irregular boundaries. This size 
range is considerably smaller than that reported for polyethylene particles [201]. It has 
been estimated that patients with MoM implants generate between 6.7x10
12
 and 2.5 x10
14
 
metal particles a year [64]. However, it not possible to measure precisely the particle load 
in tissues in vivo.  
Aims and Hypothesis  
In the current study, to better understand the immune cells response to metal alloy particles 
an in vitro cell culture model was set up. PBMCs were exposed to metal alloy particles and 
their response was then assessed. Dose dependent immune activation profile was 
investigated using metal particles that were characterised for shape, size and concentration. 
It was hypothesised that metal ions/particles induce reactivity in PBMCs which results in a 
pro-inflammatory response. The hypothesis was tested by studying proliferation profile of 
PBMCs and cytokine production capacity upon metal particle exposure. 
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5.2 Materials and Methods 
 
5.2.1 In vitro metal nanoparticle generation 
 
Several studies have described MoM wear particle characteristics and the resulting general 
consensus is that the average particle size generated in vivo is on a nanometer scale rather 
than micrometer range [34, 52]. Taking this into consideration, an in vitro system was used 
to generate nano-size metal alloy particles which would represent in vivo wear particles. A 
novel approach was undertaken where a metal hip implant was broken into nanoscale 
particles using a laser.   
An Ultima
®
 THR TPS implant, which has a Co-Cr-Mo alloy stem was laser ablated 
(Particular GmbH, Germany). Fig 5-1 shows a schematic description of the particle 
generation process.  An Ultima implant was physically ablated in sterile water using a laser 
(TruMicro 5050, TRUMF USA), at a repetition rate of 200 Hz and a reduced pulse energy 
of 50 µJ (average power: 10 W) with the laser pulse duration of 10 picoseconds. This 
procedure uses no chemicals hence it produces ligand free samples for biological 
applications. The concentration of the alloy-colloid solution was determined to be 100 
mg/L by atomic absorption spectrometry.  
The procedure above produced an alloy colloid suspension. Properties of this colloid 
suspension were investigated for particle size and particle number using NanoSight system 
(NanoSight, Malvern). Furthermore, transmission electron microscopy (TEM) was used to 
determine shape characteristics of alloy particles.  
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A                                                                 B                                                        C                                                                       
 
Figure 5-1: Colloid generation by laser ablation 
An Ultima
®
 TPS implant, a Co-Cr-Mo alloy MoM THR, was laser ablated  to generate metal particles of a similar size to those seen in 
vivo.  A: Laser irradiation: Laser (10 W) applied to material in water with 10 picosecond pulses.  B: Particle nucleation: Cleaved 
nanoparticles stay in cavitation bubble for a microsecond (s). M+ represents ionised metal particles. C: Particle realease: Cavitation 
bubble bursts and releases nanoparticles within millisecond (ms) to sesond (s).   
Laser pulse
(ps - ns)
Liquid
Implant
Cavitation
(µs)
Particle release 
(ms - s)
M+
M+
M+
M+
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5.2.2 Characterisation of metal colloid size and particle number  
 
Metal nanoparticle suspensions generated in water by laser ablation system were tested for 
particle size and number using NanoSight technology (Model: LM10 model, Malvern UK).  
Fig 5-2 depicts the instrument set up and its compartments schematically. When the laser 
hits the particles in the sample this produces a side scatter profile which is then measured 
using image capture (Fig 5-2 A). The instrument images individual particles using a 
microscope plus camera system. Nanoscale particles in liquid move with Brownian motion 
and smaller particles move faster than larger particles. The camera captures movement of 
each particle within a given time (Fig 5-2 B). Therefore the average distance of movement 
(particle diffusion coefficient, Dt) is recorded in the video. The rate of movement is 
influenced by the viscosity of the liquid that the sample is in, the temperature and size of 
the particle, and it is not related to particle density or refractive index. Because each 
particle is tracked individually this produces high resolution results for particle size 
determination. The particles’ motion is recorded by the software for each frame and the 
particle size is then calculated using the Stokes-Einstein equation.  
Equation 5-1: Stokes-Einstein formula  
Dt <x,y>2 = 
KB T ts
3 π η dh
 
Dt: diffusion coefficient, mean square of displacement 
T: temperature 
η : solvent viscosity 
dh: hydrodynamic diameter 
KB: Boltzmann's constant = 1.3806488×10
−23 
 π  = 3.14159 
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A                                                                                                   
 
B 
 
Figure 5-2: The NanoSight System 
Size distribution of nanoparticles was determined using NanoSight 
http://www.nanosight.com/technology. A: Instrument set up B: A representative read out 
of Co-Cr-Mo alloy particles 
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5.2.3 Characterisation of metal particle shape and cellular uptake  
Transmission electron microscopy produces high resolution images and provides 
information of sub-cellular biological structures, morphology of organelles and their 
interactions with treatment compounds at the molecular level. Therefore this method was 
chosen as one of the methods to test the metal alloy’s impact on immune cells.   
Cell cultures 
Primary cells were isolated as PBMCs from three healthy volunteers using Ficoll-Hypaque 
density gradient separation. The required amount of Na-Heparin whole blood was layered 
over Histopaque 1077 density (Sigma, Cat No: 10771) in an Acquspin tube (Sigma, Cat 
No: A2055-10EA) and centrifuged 15 mins at 800g at 21°C, followed by aspiration of 
opaque layer consisting of mononuclear cells. Cells were washed with isotonic Hanks’ 
Balanced Salt solution (HBSS) twice at 300g for 5 mins and resuspended in Ex-ViVo 15 
plus 10% autologous serum for down-stream processing. Cells were incubated with 100 
g/L metal nanoparticles for 2, 24 and 48 hours at 37°C in 95% O2+ 5% CO2. After the 
incubation period, the cells were transferred into 1.5 ml Eppendorfs and centrifuged at 
300g for 2.5 minutes. The supernatant was then carefully removed and replaced with 1 ml 
of 2.5% glutaraldehyde in 0.1M PIPES buffer. Cells were resuspended in glutaraldehyde 
and fixed for 2 hours at 21°C.  
Transmission Electron Microscope method  
Cell suspensions were centrifuged and washed in 0.1M piperazine-N,N'-bis-2-
ethanesulfonic acid  (PIPES) buffer three times. After the final centrifugation, the cell 
pellets were mixed 1:1 with molten 2% low gelling temperature agarose (TypeVII Sigma, 
Cat No: A-4018), which was solidified by chilling and then chopped into small pieces 
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(approximately 1mm
3
). Sample pieces were post-fixed in 1% aqueous osmium tetroxide 
for 2 hours then, after PIPES buffer washes, dehydrated through a series of ethanol 
solutions (10, 20, 30, 40, 50, 60, 70, 80, 90, 3x 100%). After the 3rd change of 100% 
ethanol: the ethanol was replaced with a 1:1 mix of 100% ethanol to LR White medium 
grade resin and put on a rotator for 1 hour 21°C. This was followed by a 1:2 and a 1:3 mix 
of 100% ethanol to LR White resin and finally 100% resin, with at least 1 hour between 
each change. The resin was changed twice with fresh 100% resin with periods of at least 8 
hours between changes. The sample pieces were each transferred into BEEM
®
 embedding 
capsules with fresh resin and polymerised overnight at 60°C. 90 nm thick sections were cut 
using an ultramicrotome (Ultracut E, Reichert-Jung) with a glass knife, collected on 
film/carbon coated copper grids, and stained sequentially with uranyl acetate and lead 
citrate. The sections were examined and imaged in a FEI Tecnai G2 20 Twin transmission 
electron microscope at 200kV. 
Images were acquired by Kathryn Cross at the Norwich Research Park Bioimaging Centre.  
5.2.4 Measurement of cell proliferation  
 
Colorimetric assay tetrazalium salt reduction in mitochondria: 2,3-Bis(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay or fluorescent labelling of 
cytoplasmic amine groups by Carboxyfluorescein succinimidyl ester (CFSE) were utilised 
for proliferation measurement. 
Measurement of cell proliferation with XTT 
Colorimetric assays that primarily use reduction of tetrazolium salts provide an estimate of 
cell proliferation indirectly by measuring mitochondrial activity in an entire cell population 
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[202]. The XTT assay is based on the principle that tetrazolium salts are reduced to 
formazan by mitochondrial dehydrogenases in viable cells. 
Foetal Bovine Serum (FBS) is commonly used in immunological experiments and human 
lymphocytes may proliferate in response to xenogeneic proteins in FBS. For this reason 
using FBS was omitted, instead autologous serum samples were supplied to culture media 
of Ex-ViVo15 (Lonza, BE04-744Q without phenol red and gentamicin). 
Phytoheamagglutinin (PHA) mitogen was used as a positive control, which primarily 
stimulates T cell proliferation. PBMC proliferation was measured using XTT at 1g/ml 
plus 1% phenazine methosulfate (PMS), (Sigma-Aldrich, Cat no; TOX2). The solution of 
XTT prepared in media is yellowish in colour; viable cells reduce the XTT ring which 
causes colorimetric change into orange. The absorbance of the resulting orange solution is 
measured spectrophotometrically at 450 nm. An absorbance reading of 690 nm was also 
measured and subtracted from the 450 nm value as background correction.  
The protocols published by Mull et al and Roehm et al, were followed [202, 203]. Briefly, 
PBMC were cultured in serum free X-ViVo 15 media plus heat inactivated (at 56°C for an 
hour) 10% autologous serum was added to each well.  As a positive proliferation control 
lectin from Phaseolus vulgaris (PHA, Sigma-Aldrich Cat no: 61764-1MG) was used at 
1g/ml final concentration.  
PBMCs were seeded at 2x10
5
 cells/well in triplicates and cultured with metal particles at 
concentrations of 10, 50 and 100 g/L. They were then incubated at 37°C with 5% CO2 in 
96-well flat bottom tissue culture plates. XTT was reconstituted in media and pre-warmed 
at 56°C for an hour to dissolve, then vortexed briefly just before use. At the end of the 
incubation period the XTT was added at a volume equal to 20% of the total culture 
volume (i.e. 50 l in 200 l cells).  This was followed by an incubation of 4 hours on a 
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gyratory rocker at 37°C with 95% O2 plus 5% CO2. All procedures were carried out 
aseptically. The absorbance was measured using a spectrophotometer (BioRad, 
Benchmark Plus microplate). 
 
Measurement of lymphocyte expansion rate with PI+CFSE  
CFSE (eBiosciences CatNo: 65-0850-84) staining was combined with propidium iodide 
(PI Sigma, P4170) to assess lymphocyte expansion rate and to discriminate live/dead cell 
populations.  
CFSE crosses intact cell membranes readily where intracellular esterases cleave the 
acetate groups of CFSE to yield the carboxyflurescein molecule which is fluorescent and 
measured by flow cytometry using 488 nm laser (ex / em: 494/521 nm). The 
succinimidyl ester group reacts with primary amines of the cell, this crosslinks the dye to 
intracellular proteins. By each cell division daughter cell contains half of the CFSE 
relative to mother cells and this is used as indication of proliferation. PI only stains dead 
cells through penetrating damaged cell walls. PI binds to nucleic acids in cells 
intercalating to DNA. Negative PI signal is indication of intact cell membrane therefore 
cell vitality (ex / em: 535/617 nm). 
PBMCs were prepared as described above and incubated with CFSE at 1M/final 
concentration.  Cells were mixed by vortexing and incubated 10 mins at 21°C in the dark. 
CFSE labelling was stopped by adding 5 x volume of complete media chilled in 4°C. 
Cells were washed three times with complete media and cultured with metal alloys at 
concentrations of (20, 100 and 200 g/L) or staphylococcal enterotoxin B (SEB), (Sigma, 
S4881) at 5g/mL final for 6 days.  On day 6, PI was added to a final concentration of 
10g/mL. Cells were acquired on a flow cytometry instrument (Accuri C6, BD 
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Biosciences). Data was analysed using FlowJo version 7.6.4. (TreeStar Inc) proliferation 
curve fitting algorithm. 
5.2.5 Assessment of cytokine production 
 
Cells were cultured as described above using XTT protocol. After a 6 days of culture 
period 100 l of culture supernatants were collected and frozen at 80°C until used. Levels 
of cytokine production by cells that exposed to metal particles were measured with a 
commercial kit Procarta 10-Plex Human (Cat No: EPX100-14040-801). Analysis of 
Leptin, GM-CSF, IFN-, IL-1, IL-10, IL-6, M-CSF, OPG, sRANKL and TNF- were 
conducted according to manufacturer’s instructions (detailed in Chapter 4). Assays were 
read in Luminex 200 system, methodology is also described in Chapter 4.  
5.2.6 Statistics  
 
The treatment groups were compared with one way ANOVA and Dunnett’s Multiple 
Comparison Test was applied as post hoc analysis for collective comparison. The 
individual treatment group comparison was conducted by unpaired, two-tailed Student t 
test with 95% Confidence Interval using GraphPad Prism.   
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5.3 Results 
 
In vitro generated Ultima alloy particles were measured for size and particle number as a 
colloid suspension. Fig 5-3 shows size distribution for the colloid suspension. It was 
observed that almost all particles were in nano-size scale with a mean of 256 (±124) nm 
and mode 183 nm. Particle number in the suspension was also calculated and found to be 
6.97 x 10
6
 particles/ ml. This equates around 7x10
4
 particles in 10 g, 3.5x105 particles in 
10 g dose and 7x105 particles in 100 g treatment concentrations. A representative result 
displayed in Fig 5-3 also details the instrument settings.  
 
 
Figure 5-3: Co-Cr-Mo metal alloy particle size and number distribution 
Characteristics of the metal colloid suspension were measured with NanoSight using the 
settings; camera shutter: 30 ms, camera gain: 560 V, Frame rate 30 fps, temperature 23.1 
°C, viscosity: 0.929 centipoise (cP). Particles size was calculated frame by frame and 
plotted against the number of particles of that size (measured between 10-1000 nm). 
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PBMCs were cultured with metal alloy suspension at 100 g/L final concentration and 
incubated for 2, 24 or 48 hours. This concentration of metal particle treatment was chosen 
for two reasons; first at lower concentrations it was not possible to visualise metal particles 
in cells by TEM, so specificity of the affect was not clear. Second this concentration was 
found to be detrimental for lymphocyte activity where proliferation of the PBMCs was 
ceased therefore, metal particles at 100 g/L concentration thought be appropriate to 
investigate.  
Cells types were identified by morphology using TEM. Macrophages characterised by size 
and lobular nucleus taking up around 2/3 of cytoplasma (Fig 5-4 A). Lymphocytes are 
characterised by being smaller in size compared to macrophages, however they contain 
larger rounded nucleus which covers around 80% of the cytoplasm (Fig 5-4 B). Metal alloy 
particles were imaged by themselves and found to be mainly spherical in shape (Fig 5-4 C 
& D). Particles were between 50-200 nm in size, consistent with NanoSight readings (Fig 
5-3).  
Metal alloy particle affect on PBMCs were assessed by comparing with non-treated cells 
over same period of time. The time course experiment revealed that non-treated cells 
remained healthy with cell and nuclear membranes appearing intact with no cytoplasmic 
extraction evident (Fig 5-5 A, C & E). On the other hand metal-treated cells displayed 
vacuolisation of plasma by 2 hours (Fig 5-5 B). The integrity of the cells was 
compromised; evident by disintegrated cell and nuclear membranes at 24 hours (Fig 5-5 
D). 48 hours of incubation resulted in the death of majority of the monocytes (Fig 5-5 F). 
These changes in cellular structure were confined to monocyte/macrophages mainly 
whereas lymphocytes were unaffected.  
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Metal alloy particles were engulfed as quickly as 2 hours by monocytic cells (Fig 5-6 A). 
Metal particles were mainly confined to vesicular pouches (Fig 5-6 B). Longer incubation 
time did not result in increased phagocytosis rate. However some cytolysis of 
monocyte/macrophages was observed at 48 hours (Fig 5-6 C). Also at this time point 
increased mitochondria size was noted which is the hallmark of necrosis.  
Fig 5-7 shows a monocyte/macrophage labelled as “necrosis” in contact with a 
lymphocyte. Monocyte/macrophage is undergoing necrosis indicated by loss of plasma 
membrane and extracted cytoplasma with intact nucleus. Another monocyte is present 
labelled as “apoptosis” which shows typical signs of apoptosis recognised by condensed 
chromatin in the nucleus and shrunk cell size. This is probably displaying an early 
apoptatic stage since signs of late apoptotic cellular events were not present i.e breakdown 
of nuclear membrane and formation of apoptotic bodies. However surrounding 
lymphocytes appeared unaffected with both plasma and nuclear membrane intact and do 
not show any signs of necrosis or apoptosis.  Some of the lymphocytes were very close to 
the monocyte/macrophage showing cell-to-cell contact after uptake of particles, suggesting 
potential antigen presentation in progress (Fig 5-7).  
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Figure 5-4: PBMC and metal alloy particle morphology 
Representative TEM micrographs are displaying typical cell types within PBMCs and 
metal alloy particles alone A: A macrophage displaying characteristics of this cell type 
lobular nucleus and dendrites branched from cytoplasm which is typical for activated 
macrophages B: A lymphocyte characterised by cells size, smooth cell membrane and 
larger nucleus/cytoplasm ratio. C: Whole particles were placed on plastic coated grids and 
imaged unstained. Metal alloy particles by themselves. Varying in size, and shape (oval 
and spherical). D: Showing zoomed in version of metal alloy particles displaying electron 
dense spheres with varying strength of density. 
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Figure 5-5: Time course treatment of PBMCs with metal alloy particles 
PBMCs were cultured with and without metal particles to visualise metal particle effect on them by TEM.  
Monocytes/macrophages were photographed at 2, 24 and 48 hours.  A: monocytes in culture for 2 hours. B: 
Monocytes plus metal particle culture. C: Monocytes in culture for 24 hours. D: monocytes plus metal 
particle culture. Cells are starting to show necrotic stage, evident with vacuolised cytoplasm. E: monocytes 
are shown after 48 hour of PBMCs cell culture alone. F: PBMCs cultured with metal particles; loss of 
cytoplasmic and nuclear membrane inflicted by metal particle exposure for 48 hours resulting in cell death.   
A: 2 hours PBMCs alone B: 2 hours PBMCs + particles
C: 24 hours PBMCs alone D: 24 hours PBMCs + particles
E: 48 hours PBMCs alone F: 48 hours PBMCs + particles
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Figure 5-6: Metal particle phagocytosis and its impact on monocytes/macrophages 
TEM images showing electron dense (visualised dark) metal particles and their cellular uptake by 
monocytes/macrophages. A: A macrophage showing recently endocytosed metal alloy particles (arrow) at 2 
hours incubation time B: extensive engulfment of metal particles by monocytes, confined to vesicles 
indicated by arrows. C: A macrophage in the processes of containing metal particles; healthy looking 
cytoplasma and several active mitochondria are present (arrows). Neighbouring cells displaying high levels 
of cytoplasmic vacuolisation plus loss of nucleus and mitochondrial structures.  
A
B
C
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Figure 5-7: Cell toxicity, necrosis and apoptosis after metal particle exposure 
Figure is showing a representative image of cells within PBMC population and their 
interactions after metal particle exposure, visualised by TEM. The micrograph is depicting 
metal particle impact on cells and interaction between lymphocytes and macrophages. A 
macrophage is undergoing necrosis (arrow) showing classical signs; enlarged cell size and 
collapse of the plasma membrane. The cell’s integrity is compromised and is displaying 
highly vacuolated cytoplasm. Another macrophage is going through apoptosis (arrow) as 
characterised by dense chromatin and shrunken cell size. This cell is probably at an early 
stage of apoptosis since cellular fragmentation is not yet evident and no sign of apoptotic 
bodies.  On the other hand lymphocytes appear to be morphologically unaffected by metal 
particles. 
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The metal alloy particles were studied for their potential stimulatory effects on PBMCs 
using physiological concentrations seen in metal implant patients (10, 50 and 100 g/L).  
Particles were generated by a laser ablation technique at a concentration 100 mg/L 
measured by atomic absorption spectroscopy and diluted with media to achieve the 
treatment concentration used in this study. Assay optimisation was carried out with these 
concentrations plus negative (PBMC only) and positive (PHA) controls. Proliferation 
assays were used as a measurement of lymphocyte reactivity.  
A time course experiment was carried out to assess the optimal response time for PBMC 
proliferation using XXT assay. Cell cultures were incubated for 1, 2, 3 and 6 days with 
increasing concentrations of metal particles (Fig 5-8). There technical repeats were 
conducted.  
Low concentration metal particle treatment (10 g/L) resulted in an increased proliferation 
response at day 2 compared to non-treated PBMCs (p = 0.023). This effect was even more 
prominent at day 3 (p = 0.0072) and reaching its peak at day 6 (p = 0.0007). On day 6 the 
stimulating effect of this concentration was even greater than positive PHA control (p = 
0.0044).  
Intermediate concentration metal particle treatment (50 g/L) was also stimulatory to 
PBMCs up to day 3 (p = 0.0003) but this effect was slightly decreased by day 6 compared 
to negative control (p =0.0054) (Fig 5-8).  
High concentration metal particle treatment (100 g/L) produced detrimental effects on 
PBMC proliferation (Fig 5-8). The number of viable cells with this treatment concentration 
was not statistically different from PBMCs only cells.  However, it was considerably lower 
than all other treatment groups. This indicates there was no expansion of PBMCs at this 
concentration.  
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The results of optimisation experiments revealed that 6 day cultures were optimal in 
assessing metal particle impact on PBMCs. This time scale is also representative of the 
time lag associated with antigen specific responses in vivo and used as the standard culture 
time for measurement of lymphocyte proliferation in DTH responses. Because the donors 
are believed not to be pre-sensitized with these particles beforehand the results seen in this 
study is an indication of generic mechanism against metal ions/particles that has resulted in 
exorbitant proliferation response.  
The assessment above was repeated using different donors to identify any host-related 
differences in response to metal particles. Again a similar pattern of response was noted in 
different donors (Fig 5-9 A). Low concentration metal particle treatment (10 g/L) showed 
high stimulatory capacity compared to non-treated cells (p = 0.0055). The proliferation 
response was also higher with intermediate concentration metal particle treatment (50 
g/L) compared with non-treated cells (p = 0.0211). However, high concentration metal 
particle treatment (100 g/L) showed no stimulatory effect on PBMCs as measured at day 
6.  
The Stimulation Index (SI) was calculated by dividing treatment response value by 
negative control value of non-treated cells. Mean SI values were found to be 3.181 for 
10g/L concentration, 2.079 for 50 g/L concentration, 1.193 for 100 g/L concentration 
and 3.342 for PHA. These results indicate that 10 g/L concentration activated immune 
cells as well as PHA positive control (Fig 5-9 B).  
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Figure 5-8: PBMC response to metal alloy particles 
Cellular proliferation as determined by XTT was assessed at different time points (Day 1, 
2, 3 and 6). Three different particle concentrations were used. Control cultures consist of 
PBMC only (negative control) and PBMC+PHA (positive control). Results showing a 
representative donor with 3 technical replicates.  
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Figure 5-9: Stimulation Index after metal alloy particle induced proliferation 
PBMCs were cultured with increasing concentration of metal alloy particles for 6 days and 
cell proliferation was measured by XTT. A: Proliferation response after treatment 10, 50 
and 100 g/L metal alloy particles. B: Relative stimulation index determined by dividing 
treatment cell response by control PBMC only. n = 3 with three technical replicates.  
ns (p ≥ 0.05),  * (p ≤ 0.05), ** (p ≤ 0.01), *** (p ≤ 0.001), **** (p ≤ 0.0001) 
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In order to measure cell viability and identify individual proliferation cycles after metal 
particle exposure a PI+CFSE assay was conducted. PBMCs were cultured with metal 
particles (20, 100 and 200 g/L) or SEB (5g/mL) as positive control for 6 days. Fig 5-10 
shows the gating strategy adopted for this acquisition. A consecutive gating was applied to 
flow data as follows; 
1) Singlet cell population gated utilising FCS-Area versus FSC-Height (Fig 5-10 A) 
2) Lymphocyte gate constructed with FSC-Area versus SSC-Area ( Fig 5-10 B) 
3) Negative PI staining to differentiate live from dead cells (Fig 5-10 C) 
4) Live cells gated and analysed for proliferation index ( Fig 5-10 D) 
 
Live/dead staining with PI revealed that there were no significant differences in the 
frequency of dead cells between different treatment groups (Table 5-1). After 20 g/L 
concentration of metal particle treatment 95.2% of the cells were alive at day 6. This was 
very similar for 100 g/L treatment (94.5%) and 200 g/L treatment (93.7 %) 
concentrations within lymphocyte population.  
The Proliferation Index (PI) was calculated within the “proliferating” gate (Fig 5-10 D) 
and results are depicted in Table 5-2. The 20 g/L treatment concentration produced a 
lymphocyte proliferation index rate at 2.070 which declined to 1.903 with 100 g/L 
concentration. The further decline was evident with 200 g/L concentration at 1.783 of 
proliferation index.  
Fig 5-11 depicts results for the effect of different treatment concentration on PBMCs. The 
20 g/L concentration resulted in 6 cycles of division (Fig 5-11 A) whereas this was 
reduced to 4 with 100 g/L concentration (Fig 5-11 B) and there were only 2 cycles of 
division with 200 g/L (Fig 5-11 C). Fig 5-11 D shows treatment with SEB, positive 
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control where 7 cycles of proliferation was seen. It was noted that there was a 
subpopulation of lymphocytes going through high proliferation rate at peak 4 (10^5 
signal). This equates around 2 days of culture (lymphocyte dividing rate is around 12 
hours). This is an indication of a subset of lymphocytes are reacting to the metal particles 
similar fashion to reacting to SEB hence same peak was also present with SEB treatment 
(Fig 5-11).  
 
These results indicate that metal particles do not cause cell death within the lymphocyte 
population. This is also in agreement with TEM images in this study where lymphocytes 
were unaffected morphologically (Fig 5-7). The 20 g/l concentration of metal particle 
has a stimulatory effect on lymphocytes and this effect was reduced at concentrations of 
100 g/L and higher. The lymphocytes are only proliferative cells within PBMC culture 
therefore proliferation that observed can be solely attributed to this population. This effect 
may be due to APC activation by metal particles and subsequent effect on lymphocytes 
induced by antigen presentation cells i.e monocytes. Alternatively, metal particle might 
have activated lymphocytes directly. To dissect these two different mechanisms further 
studies are required studding different cell subpopulations.  
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Figure 5-10: CFSE Gating Strategy 
A: Cells were cultured for 6 days during which some aggregation can occur in cell 
population therefore it was necessary to exclude doublets and aggregates. Cells are 
spherical in shape such that their diameter is proportional to cross section area; plotting 
Height versus Area creates a correlation line for single cells. Deviations off this line occur 
when cells stick together and they appear as outliers from the line. “Singlets” gate was 
drawn around this line. B: lymphocytes identified by their SSC vs FCS characteristics. In a 
culture two separate lymphocyte populations were observed, small lymphocytes which are 
dormant and larger lymphocyte which are proliferating as indicated by larger FCS showing 
size expansion and larger SSC showing increased granularity during mitosis. Small and 
large lymphocytes were gated together as “lymphocytes”. C: PI stains dead cells; negative 
PI staining identifies live cells. Therefore PI negative cells were gated as “live”.  D: CFSE 
signal in FL1 channel displaying proliferated/proliferating lymphocytes where the 
frequency of 7-8 generation of daughter cells was calculated.  
A B
C D
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Figure 5-11: PBMC proliferation assessed by CFSE staining 
PBMCs were treated with different concentrations of metal particles and incubated for 6 
days. CFSE staining was conducted on day one and on day 6 cells were analysed for 
proliferation response. Data was fitted using the Watson (Pragmatic) model in FlowJo 
version 7.6.5. A: 20 g/L metal particles B: 100 g/L metal particles C: 200 g/L metal 
particles D: SEB at 5 g/mL 
 
 
 
 
A: 20 g/L B:  100 g/L
C: 200 g/L D: SEB
- 143 - 
 
Table 5-1: Live/Dead staining with PI 
 
 
Frequency  
of cells 
 
Treatment concentrations 
 
20 g/L 100 g/L 200 g/L SEB (5g/mL) 
Live cells  95.2% 94.5% 93.7% 95.6% 
 
Dead Cells  4.73% 5.37% 6.12% 4.27% 
 
 
 
 
 
Table 5-2: Proliferation Index calculated after CFSE staining 
 
  
Treatment concentrations 
 
20 g/L 100 g/L 200 g/L SEB (5g/mL) 
 
Mean 
Proliferation 
Index (±SD)  
2.070  
(±0.02646)  
1.903  
(±0.06110)  
1.783  
(±0.2139)  
2.240  
(±0.06928)  
 
Mean Division  
Index (±SD)  
0.3760  
(±0.01609)  
0.2773  
(±0.02219)  
0.1613  
(±0.008386)  
0.4697  
(±0.01823)  
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In order to assess cytokine production by PBMCs after metal particle exposure (10 g/L, 
50 g/ and 100 g/L), culture supernatants were collected after 6 days and analysed by the 
Luminex system. Ten different cytokine levels were investigated; GM-CSF, IFN-, IL1-, 
IL-10, M-CSF, OPG, sRANKL, TNF-, IL-6 and Leptin. Leptin was undetectable in all 
samples hence this analyte was excluded from further analysis. IL-6 was high in all 
samples with all treatment concentrations. It was no possible to differentiate treatment 
effect on immune cells therefore this analyte was also excluded from further analysis.  
Leptin and IL-6 were concluded not to be confounding factors on PBMC functions upon 
particle exposure. Therefore the remaining eight analytes were analysed further.  
Analysis was conducted using three different donors. Low concentration metal particle 
treatment (10 g/L) did not show increased levels of cytokine production for the analytes 
GM-CSF, IFN-, IL1-, IL-10, OPG and TNF- compared to non-treated cells. However 
levels of M-CSF (233.8 ± 53.25, p = 0.0016) and sRANKL (39.09 ± 11.15, p = 0.0037) 
were increased with this treatment concentration (Fig 5-12, Table 5-3).   
Intermediate concentration metal particle treatment (50 g/L) produced an altered cytokine 
secretion profile of PBMCs where levels all seven cytokines were statistically significant 
compared to non-treated cells apart from IL-10 (Fig 5-12, Table 5-3).   
High concentration metal particle treatment (100 g/L) induced elevated levels of cytokine 
release from PBMCs for all eight analytes analysed (Fig 5-12, Table 5-3). IL-10 
production was also increased at this treatment concentration to 60.91 ± 26.77 pg/ml from 
7.984 ± 5.498 of low concentration of particle treatment (p = 0.0285).  
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Cytokine release assay showed a dose dependent response for all eight analytes analysed 
where increased metal particle concentrations resulted in increased cytokine production of 
PBMCs. This increase was statistically significant for M-CSF and sRANK-L at the 10 
g/L concentration whereas increased treatment concentrations of 100 g/L resulted in 
statistically significant levels of cytokine production for all analytes. These results indicate 
that leukocytes are reactivated by metal alloy particles and the immune reactive 
concentration was determined to be 10 g/L. This reaction might be mediated by M-CSF 
and RANKL in the first instance however increased treatment concentration resulted in a 
more heterogeneous response which involved several cytokines.  
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Figure 5-12: PBMC cytokine secretion after exposure to metal alloy particles 
Culture supernatants were collected and assayed on the Luminex platform to determine PBMC cytokine 
production following metal alloy exposure. Production of cytokine is represented in pg/mL and values are 
shown by whisker plots displaying min to max with mean. n = 3 biological/ 2 technical replicates.        
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Table 5-3: Cytokine production of PBMCs cultured with metal particles 
Cytokine levels in culture supernatants mean value pg/mL (± SD) 
n = 3 biological/ 2 technical replicates 
 
PBMC 
only 
+ 
10 g/L 
metal 
+ 
50 g/L 
metal 
+ 
100 g/L 
metal 
+ 
PHA 
GM-CSF 41.82 
(1.784) 
74.55 
(12.31) 
102.5 
(5.812) 
161.2 
(15.51) 
132.0 
(49.44) 
IFN- 0.2793 
(0.1343) 
330.5 
(160.3) 
1166 
(247.6) 
2024 
(413.6) 
4691 
(435.8) 
IL-1 0.3042 
(0.4296) 
55.57 
(14.37) 
137.8 
(40.94) 
197.5 
(30.70) 
178.5 
(18.45) 
IL-10 
ND 
7.984 
(5.498) 
23.96 
(9.948) 
60.91 
(26.77) 
105.6 
(4.795) 
M-CSF 
ND 
233.8 
(53.25) 
469.1 
(29.39) 
509.0 
(41.69) 
372.3 
(36.76) 
OPG 
ND 
7.915 
(6.939) 
22.27 
(3.170) 
31.13 
(5.639) 
3.579 
(3.170) 
sRANKL 
ND 
39.09 
(11.15) 
57.68 
(3.905) 
73.21 
(2.116) 
21.27 
(7.828) 
TNF- 
ND 
86.94 
(44.62) 
810.8 
(151.4) 
1773 
(233.9) 
433.4 
(98.83) 
 
ND: Not detectable 
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5.4 Discussion 
 
This in vitro study showed that Ultima alloy particles were immunologically active and 
capable of inducing lymphocyte proliferation demonstrated by CFSE+PI assay. This was 
particularly evident with 10 g/L treatment concentration whereas concentrations higher 
than 100 g/L resulted in detrimental effects on lymphocyte proliferation. Increased 
lymphocyte expansion rate after stimulation is a hallmark of immune system activation. 
Cytokine production profile substantiated this finding where non-treated cells produce very 
little or no cytokines however metal particle-treated cells produced several cytokines in a 
concentration dependant manner.  
High concentrations of metal particles (100 g/L and 200 g/L) did not adversely affect 
lymphocyte survival. However cells could not proliferate any longer, suggesting the 
functional mechanism was halted after metal exposure in these cells. Serum levels of metal 
ions are generally lower than that used to challenge PBMCs in the current study.  However 
it was deemed that metal challenge concentrations used in this study are clinically 
significant because metal concentration of peri-prosthetic environment is highly elevated 
[65] and estimated to be an order of magnitude higher locally compared to serum levels.  
At high concentrations particles might be toxic to monocytes/macrophages but not to 
lymphocytes. After exposure to 100 g/L of metal particles, TEM images revealed that 
macrophages uptake particles readily resulting in necrosis of these cells. Necrosis is an 
inflammatory process and results in activation of other immune cells. This might be one of 
the mechanisms, another one could involve a more specific route of antigen presentation. If 
lymphocyte activation by metal particles requires antigen presentation by APCs; necrotic 
status of macrophages might be the reason why lymphocyte proliferation was limited at 
higher concentrations. 
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There were also some apoptotic cells observed. TEM provides the analysis of sectioned 
specimens and allows qualitative output. The number of cells that can be processed for 
imaging is very limited therefore quantitative data is not possible. However it appeared that 
apoptotic cells were less frequent than necrotic cells, whether this is representative of 
entire sample cannot be established. Regardless how cells die, maintenance of normal 
functions in the multi-cellular organism dictates that dying cells are cleared by phagocytes. 
Metal particle-induced necrosis/apoptosis of macrophages in large scale would result in 
inefficient clearance of cellular debris. Defective clearance may contribute to persistence 
of inflammation and subsequent pathologies.  
Samples tested in these experiments were donated by healthy individuals with no metal 
implant in situ nor any known metal allergy. Therefore the expansion seen in lymphocytes 
is most likely due to de novo activation of these cells which suggests a primary activation 
rather than a memory response.  Previous studies have shown that people with no implants 
or metal sensitivity do not display activation of immune cells after a metal challenge [204], 
whereas subjects with a history of metal sensitivity respond to metal challenge strongly via 
T and B cells [65] suggesting the immune activation involves adaptive arm of immune 
system. In the current study it is demonstrated that metal challenge also induces a 
lymphocyte-mediated immune response in donors without a history of metal sensitivity. 
However, it is not known whether activation of lymphocytes is caused directly by metal 
particles or indirectly by accessory cells due to metal particles effect on these cells. It has 
been sown in the current study that metal particles are phagocytised and processed by 
macrophages. Therefore, it could be postulated that metal particles alters antigen 
presentation and results in subsequent lymphocyte activation.  
It was striking to note that low concentrations of metal particles induced stimulation 
comparable to mitogen driven responses. Metal particles may act as super-antigen hence 
- 150 - 
the response observed was much stronger than any potential antigen-specific response 
would be. The exact molecular mechanism of this activation was not investigated. 
However one could postulate a haptenisation effect after coupling to serum proteins might 
be possible. It has been demonstrated that metal ions couple with serum proteins such as 
albumin [205] [206]. Rachmawati et al showed that Cobalt activates dendritic cells through 
direct TLR-4 ligation whereas chromium mediated activation requires tissue-derived 
cofactors to induce clinical sensitization [207] . To be able to identify the exact mechanism 
of metal recognition the immunogenic epitopes need to be identified first. This was not 
possible within the scope of the current study. In the current study cells were cultured in 
autologus serum from donors to emulate the in vivo environment where the cells would be 
in a protein-rich milieu. The increased stimulation index after metal particle exposure 
suggests that serum protein coupling might be necessary for cellular uptake, however a 
serum-free system was not tested.  
Monocyte/macrophage involvement in metal particle uptake has been demonstrated before 
[195, 198]. Cytokines IL-1, IL-6 and TNF- were used as indicators of macrophage 
activation [197] in cell culture models in the absence of accessory cells. In the current 
study, PBMC cultures consisting of both monocytes/dendritic cells and lymphocytes were 
used in which lymphocyte and APC interactions can occur. Cytokine release assays 
showed concentration-dependent responses for all eight of the cytokines analysed where 
increased metal particle concentration resulted in increased cytokine production by 
PBMCs. At 10 g/L concentration only M-CSF and sRANKL had significantly increased 
levels compared to non-treated cells. T cells are known to produce these two cytokines and 
the presence of these stimulates myeloid lineage cells including monocytes and osteoclasts. 
M-CSF is necessary along with sRANKL for the complete differentiation of osteoclastic 
precursors into mature osteoclasts [208]. Osteoclasts are the main bone absorbing cells and 
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the most common indication of implant failure is peri-prosthetic osteolysis which is driven 
by osteoclasts. T cell activation by macrophages and subsequent M-CSF and sRANKL 
release might mediate osteoclast differentiation in vivo. Metal wear debris is believed to be 
continuously released from implants in vivo at low concentrations, however there are no 
reliable means of measuring the immune reactive dose of these particles in vivo. Normal 
serum levels of sRANKL range between 0.45-0.89 pg/ml [209] and in healthy individual 
M-CSF is present at 2.36 ± 0.18 ng/ml [210]. These levels were exceeded greatly in the 
current study identifying them as potential drivers of osteoclast activation and immune 
mediated osteolysis. This study determined the immune reactive dose to be 10 g/L in 
vitro and M-CSF and sRANKL might be the main drivers. 
Intermediate concentration particle treatment (50 g/L) resulted in elevated levels of all 
pro-iflammatory cytokines apart from IL-10. IL-10 is an anti-iflammatory cytokine and its 
role in immune regulation is well established. Whereas increasing the treatment 
concentration to 100 g/L showed a statistically significant IL-10 response along with 
other cytokines. Both osteogenic (IFN-, IL-10, OPG) and osteoclastogenic (GM-CSF, M-
CSF, IL-1, IL-6, RANKL, TNF-) cytokine levels were raised indiscriminately in 
culture. This appears to be similar to the cytokine storm first described in Graft Versus host 
disease (GVHD) patients [211]. The current study was restricted to an in vitro system, the 
in vivo response might be different in metal implant failure. However, the production of 
IL-10 following the onset of a cytokine storm is a marker of a counter-inflammatory 
response that has been termed as immunoparalysis. This phenomenon is associated with 
down-regulation of monocyte activity. It indicates a cut-off point where the anti-
inflammatory response starts to kick in at higher concentrations. A compensating 
mechanism is expected at higher concentrations as indicated in the current study. 
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Constrained proliferation capacity at higher concentrations might be due to increased IL-10 
production where macrophages cannot process metal alloy particles any longer.  
Catelas et al showed intracellular endocytosis of Cr
2+
 and Cr
3+
 ions in a macrophage cell 
line consisting of clusters of nanoforms. Further energy-dispersive X-ray spectroscopy 
(EDS) analysis revealed that nanoforms were chromium phosphate with an organic phase 
attached to it. Such nanoforms were not observed with Co
2+
 ions [71]. The current study 
also demonstrates wear particle endocytosis (Fig 5-6 A and B) at a concentration of 100 
g/L using primary immune cells. TEM images revealed that metal alloy particle uptake 
mainly involved monocytes, whereas lymphocytes seemed unaffected. Monocytes are 
phagocytic cells and comprise the first line of immune response, therefore one can expect 
to see monocyte driven phagocytosis.  
Colognate et al reported that Co nanoparticles were internalised by PBMC at higher rates 
compared to Co
2+
 ions and that this was time dependent. They have observed an 80 fold 
increase at 24 hours and 140 fold increase at 48 hours determined by tracking radio-
labelled Co molecules [212]. The data from the current study failed to demonstrate any 
time-dependent increase of metal particle uptake. However, the two testing systems are 
very different. The cellular uptake quantification by TEM is not possible hence the number 
of samples imaged is extremely limited. The lack of concentration dependent observations 
in TEM images might be also due to increased necrosis and apoptosis over a period of time 
because only the intact macrophages were imaged.    
Transition metals such as Ni, Co, Cr, Palladium have been found to be potent clinical 
sensitisers [207]. These compounds are usually tested in elemental state or their salt forms. 
However, the current study used the original alloy to reproduce a more realistic scenario. 
Using similar sizes and shapes of metal alloy particles as seen in vivo, generates a more 
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appropriate experimental set up. The use of exogenous FCS serum was avoided to prevent 
xenogenic activation. Instead heat-inactivated autologous serum was used to determine the 
intrinsic stimulation capacity of metal alloys. Whether serum proteins are the carrier 
molecules for metal ions or not, the immune cells are in serum proteins naturally in vivo. In 
the current study this was assumed to be a pre-requisite and an alternative system was not 
tested.  
To summarise, this study demonstrates that Co-Cr-Mo alloys induce a proliferative and 
cytokine response in PBMCs and provides evidence of immune activation. At first instance 
a high throughput whole population approach was utilised and followed by single cell 
assay of proliferation to answer initial questions. Phenotypic characterisation of PBMC 
subsets was not undertaken which could identify responding cell subsets. Further studies 
should focus on identifying affected cell subsets and their functions in metal implant 
failure.  
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6 CHAPTER 6: General Conclusions 
 
This study investigated immunological factors in both innate and adaptive immunity that 
may play a role in metal hip implant failure. Orthopaedics patients were recruited and 
stratified into four clinical sub-groups;  
 Pre-implant group as control where OA patients going through their first hip 
arthroplasty and never been exposed to a hip implant before.  
All other three groups had a metal hip implant at the point of sample collection.  
 Ultima asymptomatic group; where implant is well tolerated.  
 Ultima symptomatic group;  showing signs of implant failure hence going 
through a revision surgery  
 Other symptomatic group; patients having another type of metal implant and 
going through a revision surgery due to implant failure.  
The majority of hip implants perform well while a sub-group of THR patients experienced 
implant failure. This phenomenon is even more pronounced with MoM implants. Some of 
the patients avoided developing peri-prosthethic osteolysis whereas others did not. To 
investigate a potential genetic disposition for metal implant failure, HLA tissue typing was 
conducted in the Norfolk cohort.  
Possessing certain set of HLA alleles can lead to risk of increased susceptibility to some 
conditions as discussed in Chapter 3. HLA molecules can present disease triggering 
peptides that result in disease disposition. This could be due to alterations in self-peptides 
or MHC molecules itself induced by metal ions. Alternatively, metal ions could influence 
regulatory mechanisms where presentation of self-peptides results in a disturbed 
homeostatic mechanism due to altered MHC presentation to regulatory cells. In the 
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absence of appropriate regulatory mechanisms the host would develop aberrant immune 
response to hip implants. On the other hand some HLA alleles might be protective against 
activation of immune response after hip arthoplasty where having certain haplotype helps 
immune response to control hypersensitivity more tightly. Missing these protective alleles 
within the gene pool may contribute to disturbance in regulatory functions therefore results 
in increased susceptibility to implant failure. Therefore HLA molecules can have a direct 
role in the fate of disease development.  
It should also be noted that disease associated HLA molecules may not have a direct role in 
disease development but it might simply be a result of extensive LD at MHC loci where 
other linked genes to given haplotype are the cause of the disease but not HLA itself. SNPs 
at the location of TNF-, IL1RA, IL-6 and MMP-1 genes were implicated to be associated 
with implant failure previously [213] , however there is no study reporting HLA 
association with osteolysis.  
Strong genetic association does not necessarily mean causation. Therefore several criteria 
should be considered before making an assumption; such as strength of the association, 
biological plausibility and consistency of the results. To be able to differentiate these two 
phenomenon (association versus causation), functional assays need to be conducted where 
the role of the molecule can be tested. The first step in this direction is to identify disease 
associated/related determinants. To attempt to do so, 25 different MHC class II loci were 
typed in the current study and two alleles were found to be strongly associated with 
protecting from implant failure (HLA-DQA1*01:02 and HLA-DQB1*06). Heterodimers 
of DQA1*01:02/DQB1*06:02 confer dominant protection against type 1 diabetes (T1D) 
and strong susceptibility to narcolepsy [214]. The potential role of this haplotype in metal 
implant failure is reported for the first time through this study. The statistical testing for 
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these alleles withstood multiple testing correction which gives confidence in the potential 
biological role of these genes. Allele HLDR-DQA1*05 was found to be associated with 
implant failure development in the current study. However after multiple testing 
corrections the statistical significance was lost. This allele can be checked again with a 
second study in other population with a similar condition, repeated frequency results would 
ensure testing specificity. Multiple correction avoids type I error of getting false-positive 
results but it also increases the chance of getting type II errors where a genuine finding 
may be ruled out. Therefore a second study with a priori hypothesis offers the best 
explanation for marginal results. The degree of agreement and reproducibility of the 
current results needs to be confirmed with another population of people experiencing MoM 
hip implant failure.  
The number of subjects that were studied was limited because the implant of interest was 
discontinued around 10 years ago. HLA molecules are encoded by many genes and there 
are several variations of each gene. Also high LD is present at HLA regions requiring large 
number of subjects to be tested. The minimum number of subjects required depends on the 
frequency of that allele and whether it is rare/common in both the study and control 
populations. Study power was calculated retro-respectively and concluded that the current 
study was underpowered. As it is demonstrated in the results section by the worst and the 
best case scenario analysis; the current study needed to recruit between twice and ten times 
more patients for HLA analysis depending on which alleles studied.  
It was hypothesised in this study that antigen presenting cells were altered phenotypically 
and functionally in the failed implant patients. To test this research question an extensive 
immunophenotyping was conducted. The results of this work showed that 
immunophenotypic alterations were only present in the Ultima Asymptomatic group where 
there was increased numbers of activated T cells, classical monocytes and myeloid 
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dendritic cells. Altered numbers of immune cells have been shown in many inflammatory 
conditions [176, 215]. Such increase could be related to three main reasons;  
1) Increase in differentiation from bone marrow 
 2) Expanded half-life in the periphery due to chronic stimulation  
3) Reduced recruitment to secondary tissues.  
The blood transit time of some cells might be short lived hence single point readings must 
not be over interpreted. However, only the Ultima Asymptomatic group showed signs of 
immune-activation and the results were consistent between different cell types. This 
outcome might be an indication of immune stimulation being protective against implant 
failure. On the other hand, the number of cells and expression of activation markers were 
within normal range for the other three groups. This might be due to the fact that in the 
failed groups, there is no more systemic inflammation and cells were now polarised and 
moved to the local site of implant. However, local inflammatory responses are expected to 
be reflected in the periphery to some extent, hence the scientific justification for blood 
phenotyping in tissue-associated inflammatory conditions and tumour biology.  
The immunophenotyping approach undertaken in this study was novel as 18 different 
parameters were investigated simultaneously. Flow cytometry is a powerful technique 
which allows concurrent detection of several cell types and functional markers in large 
numbers. This assessment is the first of its kind in metal implant failure which uses a 
detailed and robust system for immune cell monitoring. Non-manipulated ex vivo blood 
samples were assayed on the same day with a perspective that it would reflect in vivo 
immune state. Immunophenotyping is a sensitive but not specific measurement therefore it 
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cannot pin point the causative reason for metal implant failure, however, blood dyscrasia is 
considered to be an indication of immune dysfunction.  
Antigen presenting cells were scrutinised to an extent which has not been reported in metal 
implant failure previously. This investigation was supported with an assessment of soluble 
mediators in blood and SF with an extensive panel of osteogenic and osteoclastogenic 
cytokines/growth factors. Surprisingly, there was no indication of systemic inflammation 
in the failed implant groups substantiated by immune cells analysis and cytokine 
measurements. Local inflammation was measured in SF samples. There was higher levels 
of tested cytokines in SF compared to serum samples of matched individuals however this 
analysis did not substantiated any indication differences between clinical groups. This 
might be due to sample size being too small hence it was not possible to obtain this sample 
type for every patient.  
Unfortunately, sampling time in these patients reflects late stages of the implant failure 
process where patients have been experiencing failure-related symptoms for many months 
or even years. This period reflects a long lag-period from the time of initial surgery when 
local homeostasis was first disturbed. It is likely that after major surgery of hip 
replacement, surgical trauma causes an inflammatory response in the peri-prosthetic tissue 
causing necrosis and ischaemia. In many patients, the inflammatory responses are averted 
and bone and soft tissue architecture is restored. However in the presence of excess 
implant wear, homeostasis can be disturbed and peri-prosthetic osteolysis may develop 
leading to aseptic loosening. The time-scale of these events is not known therefore a 
prospective study of well-functioning implants, monitoring immune response periodically 
from pre-implant to post-implant stages could provide valuable information in future 
studies. One of the limitations of the current study was that patients were sampled at only 
one time point. Pre- and post-ablution studies monitoring regulatory mechanism such as 
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M2 macrophages, Tregs and IL-10, TGF- mediated pathways could provide more insight 
to metal implant failure.  
The serum cobalt and chromium levels were also high in the Ultima Asymptomatic group 
which correlated with increased cells counts. The results were externally validated by 
comparing absolute cell readings with established normal cell counts of healthy 
individuals. Therefore this approach not only allows comparisons between clinical groups, 
but also permits comparisons against normal ranges of immune cells. Increased metal ion 
levels might be directly associated with increased cell counts in a well-functioning group 
as a result of a compensation/ regulatory mechanism.  
For the reasons mentioned above this study did not look at peri-prosthetic tissue samples 
hence this type of sample is often only available after metal implant failure where there is 
almost always extensive tissue damage, hence it might be too late. An aim of the study was 
to develop a practical assay to monitor immune response without resulting in invasive 
methodology.  
Following the results of immune monitoring it was noted that alterations in circulating 
immune cell numbers or activity are likely to be too subtle to determine ex vivo therefore 
the analysis may require an amplification which is only possible in vitro. For these reasons 
an in vitro testing system was set up to measure immune response to metal particles with 
an opinion to assess immediate effects of these particles on primary human immune cells 
which is something that is not possible in vivo. In vitro testing revealed that these particles 
were immune-reactive at low concentrations as demonstrated by T cell proliferation. The 
particles that were tested were generated from the Ultima implant in a form of nano-scale 
beads representing the original composition of Co-Cr-Mo alloys. To our knowledge this 
was the first attempt to use such material in assessment of these chemical’s bio-inertness. It 
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was interesting to see that 10 g/L concentration of metal alloy particles resulted in an 
immune stimulation as strong as positive mitogen controls. At these concentration levels of 
M-CSF and RANKL were significantly increased, both are known to be osteoclastogenic 
factors. The immune reactive concentration of metal alloys is determined to be 10 g/L 
perhaps modulated by these two cytokines.  
It has been shown with TEM images with the current study that macrophages phagocytose 
metal alloy particles resulting in necrosis of macrophages, however lymphocytes were 
unaffected morphologically. This data correlates with proliferation results where 
lymphocytes were proliferated after treatment with metal particles in mix cultures i.e. 
monocytes present. Monocytes could be involved with two different ways; initially in the 
attempt to clear wear debris results in necrotic bodies, cytokines , DAMPs which activates 
lymphocytes directly. Follow with macrophages involvement in APC-mediated 
lymphocyte activation. Either way macrophages deemed to be involved in the process and 
the results of this study provides evidence for macrophage-initiated immune activation. 
Increased metal particle concentrations resulted in cell proliferation arrest although 
lymphocytes were still viable suggesting metal ion particles are not affecting lymphocyte 
survival although they affect their cellular function. This aspect could be investigated in 
future studies by looking at cell cycle analysis and dissect which phase of mitosis might be 
affected.  Investigation of molecular pathways involved in relevant cell cycle arrest might 
help to elucidate this phenomenon further.  
Peri-prosthetic osteolysis resulting in implant failure considered to have multi-factorial 
aetiology involving genetic predisposition plus immunological dysregulation, however the 
exact mechanisms that is involved needs further elucidation. Therefore a broad and 
comprehensive investigational approach was undertaken in the current study. This study 
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demonstrates that immune system alterations were present in successful THR group and 
these mechanisms might be due to protective and homeostatic regulations. More selective 
and targeted approaches should follow for future studies taking into consideration of 
finding of the current study.  
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Appendix 2: Raw data of HLA Typing 
 
 
Study No Group NoHLA-DRB1   HLA-DRB1 HLA-DQB1 HLA-DQB1 HLA-DQA1 HLA-DQA1
001 G3 *03:01/50/68N *13:01/105/109/112/117/121 *02:01:01 *06:03P *01:03:01G *05:01P
002 G2 *01:01P *01:01P *05:01/07/11/12 *05:01/07/11/12 *01:01:01G *01:01:01G
003 G2 *01:01P *03:01/50/68N *02:01:01 *05:01/12 *01:01:01G *05:01P
004 G2 *01:01P *03:01/50/68N *02:01:01 *05:01/12 *01:01:01G *05:01P
005 G2 *07:01P *11:01/97/100/117 *03:01/27-29/35 *03:03/31/33/34/39 *02:01 *05:01:01G
006 G2 *03:01/50/68N *08:01P *02:01:01 *04:02P *04:01:01G *05:01:01G
007 G2 *01:01P *01:01P *05:01/12 *05:01/12 *01:01:01G *01:01:01G
008 G2 *13:01/105/109/112/117 *15:01P *06:02P *06:03P *01:02:01G *01:03:01G
009 G2 *01:01P *15:01P *05:01/12 *06:02P *01:01:01G *01:02:01G
010 G2 *03:01/50/68N *11:04P *02:01:01 *03:01/27-29/35 *05:01P *05:01P
011 G2 *03:01/50/68N *08:01P *02:01:01 *04:02P *04:01:01G *05:01:01G
012 G3 *03:01/50/68N *04:04/23 *02:01P *03:02/37 *03:01:01 *05:01P
013 G3 *01:01P *07:01P *03:03/31/33/34/39 *05:01/12 *01:01:01G *02:01
014 G4 *01:01P *14:01/54/113/114 *05:01/07/11/12 *05:03/06/08-10/13 *01:01:01G *01:01:01G
015 G3 *04:01P *07:01P *02:02 *03:01/27-29/35 *02:01 *03:01:01G
016 G2 *07:01P *13:01/105/112/117 *02:02 *06:03P *01:03:01G *02:01
017 G2 *11:01/97/100/117 *15:01P *03:01/27-29/35 *06:02P *01:02:01G *05:01:01G
018 G2 *03:01/50/68N *15:01P *06:02P *06:02P *01:02:01G *01:02:01G
019 G2 *04:01P *04:02P *03:02/37 *03:02/37 *03:01:01G *03:01:01G
020 G2 *01:01P *04:01P *03:01/27-29/35 *05:01/12 *01:01:01G *03:01:01G
021 G2 *03:01/50/68N *07:01P *02:01P *02:02 *02:01 *05:01P
022 G3 *03:01/50/68N *03:01/50/68N *02:01P *02:01P *05:01P *05:01P
023 G1 *01:01/20 *04:04/05/08/23 *04:02P *05:01/12 *01:01:01G *03:01:01G
024 G2 *15:01P *15:01P *06:02P *06:02P *01:02:01G *01:02:01G
025 G4 *08:01/39 *11:01/97/100/117 *03:01/27-29/35 *04:02P *04:01:01G *05:01:01G
026 G1 *01:03 *11:01/97/100/117 *03:01/27-29/35 *05:01/12 *01:01:01G *05:01:01G
027 G4 *03:01/50/68N *04:01P *02:01P *03:02/37 *03:01:01 *05:01P
028 G3 *08:04P *13:03/115 *03:01/24/27-29/35/36 *03:01/24/27-29/35/36 *05:01:01G *05:01:01G
029 G1 *04:04/23 *15:02P *03:02/37 *06:01/43 *01:03:01G *03:01:01G
030 G1 *03:01/50/68N *15:01P *02:01:01 *06:02P *01:02:01G *05:01P
031 G1 *01:01P *07:01P *02:02 *05:01/12 *01:01:01G *02:01
032 G1 *01:01P *04:01P *03:02P *05:01/12 *01:01:01G *03:01:01G
033 G1 *04:01P *12:01P *03:01/27-29/35 *03:02/37 *03:01:01 *05:01:01G
034 G1 *07:01P *07:01P *02:02 *03:03/31/33/34/39 *02:01 *02:01
035 G1 *11:04P *12:01P *03:01/24/27-29/35/36 *03:01/24/27-29/35/36 *05:01:01G *05:01:01G
036 G1 *01:01P *15:01P *05:01/12 *06:02P *01:01:01G *01:02:01G
037 G1 *01:01P *04:03/52/97 *03:05P *05:01/12 *01:01:01G *03:01:01G
038 G1 *04:04/23 *11:04P *03:01/27-29/35 *03:02/37 *03:01:01 *05:01:01G
039 G1 *07:01P *15:01P *03:03/30/31/33/34/39 *06:02/11/26N/47 *01:02:01G *02:01
040 G1 *01:02P *07:01P *02:02 *05:01/12 *01:01:01G *02:01
041 G1 *03:01/50/68N *15:01P *02:01:01 *06:02P *01:02:01G *05:01P
042 G4 *04:04/23 *11:01/97/100/117 *03:01/27-29/35 *03:02/37 *03:01:01 *05:01:01G
043 G4 *07:01P *07:01P *02:02 *03:03/31/33/34/39 *02:01 *02:01
044 G3 *01:03 *03:01/50/68N *02:01:01 *05:01/12 *01:01:01G *05:01P
045 G3 *01:01/17 *04:05/07/08/92 *03:01/27-29/35 *05:01/12 *01:01:01G *03:01:01G
046 G3 *01:01/50/52N/53 *11:01/97/100/117/133/134/140/141 *03:01/27-29/35/42/47 *05:01/12/18 *01:01:01G *05:01:01G
047 G3 *07:01P *11:01/97/100/117/133/134/140/141 *02:02 *03:01/27-29/35/42/47 *02:01 *05:01:01G
048 G3 *07:01P *15:01/74/75/79/85/86/90/91 *03:03/31/33/34/39 *06:02P *01:02:01G *02:01
049 G4 *03:01/50/68N/83 *04:01/111/112/119N/127/135 *02:01P *03:01/27-29/35/42/47 *03:01:01G *05:01P
050 G4 *03:01/50/68N/83 *07:01P *02:01P *02:02 *02:01 *05:01P
051 G4 *01:02/43/46 *04:04/23/108/118/120N/121/149 *03:02P *05:01/12/18 *01:01:01G *03:01:01G
052 G4 *04:01/111/112/119N/123/127/135/151 *11:01/97/100/117/133/134/140/141 *03:01/24/27-29/35/36/42/44/46/47 *03:01/24/27-29/35/36/42/44/46/47 *03:01:01G *05:01:01G
053 G3 *07:01P *07:01P *02:02 *02:02 *02:01 *02:01
054 G4 *07:01P *13:01/105/112/117/148/153 *03:03/31/33/34/39 *06:03P *01:03/10 *02:01
055 G4 *03:01/50/68N/82-84/86/89 *03:01/50/68N/82-84/86/89 *02:01P *02:01P *05:01P *05:01P
056 G4 *01:01/47/50/52N/53 *07:01P *02:02 *05:01/12/18 *01:01:01G *02:01
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Appendix 3: List of Antibodies 
 
